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Abstract 
Sachin Abasaheb Korde 
Solvent Free Technologies for Polymer based Crystal Engineering and Drug 
Delivery 
Keywords: Crystal Engineering, Polymer, Drug Delivery 
  
Current research focuses on the effect of different continuous solid state shear 
based processing for the production of pharmaceutical amorphous system and 
cocrystals for poorly water soluble APIs. The S3M technology is getting first 
time reported for its application in pharmaceutical field and it is considered as 
technology with good potential for development of pharmaceutical dosage 
forms. The main objectives of this study include the effect of two solid state 
shear processes on the product properties in case of solid dispersions and 
cocrystals. Hot melt extrusion technology has been widely explored for the 
production of pharmaceutical solid dispersions and cocrystals, it would be 
helpful to compare how the new invented S3M technology will differ from the 
existing solid state shear process. The S3M has been also explored for the 
advantages over HME process in terms of residence time, plasticiser free 
dispersions, effect of process on degradation of drugs during processing. For 
this purpose, the process and material modifications during operation of these 
two technologies was important aspects of this study. The pharmaceutical drugs 
chosen for the solid dispersion purpose were carbamazepine, ibuprofen, 
glibenclamide which are BCS class II drugs and paracetamol from BCS class III 
drug was selected as model drug for solid dispersion manufacturing with PVP 
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VA64, HPMCP HP55, HPMCAS, Ethyl cellulose as polymers. In case of 
cocrystals selected drugs were carabamazepine, caffeine, paracetamol and 
ibuprofen with co-formers nicotinamide, saccharin, salicylic acid, glutaric acid, 
oxalic acid, maleic acid. The selections of co-formers were done on the basis of 
functional group complementarity between drug and co-former. All the details 
about the pairs for cocrystals and for solid dispersions are given in experimental 
section. Carbamazepine has been explored in depth for solid dispersions with 
different polymers and with different co-formers in case of cocrystals. The effect 
of process variables and amount of shear applied during processing was 
deciding factor in product output and quality. The end product in case of both 
the solid dispersions and cocrystals varied in their physicochemical, 
morphological and drug release properties HME process needed addition of 
plasticisers during preparation of solid dispersions whereas S3M was plasticiser 
free process which gave good insight on how this will affect the product 
performance during evaluation studies. The solid dispersions in case of HME 
were had smooth surfaces and which are non-porous in nature whereas in case 
of S3M the solid dispersions were highly porous in nature. The differences in 
the structural and morphological features of solid dispersions somehow did not 
affect the drug release of drug during in-vitro dissolution studies and both the 
solid dispersions did not show much difference in drug release. In case of 
cocrystals processing on S3M it was observed that the S3M process is 
dependent on the use of polymer as process aid. For this purpose PEO, PVP 
VA64 and HPMCP HP55 were selected as model polymer as process aid 
during processing of cocrystals, out of which PEO has been explored widely as 
processing aid due to its process suitability, low melting and ability to withstand 
high shear during processing. PVP VA64 was used only in case of 
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carbamazepine cocrystals with salicylic acid and HPMCP HP55 in case of 
caffeine cocrystals with maleic acid. The effect of concentration of PEO in case 
of carbamazepine cocrystals as processing aid was studied (concentration 
range 5%, 10%, 15%, 25% w/w). The concentration of PEO in case of HME 
cocrystals had direct effect on the drug release of drug dissolution studies which 
was reduced in case of higher concentration of PEO (25% w/w), which was not 
observed in case of S3M processes carbamazepine cocrystals. The product in 
case of cocrystals by S3M was thread like structures whereas in case of HME 
cocrystals were in form of screw shaped compact mass. The difference in 
morphological and structural properties of cocrystals did not had major effect on 
drug release in case of S3M process but in case of HME processed cocrystals 
the higher amount of polymer slowed the drug release. 
The degradation studies in case of drugs carbamazepine, paracetamol were 
carried out whereas in case of polymer for HPMCP HP55 were carried out. It 
was found that HME processed samples showed higher degradation as 
compared to S3M processed one in both the cases solid dispersions and 
cocrystals. This can be attributed to high residence time in case of HME as 
compared to S3M process. 
The effect of two high shear processes HME and S3M had significant effect on 
the morphological and structural properties of the solid dispersions and 
cocrystals. The variation in the structural and morphological properties did not 
have direct effect on the drug release of drug during dissolution studies. HME 
and S3M both the processes had some positive and some negative aspects 
within them for processing of pharmaceutical dispersions and cocrystals. 
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In case of HME the use of plasticiser is mandatory to maintain low torque levels 
during processing and to avoid blockage of extruder barrel, whereas in case of 
S3M the process is plasticiser independent and processing of solid dispersion is 
very easy as compared to HME with low residence time. Processing of plain 
drug or co-former was easy in case of HME whereas in case of S3M processing 
it was mandatory to use polymer as processing aid specially during processing 
of cocrystals. 
In case of process controls HME has excellent control over the process 
parameters which can be controlled and manipulated as per requirement, 
whereas S3M technology needs to have technical modifications to have better 
control over its processing parameters. The S3M can be a revolutionary 
technology for pharmaceutical industry once it is upgraded with better control 
and optimised process parameters.  
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I do not know what I appear to the world; but to 
myself I seem to have been only like a boy playing 
on a sea-shore, and diverting myself in now and 
then finding a smoother pebble or a prettier shell 
than ordinary, whilst the great ocean of truth lay 
all undiscovered before me. 
Sir Issac Newton 
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Chapter 1. Introduction 
Many of the new drug entities have solubility issues associated which 
hampers their bioavailability, leading to a low therapeutic effect. Low solubility 
has created a major challenge to modify and transform existing dosage forms 
into more suitable dosage forms with improved performance (Leuner, 2000). 
Drug has to be in solution form at the site of absorption to achieve a 
pharmacological effect, which increases dose size of these low solubility 
drugs.  
Biopharmaceutical classification system (BCS) for pharmaceutical drugs has 
classified drugs into four categories owing to their solubility and permeability. 
Most pharmaceutical drugs and new chemical entities belong to the BCS 
class II category. There are many techniques evolving and reported in the 
literature to improve the solubility of BCS class II drugs, which have low 
solubility and high permeability. Among many approaches, use of different 
components and additives such as adsorbents, surfactants (Vasconcelos et 
al., 2007) and co-solvents (Majerik, et al. 2007) are some of the preliminary 
attempts reported for solubility enhancement. Micronisation is one of the most 
widely investigated techniques for solubility enhancement by reducing the 
particle size; many researchers have reported increasing therapeutic efficacy 
of the drug by decreasing its dose by micronisation (Rasenack and Muller, 
2004). Micronisation helps to increase the surface area of the drug particle 
and wettability which in turn increases the drug dissolution. Chemical 
modification of drugs has also been investigated for solubility improvement of 
poorly water soluble drugs; prodrugs are the bio-reversible form of the original 
2 
 
drug which can be obtained by derivatisation of the parent drug. Prodrugs 
include complex and salt formation of the parent drug which has higher 
solubility. In prodrugs, important attempts have been made by introducing 
ionisable components in the parent drug entity based on its ionisation 
capacity. This method has limitations due to poor ionisation ability of the 
parent drug. Salt formation of the parent drug depends on the acidic and 
basic ability of the drug, only ionisable drug molecules can be converted into 
highly soluble salts. This technique is limited to the weak acidic and basic 
nature of pharmaceutical drugs which may not be suitable for neutral drugs 
for example griseofulvin.  
Crystal engineering for solubility improvement is emerging as an excellent 
approach and has proven its potential for many BCS class II drugs. Two 
among various crystal engineering approaches which are adopted for 
solubility improvement are cocrystallisation (cocrystals) and amorphisation 
(solid dispersion). Current European Medicines Agency (EMA) guidelines 
have given a classification for types of solids and its subdivision into cocrystal 
and amorphous system ( 
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Figure 1.1).  
 
 
 
Figure 1.1: Subdivision of solid state material of an active moiety (European 
Medicine Agency, 2014) 
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Cocrystals are generally modified chemical entities which involve hydrogen 
bonding between a low water soluble active pharmaceutical drug and GRAS 
(generally regarded as safe) molecules (Schultheiss and Newman, 2009). 
Generally GRAS molecule can vary from dicarboxylic weak acids to highly 
soluble entities. Several techniques have been reported for cocrystallisation 
of pharmaceutical drugs using various GRAS molecules. Solution based 
cocrystallisation is a common technique to obtain pure cocrystals of the 
parent drug using generally an organic solvent alone or their mixture in 
specified ratios. Grinding/ co-grinding and liquid assisted grinding are some of 
the common methods of cocrystallisation (Sladkova, et al. 2014). Many milling 
technologies have also been investigated for cocrystallisation such as ball 
mill, vibratory mill or kneading (Balaz, 2008). Many advanced techniques 
have emerged in crystal engineering for cocrystal formation such as hot melt 
extrusion (HME), ultrasound techniques, microwaves, spherical 
cocrystallisation and rotary controlled vaporization from a solvent mixture 
(Pagire, et al., 2013, Aher, et al., 2010). All the solvent assisted techniques 
for cocrystal formation have a major drawback of stability; the solvent 
assisted processes show destabilisation over time. Solvent free techniques 
provide an advantage over solvent assisted techniques because of better 
stability which are more stable for long periods of time. Details of these 
techniques and processes are reviewed in the next chapter. 
Solid dispersions are the most widely investigated crystal engineering based 
approach for solubility improvement of poorly water soluble drugs. Solid 
dispersions include the amorphisation of the active pharmaceutical ingredient 
into a suitable water soluble polymer matrix (Leuner, 2000). Active 
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pharmaceutical ingredients can be completely soluble in the polymer matrix or 
dispersed in particulate form. As stated earlier, reduction in particle size of 
drug to sufficient lower level can amorphise the drug with improved solubility 
(Khadka, et al. 2014). Homogenous mixing of two components in solid 
dispersion systems is important owing to their eutectic melting; uneven mixing 
may cause failure in achieving an amorphous system. Solid dispersion 
techniques have evolved with time based solvent based techniques and in 
recent years solvent free processing. Solvent free techniques include various 
milling technologies such as ball mill, planetary mill, vibratory mill etc. 
(Sareen, et al. 2012; Yang, et al. 2014). Other than milling technologies 
freeze drying has also been successfully used for solid dispersion preparation 
for a long period of time (Bandarkar and Khattab, 2011). Solvent based 
techniques for drug amorphisation include spray drying which is an excellent 
technique for preparation of solid dispersions but has stability issues due to 
the traces of the residual solvent present (Lakshman, et al., 2008). Solvent 
free processing techniques such as HME and various solvent free milling 
technologies can overcome this issue. Current study involves the use of HME 
and Solid State Shear Mill (S3M) for developing cocrystals and solid 
dispersions for selected pharmaceutical drugs. 
Hot melt extrusion technology has been adapted from the polymer extrusion 
industry and has found applications in the pharmaceutical industry in solid 
state processing of pharmaceutical drugs and polymers (Lakshman, et al., 
2008). Hot melt extrusion is a melt shear based technology which ensures 
homogenous mixing of the drug and polymer above the softening (glass 
transition (Tg)) temperature of the polymer (Kim, et al., 2011). Not all polymer 
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and drug combinations have ideal properties for the HME process. To enable 
them to be used for this process, often different additives have to be used 
such as plasticisers and Tg lowering components. Being a high temperature 
and shear process, many of the pharmaceutical polymers and low Tg drugs 
face the degradation problems in HME (Liu, et al., 2013). Use of suitable 
plasticisers which help to reduce the processing temperature, torque during 
process will help to reduce degradation. Recrystallisation from melt extruded 
products can be stimulated by the plasticiser present during stability. 
Plasticiser free processing of the drug polymer mixture may not be always 
possible in melt extrusion process for a chosen drug polymer combination. 
S3M process is another solvent free technology investigated for preparation 
of cocrystal and solid dispersion. S3M is very high shear based milling 
technology without external heating. Unlike HME, plasticiser free processing 
is possible with S3M with considerably lower residence time and high 
throughput. Through its three dimensional scissoring mechanical stress 
mechanism each part of polymer or molecule faces a high and equal shear 
during the process. This research is the first report of S3M technology for 
pharmaceutical applications. 
The current study involves the use of hot melt extrusion and high shear 
milling processes for the formation of cocrystals and amorphous systems for 
developing amorphous dosage forms for various pharmaceutical drugs and 
assessment of their pharmaceutical performance in terms of drug release, 
crystallinity and microscopic studies. 
Aims and objectives of current study can be summarised as, 
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Current research focuses on comparative studies between two solid state 
shear processing technologies HME and S3M for production of solid 
dispersions and cocrystals and their comparative pharmaceutical assessment 
studies in sense of physicochemical properties and there performance in 
terms of drug release. 
Objectives of current study are 
 To formulate pharmaceutical cocrystal and amorphous systems using 
hot melt extrusion and solid state shear mill 
 To investigate the use of different polymers and additives during 
processing on HME and S3M and their effect on product. 
 To study how variables of S3M and hot melt extrusion affect product 
performance in terms of drug release 
 To study the effect of polymer additives on cocrystal formation using 
S3M and hot melt extrusion 
 To compare the performance behaviour of plasticised amorphous 
systems (HME processed) and non-plasticised amorphous system 
(S3M processed) in terms of drug release. 
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Chapter 2. Background 
It is necessary that a drug should be in the solution form before it is absorbed 
through the membrane (Bikiaris, 2011). Around 40 % of new active 
pharmaceutical ingredients (APIs) and many of the APIs which are already on 
the market have poor water solubility. Solubility enhancement to improve 
bioavailability of poor water soluble APIs has remained a major challenge 
over recent years. As a result of low solubility a higher dose of API is required 
to achieve the same therapeutic effect (Serajuddin, et al. 2000). Nainar et al., 
(2012) explained the biopharmaceutical classification system (BCS) which 
divided APIs into four different classes based on their solubility and 
permeability (Table 2.1). 
Table 2.1: BCS classification for pharmaceutical APIs 
CLASS I 
High Soluble, High Permeable 
CLASS II 
Low Soluble, High Permeable 
CLASS III 
High Soluble, Low Permeable 
CLASS IV 
Low Soluble, Low Permeable 
As oral dosage forms such as tablets and capsules enjoy wide popularity, the 
BCS Class II APIs, which show dissolution limited absorption, have attracted 
maximum attention of pharmaceutical scientists over the last two decades. 
2.1 Solubility improvement approaches  
In the last two decades various formulation, particle and crystal engineering 
strategies have been developed to address the issue of poor water solubility 
of APIs. Surfactant based systems, inclusion complexes, particle size 
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reduction and crystal engineering approaches such as development of salts, 
polymorphs, stabilised amorphous form and recently cocrystals are commonly 
used approaches (Hanpin, 2012).  
Surfactants improve bioavailability of the API through enhanced solubilisation, 
wettability, dissolution and reduction in in-vivo precipitation (Serajjudin, 1998). 
Surfactant based improvement is useful in liquid as well as solid oral delivery 
systems. One of the major challenges in the use of surfactant is significant 
variation in Critical Miceller Concentration (CMC) depending on the sources 
which may affect product performance. Cyclodextrin (CD) complexes of APIs 
especially with substituted β-cyclodextrins having very high water solubility 
such as hydroxypropyl β-cyclodextrin and sulfo-butyl ether β-cyclodextrin are 
commonly used.  The API molecule is accommodated in the hydrophobic 
core of the cyclodextrin and is released under physiological conditions. It has 
been recently reported that inclusion of a small amount of water-soluble 
polymers such as polyvinylpyrrolidone (PVP) can improve complexation 
efficiency (Shah et al., 2011). It is important that the API CD binding constant 
should not be too high, otherwise the complex will not readily dissociate.  The 
high molecular weight of cyclodextrins is a major challenge especially for high 
dose APIs.  
Particle size reduction to the submicron size is carried out to improve API 
solubility. Size reduction technologies include top-down approaches such as 
milling, high pressure homogenisation (Romanski et al., 2011) and various 
bottom-up approaches include ultrasound assisted crystallisation (Aher, et al. 
2010) and supercritical fluid crystallisation (Majerik, et al., 2007). Bead milling 
technologies like Elan’s Nanocrystal® have demonstrated significant 
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commercial success in the area of nanosuspensions. Stabilisation of 
nanoparticulate systems is a major challenge. 
As a focus of this research is comparative evaluation of two technologies to 
obtain stabilised amorphous forms and cocrystals, a detailed account of these 
solid forms and related technologies will be discussed here. 
The API in solid form can exist in various crystal or amorphous states 
depending on the components of the system and order of arrangement as 
shown in Figure 2.1. 
 
Figure 2.1: Solid state forms of APIs 
A salt contains an ionisable drug molecule combined with a counter ion to 
form a neutral complex. Salts exhibit higher solubility than that of parent 
compounds having weak acidic or basic characteristics. There are reports of 
lipophilic salts of drug such as propranolol oleate (Crowly et al, 2007) which 
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have lower water solubility compared to the parent API.  Salt formation of the 
parent API has shown tremendous improvement in API dissolution, which has 
increased the number of improved bioavailability APIs in the pharmaceutical 
industry. In some cases, a salt after dissolution transforms into respective 
acid and base, which may precipitate depending on solubility. It may also 
cause high alkalinity or acidity at the site of absorption leading to patient 
compliance issues. Salt formation is not possible for neutral or weakly 
ionisable APIs.  
Solvates can be defined as crystal structures containing stoichiometric or 
non-stoichiometric proportions of the solvent; if the solvent is water then it is 
termed a hydrate. The solubility of the anhydrous form of an API is higher 
compared to the hydrate, which can be attributed to the thermodynamic 
stability of the hydrate due to hydrogen bonds between the parent compound 
and water (Bartolomei, et al., 2000). Hydrates can be converted into the 
anhydrous form of API by application of heat, temperature and stress. 
A polymorph is a solid crystalline phase, which exhibits the possibility of at 
least two different molecular arrangements of the compound in the solid state 
(Kulkarni, et al. 2013). Polymorphs show differences in properties such as 
solubility, melting point, dissolution rate, lattice energy, density, optical and 
electrical properties, vapour pressure, hardness etc. Generally, the most 
stable polymorph of the drug is commercially used. The transformation of 
crystal from one form to another can occur under various conditions. 
Development and stabilisation of metastable polymorphs has been explored 
to achieve higher dissolution rates. For example, Kulkarni et al., (2013) 
produced a stabilised metastable triclinic form of artemesinin through a hot 
12 
 
extrusion technique, which showed about three times faster dissolution 
compared to the stable commercially available orthorhombic form. 
2.2 Stabilised amorphous form/Solid dispersion 
The amorphous state of solid exhibits a short range molecular order but has 
no long range order of packing molecule like in crystalline forms. In other 
words, the molecules are arranged in an ordered form in relation to the 
neighbouring molecule but such order does not exist all over the solid and the 
molecular confirmation is also flexible. Occurrence of amorphous forms is 
common in proteins, peptides, polymers and some sugars. Though 
amorphous solids show high solubility and dissolution rate their physical and 
chemical stability is lower than the crystalline form. The amorphous form 
exhibits a glass transition temperature (Tg) where due to molecular mobility it 
is transformed into a rubbery state. The amorphous form has a tendency to 
transform into a more stable crystalline form. If a stable crystalline form exists, 
an amorphous form will transform into the crystalline form upon if sufficient 
molecular mobility is allowed. The API can be maintained in the amorphous 
form by dispersing it in a high Tg substance and storing it at least 50 °C below 
the Tg of the mixture. Materials such as citric acid, urea, mannitol and 
polymers having high Tg and tendency to form hydrogen bonds are used to 
stabilise the amorphous form of a drug. The dispersion of an API into the 
matrix of these small molecules or polymers is termed solid dispersion and 
depending on the state of the dispersion these can be further defined as 
eutectic mixtures, solid solutions or solid suspensions (Table 2.2). 
Table 2.2: Types of solid dispersion (Adapted from Singh et al. 2011) 
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Sr 
No. 
Type Comment No. of 
phases 
API Matrix 
 
* ** 
1 Eutectic Very first type of solid 
dispersion reported 
2 C C 
2 Crystalline matrix 
precipitation 
Less explored 2 A C 
3 Solid solution   
 Continuous solid 
solution 
High miscibility at all 
ratios 
1 M C 
 Discontinuous 
solid solution 
Molecular dispersion of 
API with partial 
miscibility 
2 M C 
 Substitutional 
solution 
API is molecularly 
dispersed with 
difference in molecular 
diameter between two 
phases. In this the API 
and matrix are 
subsititutional  which 
can be continuous or 
discontinuous. 
1 or 2 M C 
 Interstitial solid 
solutions 
Less miscible, 
discontinuous with 
molecular diameter of 
API 59% of that of 
matrix 
 
2 M C 
4 Glass suspension Cooling rate decides 
the size of dispersed 
API in matrix after 
2 C A 
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crystallisation of drug in 
amorphous matrix. 
5 Glass suspension Cooling rate decides 
the size of dispersed 
API in matrix after 
crystallisation of API in 
amorphous matrix. 
2 A A 
6 Glass solution API and matrix should 
possess good miscibility 
or solid solubility or 
complex formation upon 
fast cooling or 
evaporation during 
preparation  
1 M A 
*A: matrix in amorphous state, C: matrix in crystalline state 
**A: Molecular dispersion of API cluster in amorphous form in matrix, C: crystalline 
API dispersed in the matrix, M: Molecular dispersion of the API throughout the matrix 
Another classification based on types of carrier used categorises solid 
dispersion into three generations (Figure 2.2)  
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Figure 2.2: Classification of solid dispersion 
The eutectic mixtures and the solid dispersions where the polymeric matrix is 
crystalline such as solid solutions are considered first generation solid 
dispersions (polyethylene glycols, urea and polyoxyethylene-
polyoxypropylene (Pluronic®) Leunar, 2000). Systems containing amorphous 
matrix states such as glass solutions and glass suspensions are considered 
as second generation solid dispersion. Examples of amorphous polymers 
include PVP (Simonelli, et al., 1969), Polyethylene glycols (Guyot, et al., 
1995), polymethacrylates (Ceballos, et al., 2005) and natural polymers such 
as hydroxypropylmethylcellulose (HPMC), ethyl cellulose (Ohara, et al., 
2005), hydroxypropylcellulose (Tanaka, et al., 2005) which are cellulose 
derivatives and starch derivates, like cyclodextrins (Rodier, et al., 2005)). 
Recently there are some reports where a surfactant has been added in 
addition to the polymer and these are classified as third generation solid 
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dispersions for example gelucire 44/14 (Chauhan, et al., 2005) and 
poloxamer 407 (Majerik, et al., 2007).  
2.2.1  Dissolution from solid dispersions 
Solid dispersions being one of the major focus areas in solubility 
enhancement involve making APIs miscible in a suitable polymer matrix in 
desired ratio (Leuner, 2000).  
The steps in the dissolution of a typical oral dosage form are shown in Figure 
2.3. The modified Noyes and Whitney equation (Hattori, et al., 2013) explains 
the relationship between rate of dissolution and various factors. 
  
  
 
        
 
 
where, dC/dt is rate of dissolution, A is the surface area available for 
dissolution, D is the diffusion coefficient, Cs is the solubility of the compound 
in the dissolution medium, C is the concentration of API at time t and h is the 
thickness of boundary layer near to the surface of the dissolving material. 
 
................. (1) 
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Figure 2.3: Steps in the dissolution of solid dosage forms (adopted from 
Gibaldi, 1977) 
In conventional tablet and capsule dosage forms generally the particle size of 
the API is more than 5 μm whereas; in solid dispersions the effect of surface 
area is not important as the API is molecularly dispersed within the matrix 
(Serajuddin 1999).  
The rate of API absorption is dependent on the concentration of API present 
in solution form at the site of absorption. High apparent solubility leads to 
achievement of higher API concentration in the solution and in turn faster 
absorption. If the rate of API dissolution is too high it causes supersaturation 
of the API in the GI fluids. In such cases a spring effect is observed due to 
precipitation of the API, as shown in Figure 2.4. 
In solid dispersions the polymer matrix maintains the API in a dissolved or 
dispersed state throughout its shelf life. If the dispersion matrix is hydrophilic 
it enhances apparent solubility of the API and accelerates its dissolution, 
which provides higher concentration at the site of absorption leading to an 
improvement in bioavailability. Sometimes the bioavailability enhancement is 
not achieved because high API concentration is not maintained long enough 
as the API precipitates out, which is the “spring effect”. Polymers help to 
maintain the solution concentration by inhibiting nucleation that is the 
“parachute effect”. Hence in solid dispersions polymers enhance apparent 
solubility and also help in avoiding the spring effect.  
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Figure 2.4:Representation of spring-parachute effect. (Babu and Nangia, 
2011) 
Li et al., (2013) compared the ability of different cellulose ester derivatives in 
solubility enhancement and stability of an ellagic acid solid dispersion. PVP 
shows high solubility enhancement in 0.1 N HCl but the high supersaturation 
levels caused precipitation of ellagic acid. Cellulose esters showed 
incomplete release at pH 6.8 but avoided any precipitation; therefore cellulose 
esters were concluded to be more useful compared to PVP.   
Mogal et al., (2012) studied the role of porosity in solid dispersions in faster 
API release, compared to other formulations. It was suggested that the 
reticular polymer which forms a web like structure (Figure 2.5) which shows a 
slower dissolution rate compared to solid dispersions prepared using linear 
polymers. 
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Figure 2.5: Porosity variation according to the type of polymer (Kim et al., 
2011) 
2.2.2 Methods of preparation of solid dispersion 
Though Sekiguchi and Obi reported the concept of solid dispersions in 1961, 
commercial exploitation of this concept was very limited until recently. A 
review of the status of solid dispersions  by Serajuddin  published in 1999 
(Serajuddin, 1999) suggested that slow progress towards commercialisation 
in almost 40 years due to a need for scalable manufacturing technologies and 
stability issues associated with the amorphous state. Solvent evaporation and 
melt fusion techniques were explored in depth.  
In solvent evaporation the API and polymer are dissolved in a solvent and the 
solvent is evaporated to achieve a uniform dispersion of API in the polymer 
matrix. Chiou and Riegelman (1971) first reported use of this technique 
griseofulvin - PEG 6000 pair. The main challenge is selection of a solvent 
which has the ability to dissolve a hydrophobic API and hydrophilic polymer in 
the desired ratio. For example, for preparation of a solid dispersion containing 
10% griseofulvin in PEG 6000 the solid: ethanol ratio was 1:100. The 
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requirement of high amounts of solvent makes the process expensive and 
environment of unfriendly. Attempts were made to reduce the solvent amount 
using solvent mixtures, surfactants, pH optimisation which could bring down 
the solid: solvent ratio in the range of 1:25 to 1:60 but still issues like residual 
solvent and long duration of evaporation remained the major limiting factors 
(Serajuddin, 1999).  
Spray drying has proved to be a scalable and commercially viable technology 
for solid dispersion. Though spray dried solid dispersions have been 
successfully launched it still suffers from the challenges associated with use 
of solvent (Paradkar et al., 2004).  
2.2.2.1 Melting method 
Sekiguchi prepared solid dispersion by melting using urea as a carrier 
(Sekiguchi, 1961). The melting method consists of melting of the API and 
carrier in a desired ratio to form a homogenous molten mixture and its 
subsequent cooling using a suitable cooling method. Later this solid form is 
pulverised and formulated into a suitable dosage form (Owusu-Ababio, 1998). 
Several drawbacks are associated with melting methods, when the API 
polymer mixture is subjected to high temperature; there are chances of 
degradation attributed to the thermal properties of either of the components or 
interaction between the two components at high temperature (Serajuddin, 
1999). The molten mass during cooling may crystallise or entrap moisture 
(Venkitachalam, 1992). Miscibility of the molten components is essential to 
achieve homogeneity in the final product (Lordi, 1984). Depending on the 
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process the nature of the end product and its physicochemical properties will 
change and in turn affect API release. 
Recently, Taylor’s group reported the role of polymers in inhibition of 
nucleation and growth of paracetamol crystals from the melt. Polyacrylic acid 
enhanced nucleation rate whereas HPMCAS inhibited nucleation (Ilevbare et 
al., 2012). Polyacrylic acid and PVP were found to be good inhibitors of 
crystal growth while HPMCAS had no effect. This investigation provides an 
approach for understanding and selection of polymers for solid dispersions to 
be prepared by melt method. 
Melt extrusion has proved to be a solvent free, scalable approach for 
manufacturing of solid dispersions and Kaletra (Zolidex) was the first product 
introduced by Abbott using this technology (Breitenbach, 2002). Further 
details of melt extrusion technology are provided in the later parts of this 
section. 
Although melting methods have several disadvantages, hot melt extrusion 
can be used as the best tool for effective melt solid dispersion manufacturing 
(Breitenbach, 2002). Hot melt extrusion is a modified melt and shear based 
manufacturing process which can assure effective mixing of two components 
irrespective of their individual melting differences by applying simultaneous 
stress and temperature. Hot melt extrusion has proven to be a viable option 
for development of oral delivery systems for various APIs.   
There are many reports on solid dispersions by hot melt extrusion which are 
summarised below, 
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Lakshman, (2008) studied the effect and applications of HME in development 
of physic-chemically stable sold dispersions for low water soluble drugs. The 
solid dispersions were prepared by solvent evaporation and HME. The drug 
loading achieved was 20% with low or no degradation. The use of surfactant 
improved dissolution. Sarode, (2013) studied the effect of drug polymer 
interactions on the supersaturation levels in solid dispersions. Indomethacin, 
Itraconazole and griseofulvin with hydrophilic polymers such as Eudragit 
EPO, Eudragit L-100-55, Eudragit L-100, HPMCAS-LF, HPMCAS-MF, 
Pharmacoat 603, and Kollidon VA-64 were used. The improved dissolution 
profiles of resulting solid dispersions were contributed to drug polymer 
interaction during extrusion.  
In case of thermally unstable drugs polymer combination approaches were 
used to avoid any degradation during extrusion. Liu et al., (2013) studied the 
use of polymer combination using carbamazepine as model drug with 
Kollidon® VA64, Soluplus® and Eudragit® EPO. The drug polymer miscibility 
at temperatures below melting point of carbamazepine was achieved. Solid 
dispersions with soluplus and EPO combination were most stable. HME 
processed solid dispersions have been compared with other processes, Dong 
et al., (2008) studied the effect of different processes on the solid state 
characteristics of the solid dispersions. HME process yielded more stable 
solid dispersion when compared against co-precipitation. The suitability of 
HME process for various drugs have been examined in combination with 
suitable polymers, Chokshi et al., (2005) studied the suitability of HME 
process for indomethacin solid dispersions using PVP and poloxomer 
polymers, Indomethacin poloxomer combination showed poor solubility. 
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Zhang and McGinity, (1999) have studied the use of HME for manufacturing 
sustained release tablets, Chlorpheniramine maleate was used as model drug 
and polyethylene oxide (PEO) as polymer, the resultant tablets were stable 
and dissolution of these tablets were controlled by swelling phenomena by 
PEO. 
Recently, McGinity’s group reported a novel continuous technology KinetiSol® 
(Hughey et al., 2010) (Little and Rice et al. (2004) US6709146) based on 
thermokinetic mixing. Thermokinetic mixing involves application of very high 
mechanochemical stress   through friction for a very short period of time, 
which helps avoid resultant degradation due to the high stress environment 
(Figure 2.6). The mechanism is described as fusion owing to the shear and 
fiction, which help to process and transform APIs in amorphous state in a very 
short residence time with minimum thermal exposure. This process has been 
utilised for manufacturing solid dispersions of many APIs such as 
itraconazole, meloxicam etc. Formulation of low melting APIs is also possible 
using this technique due low thermal exposure to avoid resultant degradation. 
Plasticiser free processing is claimed to be one of the major advantages of 
this technology. 
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Figure 2.6: Thermokinetic Mixer (Little and Rice, US6709146) 
2.2.2.2 Milling 
Milling technologies have been used in the pharmaceutical industry for size 
reduction purpose for many years. Extensive size reduction during milling can 
lead to a breakdown of crystalline structures of API to very fine powder in the 
amorphous state. There are a few reports of use of different types of mills to 
obtain solid dispersions. 
Zhao et al., (2011) used laboratory planetary scale ball mill with Tanshinone 
IIA as model drug, poloxomer 188 was used as surfactant. The resultant ball 
milled solid dispersion showed improved dissolution rate with improved 
stability for 60 days. Shin et al., (1998) used ceramic ball mill to prepare 
furosemide solid dispersion with crosspovidone, the resultant was stable over 
one year at room temperature, it was concluded that drug dissolution was 
improved due to improved drug polymer interaction. 
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Nokhodchi et al., (2007) used vibratory ball mill for preparation of solid 
dispersion for chlordiazepoxide. The solid dispersion by ball mill was 
compared with solvent evaporated dispersion which showed higher drug 
release. Al-obaidia et al., (2013) studied solid dispersion for griseofulvin with 
hydroxypropyl methyl cellulose acetate succinate. Retsch MM20 95 vibratory 
ball mill was able to form a good hydrogen bonding between drug and 
polymer. 
High energy ball mill is also a better process for converting drug polymer into 
amorphous state, Branham et al., (2012) prepared a saquinavirmesylate solid 
dispersion using high energy ball mill. They could achieve unique non-porous 
particles with unique structural features, there was no metal contamination 
observed upon 15 hours of milling.      
Ball milling is mainly a batch process which requires long milling times of at 
least a few hours to achieve the amorphous state and the control on product 
quality is difficult. 
The major focus of this research is evaluation of a continuous solid state 
shear milling (S3M) technology developed at Sichuan University, for 
processing of solid dispersions. The details of S3M technology are discussed 
in later parts of this Chapter. 
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Table 2.3: FDA approved marketed solid dispersions (Huang and Dai, 2014) 
Product 
name 
Drug Polymer Dose 
(mg) 
Drug 
melting 
point 
(°C) 
Technology Approval 
year 
Cesamet Nabilone PVP 1 160 --- 1985 
Sporanox Itraconazole HPMC 100 166 Spray 
drying on 
sugar beads 
1992 
Prograf Tacrolimus HPMC 5 128 Spray 
drying 
1994 
Kaletra Lopinavir/ 
ritonavir 
PVP/VA 200/50 125/122 Melt 
extrusion 
2005 
Intelence Etravirine HPMC 200 265 Spray 
drying  
2008 
Zotress Everolimus HPMC 0.75 115 Spray 
drying 
2010 
Novir Ritonavir PVP/VA 100 122 Melt 
extrusion 
2010 
Onmel Itraconazole HPMC 200 166 Melt 
extrusion 
2010 
Incivek Telaprevir HPMCAS 375 246 Spray 
drying 
2011 
Zelboraf Vemurafenib HPMCAS 240 272 Co-
precipitation 
2011 
Kalydeco Ivacaftor HPMCAS 150 291 Spray 
drying 
2012 
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2.3 Cocrystallisation 
In recent year’s cocrystals have been widely explored for the dissolution rate 
enhancement of the poorly water soluble drugs. Cocrystals are 
multicomponent crystals containing components in a stoichiometric ratio. The 
components forming cocrystals are solid at ambient temperature and may be 
atoms, ions or molecules held by non-covalent bonding such as hydrogen or 
halogen bonds. (Jones et al.,2006). 
Desiraju (1995) was the first to report cocrystals as molecular complexes 
which include multicomponent systems bonded by intermolecular non-
covalent interactions. After much discussion a generally considered definition 
of a cocrystal as defined by Shan and Zaworotko (2008) is a cocrystal is a 
multiple component crystal in which all components are solid under ambient 
conditions when in their pure form. These components co-exist as a 
stoichiometric ratio of a target molecule or ion and a neutral molecular 
cocrystal former(s)” (Shan and Zaworotko, 2008).  
 Cocrystals are "solids that are crystalline materials composed of two or more 
molecules in the same crystal lattice", as per USFDA. An API and a co-former 
are the two components in pharmaceutical cocrystals. Cocrystals show 
significantly different physicochemical properties compared to that of the API. 
US FDA in its Novel drug applications (NDAs) or abbreviated new drug 
applications (ANDAs) approval claims of cocrystals requires 1. Need to 
investigate when the API and co-former interact and which kind of interaction 
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exists between them, unlike ionic interaction in salts, neutral or non-ionic 
interactions should exist. Generally the difference between pKa (ΔpKa) 
values of the API and co-former is less than zero, the proton transfer will be 
negligible which tends to form a cocrystal. If the ΔpKa difference is more than 
3 there will be a complete proton transfer and it will form a salt. When the 
ΔpKa value is between 0-3 then the ionization behaviour and extent of proton 
transfer is unpredictable. 
According to USFDA guidelines the API should dissociate from its co-former/ 
excipients before reaching to the site action. In case of a cocrystal the 'API-
co-former' complex should be treated as an intermediate product. Cocrystal 
containing pharmaceutical products is not considered to contain a new API 
but a specifically designed drug product intermediate which will contribute to 
its improved performance. 
2.3.1 Co-former selection 
As the co-former is an important part of successful cocrystal formation, co-
former selection has become a very crucial step, mainly based on "synthon" 
approaches (Desiraju, 1995). The co-former molecule should possess 
specific molecular fragments to form "supramolecular synthons". The synthon 
approach basically suggests that one particular group on the parent API and 
the co-former play an important role in successful cocrystallisation. Because 
of these co-formers with complementary functional groups should be 
selected. Some of the major molecular synthons used are carboxylic acid-
acid, amide-amide, acid-pyridine and the acid amide (Thakuria, et al., 2013). 
The synthon approach has some disadvantages that formation of 
supramolecules is not quantitative in the sense that even after formation a 
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supramolecule might not fit well into the ordered crystalline space.   A 
computational approach has been reported for selection of co-formers, based 
on the polarity and shape complementarity for   cocrystallisation (Qiao, et al., 
2011). Abramov et al., (2012) considered the influence of fluid phase 
thermodynamics for co-former selection, based on the comparative study of 
excess enthalpy of the API and co-former (Abramov et al., 2012). 
2.3.2 Methods of cocrystal formation 
To date, many methods have been reported for cocrystal formation. Among 
the reported techniques, solution cocrystallisation and grinding are the most 
commonly used and have been widely explored. Solution based methods 
include evaporation, reactive crystallisation and cooling crystallisation (Figure 
2.7). Grinding method generally includes solvent assisted grinding and neat 
grinding. 
 
Figure 2.7: Classification of cocrystal preparation methods 
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There has been an emergence of new techniques for cocrystal formation 
such as supercritical fluid cocrystallisation (Padrela et al. 2009), hot-stage 
microscopy (Berry et al. 2008), ultrasound assisted cocrystallisation (Aher et 
al. 2010), microwave assisted cocrystallisation (Pagire et al. 2013) and 
spherical cocrystallisation (Pagire et al. 2013). 
2.3.2.1 Solution crystallisation 
In solution crystallisation the two components are dissolved in a suitable 
solvent system and supersaturation is achieved to obtain a cocrystal phase. 
Supersaturation may be achieved by any conventional technique such as 
evaporation or cooling. 
The solution process is complex as it depends on solubility of the two 
components and rate of supersaturating the solution. Selection of suitable 
solvent or solvent mixture becomes more challenging in the case of non-
congruently soluble drug co-former pair for example caffeine: maleic acid 
(Aher et al., 2010) compared to congruently soluble pairs such as 
carbamazepine: saccharin (Pagire et al., 2013). Generally, a ternary phase 
diagram is used to select suitable compositions for cocrystallisation (Blagden 
et al., 2007). The major disadvantages of solution cocrystallisation include low 
yield, chances of unreacted components present as impurities, generation of 
polymorphs and solvates, degradation of API or co-former due to solvent 
based reactions such as hydrolysis.  
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2.3.2.2 Grinding method  
Grinding methods are categorised as neat grinding and solvent assisted 
grinding. Neat grinding or dry grinding is a solvent free technique  and 
involves a stoichiometric concentration of both the components subjected to 
grinding manually using a mortar and pestle or any mechanical mixing device 
such as a ball mill or a vibratory mill. Dry grinding needs one or both 
components to have a higher vapour pressure in the solid state (Friscic and 
Jones, 2009). Many cocrystal pairs have been reported to form cocrystals by 
dry grinding (Karki et al., 2009). The mechanism for dry grinding is reported 
by many researchers to include different types of intermediate phases, 
molecular level diffusion, eutectic formation or amorphous state in which one 
of the distinctive phase (gas, liquid or a amorphous solid) should exhibit 
higher mobility than the parent components (Friscic and Jones, 2009).   
Solvent assisted grinding or kneading is a wet grinding technique where 
mixing of the two components is assisted by use of a small amount of a 
suitable solvent (Shan et al., 2002). The improved mixing causes effective 
orientation and conformation with improved interfaces exposure and collision 
of the two components in the presence of solvent (Trask et al., 2004). The 
formation of cocrystal nuclei in solvent may enhance the overall 
cocrystallisation rate of the system and provide control of polymorphic 
transformation of the cocrystal. The solvent assisted grinding technique has 
been widely used for formation of new cocrystals as well in improvement of 
existing cocrystals (Weyna et al., 2009).   
There has been an emergence of new techniques for cocrystallisation in the 
last few years some of which are described below. 
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2.3.2.3 Supercritical fluid technology (SCF)  
SCF based crystal engineering has seen a large growth in the past decade in 
various applications for processing of materials and as a substitute to many 
solvent based processes.  The SCF as a solvent provides advantages such 
as high solubility for many molecules, miscibility with other organic solvents 
which can be used as an anti-solvent. The SCF technique uses lower amount 
of organic solvent compared to other conventional solution based processes 
hence can be utilised with thermally sensitive and structurally unstable APIs 
(Qiao et al., 2011). Padrela et al., (2009) studied the three important aspects 
of the supercritical fluid in terms of power of solvent, atomization improvement 
and anti-solvent effect for indomethacin - saccharin cocrystals with different 
sizes.  
2.3.2.4 Ultrasound assisted cocrystallisation 
Ultrasound waves can be used for the formation of cocrystal from solution or 
slurry. The Cavitation energy of ultrasound waves form cocrystal nuclei in 
solutions or slurries. Aher et al., (2013) reported ultrasound assisted solution 
crystallisation of a non-congruently soluble pair of caffeine - maleic acid. The 
process generated 2:1 cocrystals compared to a 1: 1 stoichiometry, which 
was attributed to high levels of supersaturation resulting from the application 
of ultrasound energy.  
2.3.2.5 Microwave assisted cocrystallisation 
Microwaves can be an effective energy source in cocrystal formation. It is 
believed that microwaves can excite the molecular dipole moment and excite 
the dipolar rotation, which helps to increase the molecular mobility of the 
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system (Pagire et al., 2013). This increased molecular mobility converts 
energy through dielectric heating. Pagire et al., has reported that caffeine 
maleic acid cocrystal 1:1 can be obtained using microwave heating which is 
attributed to controlled saturation at the interface of components and dielectric 
properties of the solvents used. 
Solvent based techniques have several disadvantages with regard to the 
stability of the cocrystal formed. Solvent free techniques other than grinding 
are emerging as alternative green techniques for cocrystal formation. HME 
and S3M or pan mill have been explored for formation of various cocrystals in 
the current study.   
2.3.2.6 Cocrystallisation by hot melt extrusion 
Solvent Free Continuous Cocrystallisation (SFCC) using hot melt extrusion is 
a continuous, green technique for cocrystal formation reported by Paradkar et 
al., (WO2010013035).  SFCC involves cocrystallisation by application of 
shear and heat in a twin screw extruder (Figure 2.8). The shear is controlled 
using a suitable screw geometry, screw speed and residence time. The 
temperature inducing processing is maintained at the melting point of the 
lower melting component or eutectic point of the mixture.  Melt extrusion 
involves efficient mixing and increased surface area of contact between the 
components which accelerates the non-covalent bonding between the API 
and co-former.  
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Figure 2.8:  Schematics of cocrystallisation by HME 
Application of SFCC has been demonstrated for successful cocrystallisation 
of many pairs such as ibuprofen - nicotinamide (1:1), carbamazepine - 
saccharin (1:1), carbamazepine - nicotinamide (1:1), caffeine - maleic acid 
(1:1 and 2:1), theophylline: maleic acid (1:1) etc. Dhumal et al. (2010) 
successfully prepared ibuprofen: nicotinamide (1:1) cocrystals in the form of 
agglomerates by hot melt extrusion (Dhumal et al., 2010). The additional 
advantage of the melt extrusion process is that it can form agglomerates of 
the cocrystals which is advantageous in downstream processing. The hot 
melt extrusion process is explained in detail in the later parts of this chapter. 
2.3.3  Characterisation of cocrystals 
Pharmaceutical cocrystals are generally characterised based on their 
chemical structure and physical properties. Cocrystal structural determination 
can be carried out by powder X-ray diffraction, single crystal X-ray 
crysatllography, Raman spectroscopy and Infrared spectroscopy (IR 
spectroscopy). Each cocrystal formed has a different crystallinity than the 
Co-former API 
Cocrystal 
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starting components, which can be differentiated by X-ray scattering 
(Schultheiss and Newman, 2009). The change in crystallinity pattern occurs 
due to the non-covalent hydrogen bond formation between the API and co-
former.  Raman and IR spectroscopy are mainly used for structural analysis 
and detecting hydrogen bonding between API and co-former. IR spectroscopy 
has proved to be an excellent technique for differentiating hydrogen bond 
formation in cocrystal entities (Jaysankar et al., 2006), whereas Raman 
spectroscopy is a unique technique to find out polymorphism in cocrystals 
and starting crystal component. 
Carbamazepine: saccharin (CBZ:SACC) 1:1 cocrystal exists in two 
polymorphic forms. FT-IR analysis helps understand and differentiate 
between two polymorphs of CBZ: SACC 1:1 cocrystal polymorphs. Polymorph 
I shows -N-H functional bond streching at 3500-3300 cm-1, whereas in case of 
polymorph II the -N-H stretching can be seen at 3430 cm-1 and 3350 cm-1 
(Portar et al. 2008). Differential scanning calorimetry (DSC) and hot stage 
microscopy are used as tools for screening as well as characterisation of 
cocrystal including detection of polymorphs and unreacted components. 
To study crystal shape and size properties, microscopic studies like scanning 
electron microscopy (SEM) can be used. Surface energy measurement is one 
of the most important aspects of cocrystal characterisation processed by 
different shear based processes HME and S3M. The change in crystal habits 
and surface properties of cocrystals by different methods will show 
differences in surface energies which will affect the overall pharmaceutical 
performance. Surface heterogeneity measurement will provide an idea about 
the change in surface energy of the respective material. Differential vapour 
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sorption analysis is another important tool to study the behaviour of the water 
vapour sorption by different cocrystals and the amount of vapour sorbed can 
be correlated to the total crystalline content of system.  
Both the approaches can be the solution for low water solubility issues of 
selected BCS class II drugs. Solid dispersions mainly deals with the making 
drug amorphous by solubilising or dispersing it in polymer matrix whereas in 
case of cocrystal the conversion of drug into a cocrystalline complex by 
bonding with co-former. The characterisation method and processes used for 
solid dispersions and cocrystals can be used for each other, for example 
HME, S3M like solid state high shear processes can be used for 
manufacturing solid dispersions as well as cocrystals. Characterisation 
method will include same all basic technologies such as thermogravemetric 
analysis (DSC), X-ray diffraction analysis, FT-IR, NIR and dissolution studies. 
DSC analysis will focus on the absence of melting endotherm for drug in solid 
dispersion whereas in case of cocrystal it will focus on typical endotherm 
generated by newly formed cocrystal which will be different from drug and co-
former. In case of X-ray diffraction analysis due to the absence of any 
crystalline entity in solid dispersion will confirm its amorphous nature whereas 
in case of cocrystal there will be unique crystalline pattern will be observed 
which will be different from both drug and co-former. 
Advantages of solid dispersion over cocrystals will be more based on the 
nature and structure of drug molecule. If drug molecule does not have 
hydrogen bond forming ability with co-former or if it does not have 
complementary functional group to form hydrogen bond with the co-former, in 
such case forming solid dispersion for that particular drug will be more 
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advisable. Disadvantage of solid dispersion cab be focussed on the stability 
issues of the system, amorphous systems are generally high energy systems 
which usually tend to convert into crystalline form and hence disturbing or 
breaking the amorphous nature. Disadvantage of cocrystal formulation can be 
owed to nature of process, unlike solution crystallisation one has to optimised 
any other process to higher precision to get phase pure cocrystal.  
It will be more convenient to choose one approach among solid dispersion 
and cocrystal depending upon nature of drug, its functional group, its ability to 
form amorphous system, its ability to form cocrystals etc. In terms of scale up 
it will very challenging to confirm which approach will be better than other as 
both the approaches solves the low solubility issues related with drug and its 
other physicochemical properties. Performance of both the system will be 
based more on the need of drug release pattern, stability of the system. It will 
not be wise to choose one over other in terms of their performance because 
performance will vary according to the need of the formulation. In term of 
sustained, controlled release of drug solid dispersion will be better option than 
cocrystal whereas in terms of rapid release vice versa.  In terms of scalability 
and economic point of view it will be difficult to compare directly which will be 
more feasible and cost effective. It will be wiser to say the nature of starting 
material will decide the total cost and scalability challenge for solid dispersion 
and cocrystals. It will change with type of drug, polymer and co-former 
respectively.  
The current study has also explored formulation of solid dispersion system 
using different polymer and processes. 
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2.4 Processing technologies 
Cocrystal and solid dispersion technologies have proved their potential in 
solubility enhancement and have been widely accepted by the industry. The 
current study includes the solid state processing of pharmaceutical drugs, co-
formers and different polymers for continuous manufacturing of cocrystals 
and solid dispersion dosage forms. The two solid state processing techniques 
adopted are,  
1. Hot melt extrusion and 
2. Solid state shear milling (S3M/ Pan Mill) 
2.4.1 Hot melt extrusion 
Since its introduction into the pharmaceutical industry hot melt extrusion has 
proven to be a useful complementary technique compared to routine 
pharmaceutical processes.  
2.4.1.1 Hot Melt Extrusion overview 
Hot melt extrusion technology is a very commonly used technique in the 
plastics industry for the extrusion of different plastics and polymers to achieve 
mixing and to tailor the properties of the polymer composites (Kaufman and 
Falcetta,1977). 
The plastics industry extruder has been modified for application in the 
pharmaceutical industry. Pharmaceutical grade extruders use stainless steel 
(SS 316) contact parts, have improved temperature control and are designed 
to achieve easy cleaning.  
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Extruders can be divided into two types (Crowley et al., 2007), namely ram 
extruders and screw extruders. A broad classification of extruders is given in 
Figure 2.9, 
 
Figure 2.9:  Various types of hot melt extruder 
Ram extrusion is also called vertical extrusion, which involves the use of a 
piston to force a molten polymer through a die of desired shape. There are no 
specific mixing mechanisms in the ram extruder, the cylindrical conveying 
compartment in which premixed polymer blend is kept at a required 
temperature profile, once the polymer blend softens it is then forced through 
the desired die with the use of ram piston to achieve a required shape. It is 
difficult to achieve homogenous extrudates using ram extrusion because of a 
lack of an effective mixing mechanism which can be overcome by screw 
extrusion.     
Extruder 
RAM 
Screw 
Extruder 
Single Screw 
Extruder  
Flood 
Fed 
Starve 
Fed 
Twin Screw 
Extruder  
Co-rotating 
Intermeshing 
Non-
intermeshing 
Counter-rotating 
Intermeshing 
Non-
intermeshing 
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A typical HME process involves three important steps, a) upstream 
processing which involves feeding of the material (polymer and API) b) 
compounding or extrusion step which involves melting, mixing and discharge 
of the homogenise molten mass, c) downstream steps which involve cooling 
and shaping of the extrudates also called pelletizing. The steps are shown in 
Figure 2.10.  
 
Figure 2.10: Hot melt extrusion steps (Courtesy Particle science, 2011) 
Screw extruders are again divided into two types, single screw and twin screw 
extruders (Figure 2.11).  A single screw extruder is generally used for melt 
conveying purposes and does not provide significant mixing. A twin screw 
extruder is composed of two screws placed side by side with range of 
configurations and different zones. The molten mass is transported and 
sheared until the end zone where the extruded product is collected. Twin 
screw extrusion is used where there is need for effective homogeneity in the 
end product.    
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Figure 2.11: Representative images for single and twin screw extruder 
(Courtesy Particle science 2011). 
The movement of the two screws in a twin screw extruder can be co-rotating 
or counter-rotating (Figure 2.12). Counter rotating screws involve high shear 
compared to co rotating screws, so whenever there is a need for high stress 
to deform and process material, counter rotating screws are preferred over 
co-rotating where conveying of material is required at a given temperature 
with optimum mixing, co-rotating screws are preferred. The high stress 
involved in the extrusion process with counter rotating screws may cause 
material entrapment, high pressure and lower output whereas co-rotating 
screws are easier to operate (Breitenbach, 2002). 
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Figure 2.12: Counter rotating and co-rotating screws (Courtesy Particle 
science 2011) 
The operation of a pharmaceutical extruder involves the following steps. a) 
The extruder preheated to get the optimum temperature profile before adding 
the drug polymer mixture, the different zones are adjusted to different set 
temperatures according to the ease of extrusion process and according to the 
melting temperature profile of the carrier polymer and drug mixture. 
Preheating helps to melt the polymer effectively and avoids the barrel 
jamming and creating the high torque which may start accumulating unmelted 
drug polymer mixture (Doetsch, 2003). b) The polymer drug mixture melts in 
the melting zone where temperature is maintained based on the melting or 
eutectic point and rheological properties of the mixture. The forward 
movement of the material is caused by the shear applied between the screw 
and barrel wall and by forward movement of the conveying screws which help 
to deliver the mixture to the die. Material is subjected to higher friction along 
the wall of the barrel and less friction between the screws (Luker, 2003). 
The current hot melt extrusion studies have done using a Thermo Scientific 
Pharmalab 16mm twin screw extruder (Figure 2.13) 
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Figure 2.13: Thermo Fisher Pharmalab 16mm extruder (Thermoscientific, 
2012) 
Many low Tg drugs cannot be processed through hot melt extrusion due to 
potential degradation (Crowely et al., 2007). Residence time is relatively high 
in the case of melt extrusion which may result in degradation of some APIs 
(Crowely et al., 2007). Die blocking is another problem in the case of melt 
extrusion, in many cases temperature of extrusion process kept at Tg of the 
carrier polymer, but it cannot assure effective mixing of the drug in polymer 
matrix as this unmolten mass creates huge pressure in the system and 
causes die blocking. Use of plasticizers due to these problems has become 
common in extrusion processes for many polymer drug combinations. 
Plasticisation affects the physicochemical properties, stability and 
downstream processability of the extrudates (Bounartzi et al., 2014).  
The energy consumption in hot melt extrusion processing is generally 
governed by torque levels and temperature during processing. The energy 
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consumption during melt extrusion can be reduced by use of a suitable 
plasticiser.   
Downstream operations involve milling of melt extruded products to formulate 
them into suitable dosage forms such as tablets and capsules. The reduction 
in energy consumption during downstream processing of the extrudates is 
important as it will have direct effect on stability of the milled materials.  
2.4.2 Solid state shear mill (S3M) 
A solid state shear mill (Xu et al., 1996) based on the pan mill design has 
been developed at Sichuan University, China. S3M is a continuous milling 
technology and differs from other milling technology in its mechanochemical 
behaviour (Balaz, 2008). S3M is a pan mill designed in such a way that it will 
subject material to ultra-high shear and stress conditions by three principle 
processes namely pulverisation, high shear mixing and stress reaction 
caused due to high shear. The stress created during processing plays an 
important role in mechanochemistry. This mill has been used successfully for 
mechanochemical applications ranging from pulverisation, depolymerisation, 
and composite formation and grafting which are summarised in the next 
section. 
A schematic diagram showing the design of pan mill is shown in Figure 2.14. 
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Figure 2.14: Pan mill equipment design (Xu et al., 1996) 
The S3M consists of two in-laid pans, a rotar and a stator made up of wear 
resistant materials with specially treated surfaces. The pans have specifically 
engineered diametrical lines equally engraved into the surface (Figure 2.15) 
which create high shear during milling, an ideal feature for particle size 
reduction. 
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Figure 2.15: Typical pan surface  
The stator is fixed on the equipment case and a rotor pan is mounted on the 
axis attached with motor. The motor power varies between 2-20 kW, 
depending upon mode of equipment. The pressure exerted on the pan can be 
adjusted with the handle which can be varied in the range 800-10000 N. Pan 
mill speed can be adjusted in the range of 10-200 rpm. The system is sealed 
and in the advanced version there is provision for circulation of gas or water 
in the jacket of the moving pan for temperature control. S3M is designed with 
different modes horizontal, vertical or series (two or three system one below 
other) for a more efficient milling process.   
Both the surfaces of the stationary and moving pans are equally divided into a 
series of diametrical lines. On each region there are several bevels and the 
ridges of the bevels are parallel to dividing lines. The pair of pans are placed 
facing each other such that the bevels and ridges of both pans creating many 
unit cells. The shape and volume of these unit cells changes during 
movement of the moving pan on the stationary pan, resulting reduction in 
particle size. It forms a three dimensional schemes because of these bevels 
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and ridges during movement of the moving pan. Theoretical analysis and 
optimization of these ingenious structures has led to the formation of pan mill 
equipment a schematic of the pans is shown in Figure 2.16, 
 
Figure 2.16: a) Pattern of moving pan on stationary pan, b) Three dimensional 
scheme for unit cell CDEF-CHGB (Xu et al., 1996) 
The characteristic shear mechanism in S3M involves three steps, stress 
activation, stress degradation and stress synthesis. Simultaneous application 
of very high shear and stress on the material during the S3M process causes 
generation of new surfaces and may also rupture of bonds and formation of 
new bonds which initiates the formation of new structures (Xu et al., 1996). 
These high stresses may enhance elongation of the bonds between polymers 
and additive material and breaking bonds to form new surfaces which help to 
generate free radicals, cross-linking and branching.  
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Various polymers have been processed on S3M mostly higher molecular 
weight plastic polymers have been processed on the solid state shear mill 
such as polypropylene, polystyrene, poly (vinyl chloride), polyethylene with 
respect to size reduction, nanocomposite preparation and solid state grafting. 
S3M technology has been applied for processing of plastic materials and 
higher molecular weight polymers. 
Zhang et al., (2007) has studied morphological and structural development of 
hardwood cellulose during mechanochemical pre-treatment using S3M. The 
mechanochemical properties were changed drastically in case of cellulose 
wood. The characteristic properties including particle size, molecular 
structure, and crystal structure were analysed by particle size analyser SEM, 
FT-IR and wide angle X-ray analysis. The thermal stability of S3M processed 
cellulose wood showed good thermal stability and higher solubility in aqueous 
alkali. S3M application in case of rubber polymer has been investigated 
widely, Zhu et al., (2010) has studied the effect of S3M for better 
processability and foamability of ground tire rubber. The resultant composite 
properties were improved upon S3M processing. The composite properties 
showed excellent foamability when compared against conventional melt 
method. 
S3M has been explored for pulverisation ability on different polymers. Wang 
et al., (2002) showed that the S3M processing parameters can be optimised 
for better pulverisation of the polymers. Effect of different processing 
parameters of S3M on pulverisation showed it can be improved as per 
requirement. The most effective S3M way to pulverise given polymers was 
found at low rotational speed and high load. Another S3M application includes 
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delamination of layered minerals. Shao et al., (2005) studied the intercalation 
and exfoliation of talc using S3M. It was observed that intercalation can be 
achieved using S3M without use of any liquid additive. 
Reduction in size of carbon nanotubes using S3M was achieved in case of 
polyamide 6 (Shao et al., 2006). The cutting of multi-walled carbon nanotubes 
gave significant reduction in size with straighter open ends; SEM studies 
revealed that there is homogenous dispersion of carbon nanotubes 
throughout polyamide 6. Size reduction being the major application for S3M, 
Lua and Wang, (2004) studied the formation of polypropylene/iron composite 
powders using S3M. It was observed that size reduction was scale down to 
nanometre level and the crystalline structure of polypropylene was completely 
disappeared. The size reduction to nanometre level is attributed to 
compression, stretching and fracture of cracks during S3M. Similar way Liu 
and Wang, studied the composite formation for high dielectric constant 
PP/BaTiO_3 using S3M. 
Xia et al., (2004) studied the preparation of polypropylene/carbon nanotubes 
composite powder by mechanochemical pulverisation using S3M. Liu et al., 
(2007) studied the preparation of high flame retardant polypropylene by 
loading it with magnesium hydroxide using S3M, it was observed that there 
was high degree of blending and dispersion with improved chemical 
interaction and compatibility. The melt flow ability and processability was also 
improved.  
S3M has been widely explored for solid state grafting of the higher molecular 
weight plastic polymers. Liu et al., (2008) studied the solid phase grafting of 
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hydroxymethyl acrylamide onto polypropylene using S3M. High shear and 
stress forced bonding in grafting was observed with macromolecular radical 
generation. The surface area was significantly improved due to size 
reduction. 
To improve mechanical properties of different composites S3M process can 
be modified as per the need of end product. Shao et al., (2006) studied the 
effect of S3M on polymer blends of polyamide and polypropylene. It was 
observed that there was excellent control on morphology of resultant blend 
with improved mechanical properties. This resultant blend showed improved 
melt processing when subjected to melt extrusion and injection moulding.  
S3M has three dimensional unique shear forces which act on the processing 
material. As compared to other mills all type of materials can be processed on 
pan mill hard, brittle, ductile etc.  
It has been reported that high shear milling can induce amorphisation in the 
processing material by breaking down its crystalline structure to very fine size 
and convert it into amorphous form. Milling technology has great potential for 
manufacturing and processing materials to its amorphous form. 
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Chapter 3. Experimental 
This chapter will provide details about materials used, drug profiles, 
processing methodologies used for generation of solid dispersions and 
cocrystals and characterisation techniques.  
3.1 Materials 
Drugs: Carbamazepine (TAJ pharmaceuticals lot no. TPL/CARB/002), 
Ibuprofen (TAJ pharmaceuticals), Caffeine (Sigma-Aldrich), Paracetamol 
(Medex), Glibenclamide (Medex) 
Co-formers: Salicylic acid, Nicotinamide, Oxalic acid, Saccharin, Glutaric 
acid, Maleic acid. All the co-formers were obtained from Sigma-Aldrich Ltd. 
UK. 
Polymers: HPMCP HP55 (ShinEtsu), HPMCAS (ShinEtsu), PVP VA64 
(BASF), Ethyl Cellulose (BASF), Polyethylene oxide (PEO N80) (Colorcon) 
3.2 Material profiles 
3.2.1 Drugs 
Four poorly water soluble drugs having different physicochemical properties 
and challenges were selected as model molecules for preparation of solid 
dispersions and cocrystals using HME and S3M. The rationale for selection 
of drug was based on the challenges related to them for formulating into solid 
dispersions and cocrystals for improving solubility was the main aspect, other 
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related challenges are enlisted in  Table 3.1 and 3.2. All the selected drugs 
were BCS class 2 drugs except paracetamol which is BCS class 3 drug 
which has fair solubility in water but there many problems associated with 
formulation of paracetamol, one of which is its bitter taste and other is 
compressibility problem during tabletting of paracetamol (Karki, et al. 2009). 
The physicochemical data and related information about these drugs is 
summarised in Table 3.1. 
Table 3.1: Drug profiles 
Property Ibuprofen Paracetamol Glibenclamide Carbamazepine 
Chemical 
structure 
  
 
 
Molecular 
weight 
(g/mol) 
206.29  151.169 494 236.26 
Solubility 
(mg/L) 
21 20 4 17.7 
BCS class II III II III 
Dose (mg) 400 500 5 200 
Melting 
point (°C) 
76 169 170 190 
Glass 
transition 
temperatur
e (°C) 
-50 23 60 50 
Solid √ √ √ √ 
 
 
53 
 
dispersion 
 Cocrystals √ √ X √ 
Challenges Low Tg Low Tg, 
degradation, 
high dose 
Low dose, 
erratic absorption 
Degradation, 
polymorphism 
References 
 
Brabender C, 
et al. 2002 
Sibik et al. 2014, 
Nainar et al. 
2012 
Babu and pandit, 
1999, Chauhan et al. 
2005 
Sethia and 
Squillante, 2004, 
Patterson et al. 
2008 
 
3.2.2 Polymers 
Polymers were selected on the basis of variable physicochemical properties 
and nature. The details of polymers are given in Table 3.2 
Table 3.2: Polymer profiles  
Properties PEO  PVP VA64 HPMCP HP55 HPMCAS Ethyl 
cellulos
e 
Description Synthetic 
polyether, 
hydrophilic, 
suitable for 
solid 
dispersion 
and as 
plasticiser 
Vinylpyrrolidone
-vinyl acetate 
copolymer, 
hydrophilic, 
suitable for solid 
dispersion 
Cellulose ester 
with pH 
dependent 
solubility, 
soluble at pH 
6.8, used for 
enteric coating 
Cellulose ester 
with pH 
dependent 
solubility, soluble 
at pH 6.8, 
nucleation and 
crystal growth 
inhibitor, used for 
enteric coating 
Cellulos
e ether, 
hydroph
obic, 
suitable 
for 
controlle
d 
release 
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and solid 
dispersion 
Class 
  
 
  
Amorphous
/crystalline 
Crystalline Amorphous Amorphous Amorphous Amorph
ous 
Tm/Tg (°C) 75 110 145 123 140 
Challenges Low melting 
point, 
depolymerisa
tion, 
hygroscopic 
Medium Tg, 
hygroscopic 
Breaking of 
ester linkage 
due to 
temperature and 
shear, 
destabilisation 
of drug, 
phthalate 
impurities, high 
Tg 
Breaking of ester 
linkage due to 
temperature and 
shear, 
destabilisation of 
drug, high Tg 
High Tg 
References DOW, 2002 BASF, 2011 Ghosh, et al. 
2011, ShinEtsu, 
2009 
Ghosh, et al. 
2011, ShinEtsu, 
2009 
Hercule
s, 2011 
3.3 Methods 
 This section will explain in details the general experimentation on S3M and 
HME technologies followed by general characterisation techniques used.  A 
separate section on solid dispersions and cocrystals will provide details 
about specific batches prepared by these two techniques and specific 
evaluation methods. At the end of this chapter a section has been included 
about the preliminary studies on energy consumption during milling.  
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3.3.1 S3M technology 
The solid state shear mill which is used in this research was fabricated at 
Sichuan University. The experiments were conducted in Professor Qi Wang’s 
laboratory at State Key Lab of Polymer Materials Engineering, Polymer 
Research Institute, Sichuan University. The principle and theory of S3M are 
described in detail in Section 2.4.2.  A typical S3M is shown in Figure 3.1.    
 
Figure 3.1: A typical S3M equipment 
3.3.1.1 Preliminary trials  
Three S3M mills S3M1, S3M2 and S3M3 with different configurations were 
used for preliminary trials. The parameters of the three mills are summarised 
in Table 3.3 and explained using Figure 3.2. The photographs of the three 
mills are shown in Figure 3.3. 
Table 3.3: Different S3M mills with different parameters 
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S3M 
type/Parameters 
Radius 
(R) (cm) 
Division 
number (n) 
Slot 
number 
(m) 
Slot top 
width (δ) 
Bevel 
angle (α) 
S3M 1 10 8 14 Low Small 
S3M 2 30 8 14 Medium High 
S3M 3 30 8 14 High Medium 
The parameters R, η, m, d and bevel angle η are explained using Figure 18 
 
Figure 3.2: S3M in-laid pans A) Schematic B) Original 
Preliminary trials for solid dispersions were conducted using salicylic acid 
and VA64 as model drug and polymer respectively. Salicylic acid was sieved 
through an 80 mesh to break any agglomerates. For each batch 300 gm of 
drug: polymer mixture containing the two components in a 1:1 weight ratio 
was prepared by mixing the two components in a turbula mixer. The mixture 
was fed separately to S3M1, S3M2 and S3M3. The gap between the pans 
was adjusted to ensure a residence time of each mixture in the mill for at 
least 30 secs. A retention time of only 10 secs could be achieved in S3M2 
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even at lowest clearance between the pans. The speed of rotation was set 
between 20 to 50 rpm (available range 20-200 rpm). The product was 
collected and characterised using PXRD as described in section 3.4.2. The 
drug: polymer mixture showed good flowability in all mills with a retention 
time of 30-40 secs achieved in S3M1 and S3M3. The PXRD data showed 
that the drug was partially converted into the amorphous form at the end of 
the first cycle in S3M3, whereas S3M1 and S3M2 did not show any 
amorphous conversion. Therefore, product obtained at the end of cycle 1 
from S3M3 was again subjected to additional cycles. The product samples 
were collected at the end of each cycle and subjected to PXRD analysis. The 
amorphous solid dispersion was formed at the end of cycle 3. Therefore 
S3M3 was used for preparation of solid dispersions in the next phase of 
study. 
 Feasibility for cocrystal formulation using S3M was carried out using salicylic 
acid: nicotinamide 1:1 as a model cocrystal pair. Both the components were 
sieved through an 80 mesh separately and a 300 gm mixture containing a 
1:1 molar ratio of the 2 components was mixed in a turbula mixer for 10 min. 
The binary mixture was fed to S3M1, S3M2 and S3M3 separately. The 
powder could not flow through the gaps between the pans and clogged all 
the mills. The batches when processed at higher pan clearance could not 
retain the mixture for more than 10 sec providing no shearing action. 
Therefore next batches were processed with the addition of 10% PEO N80 
by weight to the binary mixture; pan clearance was maintained at minimum 
with rotation speed between 20-50 rpm. 
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Figure 3.3: Three S3M mills used S3M1, S3M2 and S3M3 
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The material showed good flowability with residence time between 30-40 sec 
in S3M1 and S3M3, whereas it was 10 sec for S3M2. The product obtained 
was subjected to PXRD evaluation. The PXRD studied revealed that product 
obtained from S3M3 was only subjected to complete amorphisation and 
formation of phase pure cocrystals. Therefore S3M3 mill was used for all 
cocrystal trials in the next part of the study.  
3.3.2 Hot melt extrusion process 
Hot melt extrusion trials were conducted using a Pharmalab 16 (Thermo 
Fisher Scientific, Karlsruhe Germany) co-rotating twin screw extruder with 16 
mm screw diameter and screw length to diameter ratio of 40:1 (Figure 3.4). 
Details about the principles of hot melt extrusion were explained in section 
2.4.1.  
 
Figure 3.4: Pharmalab 16 co-rotating twin screw extruder 
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The screws are made up of different screw elements. Conveying elements 
help to carry material along the length of the extruder and mixing elements 
apply high shear to ensure homogenous mixing under a given temperature 
profile. Typical screw elements are shown in Figure 3.5. 
 
Figure 3.5: Typical screw elements with different geometry   
The screw configuration was comprised of three identical mixing zones 
separated by three conveying elements. In the mixing zone the screw 
elements were arranged in the order 30°, 30° and 90° in a direction from the 
hopper to discharge end.  This configuration provides high shear to the 
material in the mixing zone.  The typical conveying zone and mixing zone 
geometries are shown in Figure 3.6 and their distribution over the screw 
length are summarised in Table 3.4. 
The screw rotation speed was set at 100 rpm for all batches, and the 
temperatures of the nine heated barrel and die zones were set according to 
the requirements of the respective solid dispersion and cocrystal batches.  
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Pressure and temperature sensors were provided near the discharge zone 
as shown in Figure 3.7. The temperature, pressure and torque are monitored 
using a Programmable logic controller (PLC) display. 
 
Figure 3.6: Twin screw with different zone A. Conveying, B. Dispersive 
mixing, C. Discharge 
Table 3.4: Screw configuration used for extrusion trials on Pharma lab 16 
Length (mm) Element type 
22 Forward conveying 
0.5 30 forward mixing 
0.5 60 forward mixing 
0.5 90 mixing 
3 Forward conveying 
0.5 30 forward mixing 
0.5 60 forward mixing 
0.5 90 mixing 
3 Forward conveying 
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0.5 30 forward mixing 
0.5 60 forward mixing 
0.5 90 mixing 
6 Forward conveying 
1.5 Discharge 
 
Figure 3.7: Temperature and pressure sensors and PLC display 
Pharmalab 16 provides nine temperature controlled zones across the barrel.  
The HME preliminary trials were performed using salicylic acid – PVP VA 64 
pairs for solid dispersions and salicylic acid – nicotinamide for cocrystals. 
The temperature profiles used for the solid dispersion and cocrystal batches 
are provided in Table 3.7 and     Table 3.9  respectively.  
The batch size was kept constant at 300 gm for all batches. Feed rate was 
kept the same for all the batches at 0.3 kg/h using a gravimetric twin screw 
feeder (Congrav OP1T, Brabender, Germany, Figure 3.8). An extruder die 
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was used in case of all solid dispersion batches, whereas all cocrystal 
batches were carried out without an extruder die.  
 
Figure 3.8: Gravimetric feeder (Congrav OP1T,  Brabender, Germany) 
3.4 Characterisation techniques 
3.4.1 Differential Scanning Calorimetry (DSC) 
A TA Instruments Q2000 differential scanning calorimeter (Crawley, UK) was 
used for recording thermograms of pure and processed cocrystal and solid 
dispersion batches which is equipped with an RSC90 cooling unit. This was 
used to analyse and comprehend heat flow in the starting crystalline 
components as well as the resulting products. Indium metal was used for the 
calibration of instrument. Around 1.5-3 mg of each sample was loaded into 
the aluminium pan. An accurately weighed blank aluminium pan was used as 
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reference. All samples were recorded using suitable temperature profile 
according to the melting behaviour of the API. A heating rate of 10°C/ min or 
20°C/ min was used and a nitrogen flow rate was kept at 50 mL/min to 
maintain inert environment. 
3.4.2  Powder X-ray Diffraction (PXRD) 
All the cocrystal and solid dispersion samples were crushed to reduce their 
particle size by milling or grinding in mortar and pestle and then subjected to 
powder X-ray diffraction analysis. A Bruker D8 diffractometer (Coventry, UK) 
was used, having X-ray wavelength 0.154 nm and a 40 KV Cu source with 
filament emission 40 mA. Scanning range for all the samples was kept 
between 2 to 30° (2θ) using a 0.01° step width and  1 s time count, while the 
scatter slit and receiving slit were 0.2○ and 1○ respectively. A silica sample 
holder was used in cases where the available sample size was limited. 
3.4.3 Fourier Transform Infrared Spectroscopy (FT-IR) 
All the samples were analysed by FT-IR analysis using a Perkin Elmer 
Spectrum 100 FT-IR spectrometer. A small amount of powder or extrudate 
sample was kept on the diamond crystal in such a way that it should cover 
the area of diamond crystal and with the help of rotating vertical shaft. 
Powdered material or extrudate was pressed against the diamond crystal to 
a predetermined pressure which was confirmed by generation of signal 
sound. Once the sample was placed properly, measurements were recorded. 
For all the samples the scanning scale was kept in the range of 600 to 4000 
cm-1 with 16 scans per sample. 
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The assembly involves an electronically stabilised source and detector for 
accurate results with high repeatability. The obtained spectrum was 
processed using GRAMS/AI   software. All the solid dispersion samples were 
analysed by FT-IR and compared with the spectrum of the pure drug and the 
polymer. 
3.4.4 Near Infrared Spectroscopy (NIR) 
All the cocrystal and solid dispersion samples were subjected to NIR 
analysis. An FT-NIR analyser (Antaris II, Thermo Scientific, UK) with the 
halogen lamp assembly made up of quartz with a fibre-optic probe assisted 
with detector (InGaAs). Powdered samples were kept in glass vials with a 
clear and transparent bottom and placed on the NIR integrating sphere 
covering the exposed sample area of the vial bottom. A spectra 
measurement was performed every 30 seconds in the wave number range of 
4500-9000 cm-1, an average of 32 scans and resolution of 16 cm-1. Samples 
of pure components of drug and polymer were also analysed by NIR 
analysis. Data processing was performed using Thermo Scientific, version 
3.0 , TQ Analyst Operation software. 
3.4.5 Scanning Electron Microscopy (SEM) 
SEM was used to study morphology and structural features of solid 
dispersion and cocrystals batches. Self-adhesive carbon mounts were used 
to mount samples on aluminium pin stubs (Agar Scientific, Stansted, UK). 
SEM images of the mounted samples were collected using an FEI Quanta 
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400 scanning electron microscope (Cambridge UK) under vacuum and XTM 
microscope control software V 2.3. 
3.4.6 Dynamic Vapour Sorption analysis (DVS) 
Dynamic vapour sorption study was conducted for selected sold dispersion 
and cocrystal samples to evaluate water sorption at different humidity 
conditions at a constant temperature. A DVS Advantage (Surface 
Measurement Systems, UK) instrument was used for all DVS studies. A 
schematic representation of the instrument is shown in Figure 3.9. Isotherms 
were recorded at a constant temperature of 25 ºC. The % RH change for the 
sorption and desorption steps was kept at 20% RH at each step and the 
equilibration time was 60 min. Distilled water was used as a solvent for all 
the DVS analyse. Nitrogen (N2) was used as inert gas for constant pressure 
(2.5 N/m2) 
 
Figure 3.9: Schematic for DVS instrument (SMS, UK, 2014) 
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Selected solid dispersion samples were analysed for water sorption, 
desorption, % weight gain and % weight loss at defined %RH were 
calculated. 
3.4.7 Surface energy analysis  
Solid dispersion and cocrystal samples which were subjected for DVS 
analysis were also subjected to surface energy analysis using inverse gas 
chromatography. The instrument used for surface energy analysis was a 
Surface Measurement Systems (SMS, UK) iGC surface energy analyser, 
which is 2nd generation equipment for chromatographic sorption. It has 12 
reservoirs for different solvent vapour application and holds two columns. 
The column temperature was maintained at 30 ºC and   flame ionisation 
detector (FID) was used for estimation of the probe molecule. The 
experimental parameters are given in Table 3.5. 
Table 3.5: Experimental parameters for surface energy measurement 
Probe 
Solvent 
% 
coverage 
Column 
temperature 
Flow  
(sccm) 
Flow time 
(minutes) 
FID gain 
Octane  0.06 30 °C 5 20 1 X 
Octane 0.065 30 °C 5 20 1 X 
Octane 0.07 30 °C 5 20 1 X 
Octane 0.08 30 °C 5 20 1 X 
Octane 0.09 30 °C 5 20 1 X 
Octane 0.095 30 °C 5 20 1 X 
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Octane 0.1 30 °C 5 20 1 X 
Nonane 0.06 30 °C 5 20 1 X 
Nonane 0.065 30 °C 5 20 1 X 
Nonane 0.07 30 °C 5 20 1 X 
Nonane 0.08 30 °C 5 20 1 X 
Nonane 0.09 30 °C 5 20 1 X 
Nonane 0.095 30 °C 5 20 1 X 
Nonane 0.1 30 °C 5 20 1 X 
Decane   0.06 30 °C 5 20 1 X 
Decane 0.065 30 °C 5 20 1 X 
Decane 0.07 30 °C 5 20 1 X 
Decane 0.08 30 °C 5 20 1 X 
Decane 0.09 30 °C 5 20 1 X 
Decane 0.095 30 °C 5 20 1 X 
Decane 0.1 30 °C 5 20 1 X 
The columns used for the current study were Silane treated columns made 
up of glass with size length 30 cm and 3 mm internal diameter.  Sample 
loading used for all the cocrystal and solid dispersion was in the range of 
200-300 mg. The average surface area exposed for surface energy 
measurement was around 0.5 m2. The column was conditioned at 30 °C at 
0% RH. The surface energy data was analysed by SMS Cirrus software. 
3.5 Solid dispersion 
Solid dispersions were prepared by S3M and HME techniques. This section 
provides details about composition the of solid dispersion batches, 
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processing variables and performance and degradation testing carried out for 
different batches.   
3.5.1 Solid dispersions using S3M technology 
 Four drugs, ibuprofen (IBU), paracetamol (PARA), glibenclamide (GLB) and 
carbamazepine (CBZ) and four polymers PVP VA64 (VA), ethylcellulose 
(EC), HPMCP (HP) and HPMCAS (AS) were selected for preparation of solid 
dispersions.  
The selection of drug was based on the various challenges associated with 
them as described in Table 3.1. Being BCS class II drugs Ibuprofen, 
glibenclamide and carbamazepine were selected majorly due to their low 
solubility issues. Paracetamol was selected enhance its physicochemical 
properties in terms of tabletting and compression. Similar way polymers were 
selected as per challenges associated with them as mentioned in Table 3.2. 
The use of PVP VA64 as carrier polymer in solid dispersion system has been 
widely explored, whereas HPMCP HP 55 and HPMCAS being coating 
polymer and majorly used in coating of tablets are been explored for their 
potential to form a solid dispersion with considering their degradation 
challenge. Similar way ethyl cellulose has been explored coating and 
controlled release coating purposes; here it has been tried for carrier in solid 
dispersion system for slower drug release over the time period. 
The ratio of drug to polymer was kept 1:2 w/w based on the trials previously 
carried out on hot melt extrusion prior commencing the actual work. Loading 
of 33% drug of drug into polymer was observed to give amorphous system 
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using hot melt extrusion process, the 50% loading of drug (CBZ) was tried in 
case of PVP VA64 and HPMCP HP55 polymers to check the potential of 
those polymers to load higher amount of drugs and to form solid dispersion 
of CBZ. The higher drug loading in solid dispersion will help to increase the 
drug dose where it is needed in case of some drugs with low water solubility. 
A total of 11 batches were processed using different drug polymer 
combinations and ratios. Details of these batches are summarised in Table 
3.6. The batch code includes drug code, polymer code and ratio followed by 
the letter S in parentheses indicating S3M technology.   The basis of 
selection of the drugs and polymers is explained in the results and 
discussion section (Chapter 5). 
All batches were processed using S3M3 mill and batch size was maintained 
at 300 g. Process parameters were maintained as explained in the 
preliminary trials in section 3.3.1.1. The residence time of the material was 
between 30 -40 sec for each cycle but it could not be measured accurately 
as the mill did not have a rate measurement system and has very high 
throughput. The number of cycles was kept constant at three for all batches 
except for batch IBUVA12(S). IBUVA12(S) showed low Tg values and 
yielded a product in first cycle. All other solid dispersion batches were 
subjected to three S3M cycles respectively. 
Table 3.6: Solid dispersion batches prepared by S3M technology 
Sr Batch code Drug Polymer Drug:polymer  No.of 
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No ratio by 
weight  
cycles 
1 IBUVA12(S) Ibuprofen PVP VA64 1:2 2 
2 IBUHP12(S) Ibuprofen HPMCP HP55 1:2 3 
3 PARAHP12(S) Paracetamol HPMCP HP55 1:2 3 
4 GLBVA12(S) Glibenclamide PVP VA64 1:2 3 
5 GLBEC12(S) Glibenclamide Ethylcellulose 1:2 3 
6 CBZVA12(S) Carbamazepine PVP VA64 1:2 3 
7 CBZVA11(S) Carbamazepine PVP VA64 1:1 3 
8 CBZHP12(S) Carbamazepine HPMCP HP55 1:2 3 
9 CBZHP11(S) Carbamazepine HPMCP HP55 1:1 3 
10 CBZAS12 (S) Carbamazepine HPMCAS 1:2 3 
11 CBZEC12(S) Carbamazepine Ethylcellulose 1:2 3 
 Products obtained from all batches were subjected to characterisation using 
PXRD, DSC, SEM, FTIR and NIR techniques as described in section 3.4. 
Selected batches were subjected to DVS and surface energy analysis as per 
the procedures elaborated in section 3.4. The release of drug from all 
batches was studied using the method described in section 3.5.3.1, while 
process induced degradation of paracetamol and carbamazepine was 
evaluated using the HPLC technique described in section 3.5.3.2.   
3.5.2 Solid dispersion using HME  
All drug polymer combinations processed for solid dispersions using S3M 
were also subjected to HME.  Processing of some of the drug polymer 
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combinations using melt extrusion was difficult due to very high torque; 
therefore a suitable plasticiser was used to aid processing of these batches. 
Selection of plasticisers were based on trial and error approach, both the 
plasticisers were tried for all the combination of drug and polymers in 25 
gram batches and accordingly the most process suitable plasticiser for 
respective drug: polymer combination were chosen. Triethyl citrate (TEC) 
and Polyethylene glycol 2000 (PEG) in concentration 10 – 15 % w/w were 
used as plasticisers to achieve processability of the solid dispersion. All other 
parameters were kept constant for all solid dispersion batches. 
HME and S3M process were carried out as described in section 3.5 of this 
chapter. The temperature profile and plasticiser concentration used during 
HME processing with Batch codes are described in Table 3.7.   
Table 3.7: Solid dispersion hot melt extrusion batches 
Sr no. Batch details 
1  IBUVA12(H) 
Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 80 80 80 80 80 50 40 35 25 
2 IBUHP12(H) 
Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 130 130 130 130 110 100 75 50 25 
3 PARAHP12(H)+ 10% TEC 
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Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 150 150 150 150 130 110 75 50 25 
4 GLBVA12(H)+ 10% PEG 
Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 120 120 120 120 110 100 75 50 25 
5 GLBEC12(H)+ 10% PEG 
Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 160 160 160 160 140 100 75 50 25 
6 CBZVA12(H) + 10% PEG 
Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 110 110 110 110 90 80 60 40 25 
7 CBZVA11(H) + 15% PEG 
Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 100 100 100 100 90 80 60 40 25 
8 CBZHP12(H) + 10% TEC 
Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 160 160 160 160 140 120 80 60 35 
9 CBZHP11(H) + 15% TEC 
Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 150 150 150 150 135 110 80 60 35 
10 CBZAS12 (H) + 10% PEG 
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Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 150 150 150 150 135 110 80 60 35 
11 CBZEC12(H) + 10% TEC 
Extruder barrel 
zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 140 140 140 140 125 100 80 60 35 
All solid dispersion batches were analysed for DSC, XRD, FT-IR, NIR, DVS 
and surface energy analysis as described in section 3.4.  
3.5.3 Product performance testing 
The solid dispersion batches obtained were subjected to evaluation of drug 
release and investigation of potential process induced degradation. This 
section will provide details of the methodology for this testing.  
3.5.3.1 Drug release 
Drug release from the solid dispersion batches was studied using USP 2 
dissolution test apparatus (Copley Scientific, Type NE4-COP, Serial No. 
14355). Samples were analysed using a suitable UV spectrophotometric 
method. The dissolution medium volume used during testing was 900 ml at 
37°C, other details about dissolution testing parameter such as dissolution 
medium and speed of rotation are summarised in Table 3.8. 
Selection of dissolution medium was done using USP reference dissolution 
medium for respective drugs. In case of HPMCP HP55 and HPMCAS the 
selection of dissolution medium was done according to the nature of polymer 
 
 
75 
 
and not according to drug. As HPMCP HP55 and HPMCAS are pH 
dependent polymers dissolution medium selected was buffer pH 6.8 to 
dissolve the entire drug present in dissolution samples over the period of 
dissolution time. All other dissolution medium was selected according to USP 
standards for respective drugs (Table 3.8).  
 All solid dispersion batches dissolution samples were analysed using a 
JASCO V-630 spectrophotometer. The spectral measurements were carried 
out using Spectra Manager 2.0 software. Calibration curves for the APIs 
were obtained using the respective dissolution medium in the range of 1-10 
microgram/ml strength of the drug solution. Calibration curve equations and 
R2 values were obtained by regression analysis. Timely samples were 
withdrawn during dissolution and UV absorbance was recorded at 
wavelengths reported in Table 3.8.  
Table 3.8: Dissolution parameters for solid dispersion batches 
Sr. 
No. 
Batch Dissolution Media Wavelength 
(nm) 
RPM 
1 IBUVA Phosphate Buffer pH 7.2 221 50 
2 IBUHP Phosphate Buffer pH 7.2 221 50 
3 CBZVA Water 1% SLS 288 75 
4 CBZHP Phosphate Buffer pH 7.2 288 75 
5 CBZAS Phosphate Buffer pH 7.2 288 75 
6 CBZEC Water 288 100 
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7 PARAHP Phosphate buffer pH 6.8 243 75 
8 GLIBVA Phosphate buffer 7.4 240 50 
9 GLIBEC 0.1 M HCl (pH 1.2) 240 75 
3.5.3.2 Drug and polymer degradation   
S3M and HME are shear based technologies which may cause degradation 
of the temperature or shear sensitive APIs and polymers during processing.  
Degradation of carbamazepine, paracetamol and HPMCP were investigated 
using suitable HPLC method.  
HPLC analyses were performed using a Waters HPLC system comprising a 
separation module (Waters e-2695) integrated with a degasser and a 
photodiode array detector (PDA-2998). The HPLC chromatograms collected 
at suitable wavelengths were analysed using Empower 3 software.  
3.5.3.2.1 Carbamazepine  
Iminostilbene is a thermal degradation product of carbamazepine (Naima et 
al., 2001).  A reported gradient HPLC method was used for the simultaneous 
detection of carbamazepine and Iminostilbene.  The HPLC conditions used 
were as follows:  
Column: C18 Waters Symmetry, dimensions of 4.6× 250 mm with 5 um 
particles size. 
Solvent system: Solvent A: acetonitrile acidified with 0.1 % v/v formic acid 
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                          Solvent B: deionised water acidified with 0.1 % v/v formic 
acid. 
Injection volume: 10 μL;   
Flow rate: 1.2 mL/min. 
Wavelengths: 285 nm, 253 nm, 219 nm 
Linearity range: 10 -60 μg/mL 
3.5.3.2.2 Paracetamol 
The degradation product of paracetamol is 4-amino phenol (Bhimavarapu et 
al. 2011). A reported gradient HPLC method was used for analysis details 
are as follows, 
Column: C18 Waters Symmetry, dimensions of 4.6× 250 mm with 5 um 
particle size. 
Solvent system: Solvent A: Acetonitrile  
                          Solvent B: phosphate buffer pH 3 
Injection volume: 10 μL;   
Flow rate: 0.5 mL/min. 
Wavelengths: 227 nm 
Linearity range: 20 -160 μg/mL 
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3.5.3.2.3 HPMCP 
The degradation products of HPMCP are phthalic acid and phthalic 
anhydride (Karandikar, et al. 2015). A reported gradient HPLC method was 
used for analysis of phthalic acid and phthalic anhydride (Karandikar, et al. 
2015). The HPLC conditions  are as follows, 
Column: Waters spherisorb ODS 2 column with the dimension of 3 µm 
particle size, 4.6 internal diameter and 60 mm length  
Solvent system: Solvent A: 0.5 M potassium dihydrogen phosphate 
(KH2PO4) 
                          Solvent B: Methanol 
Injection volume: 50 μL;   
Flow rate: 1 mL/min. 
Wavelengths: 215 nm 
Linearity range: 10 -50 μg/mL 
3.6 Cocrystals 
Cocrystals of ibuprofen, caffeine, paracetamol and carbamazepine with 
different co-formers were attempted using solution crystallisaton, HME and 
S3M. Solution crystallisation was carried out to obtain pure cocrystals and to 
investigate difference in the properties as per the method of preparation.  
The coformers used include nicotinamide (NIC), maleic acid (MAL), oxalic 
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acid (OXA), salicylic acid (SAL), saccharin (SAC) and glutaric acid (GLU). 
The different batches and method used are summarised in Table 3.9. 
Processing of cocrystals was carried out as per the S3M and HME methods 
described earlier in Sections 3.3.1 and 3.3.2.  
Table 3.9: Cocrystal batch details 
Sr. 
No. 
Cocrystal Solution HME S3M 
1 IBU:NIC 1:1 √ --- √ 
2 IBU:NIC 1:1 10% PEO --- √ √ 
3 IBU:NIC 1:1 10% VA64 --- √ √ 
4 CAF:MAL 1:1 √ √ --- 
5 CAF:MAL 1:1 15% HP55 --- √ √ 
6 PARA:OXA 1:1 √ √ --- 
7 PARA:OXA 1:1 15% PEO --- √ √ 
8 CBZ:SAL 1:1 √ √ --- 
9 CBZ:SAL 1:1 5% PEO --- √ √ 
10 CBZ:SAL 1:1 10% PEO --- √ √ 
11 CBZ:SAL 1:1 15% PEO --- √ √ 
12 CBZ:SAL 1:1 25% PEO --- √ √ 
13 CBZ:SAL 1:1 15% PVP VA64 --- √ √ 
14 CBZ:SAL 1:1 25% PVP VA64 --- √ √ 
15 CBZ:SAC 1:1 √ √ --- 
16 CBZ:SAC 1:1 15% PEO --- √ √ 
17 CBZ:NIC 1:1 √ √ --- 
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18 CBZ:NIC 1:1 15% PEO --- √ √ 
19 CBZ:GLUT 1:1 √ √ --- 
20 CBZ:GLUT 1:1 15% PEO --- √ √ 
For all S3M processing of crocrystals the processing conditions were 
maintained constant as described for preliminary trials using S3M3 mill.   
The temperature profiles used for HME processing of different cocrystals are 
summarised in Table 3.10. 
Table 3.10: Cocrystal batch and process details for hot melt extrusion 
Sr. no. Batch details 
1. Ibuprofen: Nicotinamide 1:1 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 70 70 70 60 50 40 30 25 
2. Ibuprofen: Nicotinamide 1:1 + 10% PEO 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 70 70 70 60 50 40 30 25 
3. Ibuprofen: Nicotinamide 1:1 + 10% VA64 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 70 70 70 60 50 40 30 25 
4. Caffeine: Maleic acid 1:1 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
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Temp.(°C) 25 110 110 110 90 70 50 40 25 
5. Caffeine: Maleic acid 1:1 + 15% HPMCP HP55 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 100 100 100 80 60 40 30 20 
6. Paracetamol: Oxalic acid 1:1 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 100 100 100 80 60 40 30 20 
7. Paracetamol: Oxalic acid 1:1 +  15% PEO 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 100 100 100 80 60 40 30 20 
8. Carbamazepine: Salicylic acid 1:1 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 150 150 150 135 110 80 50 25 
9. Carbamazepine : Salicylic acid 1:1 + 5% PEO 
10. Carbamazepine : Salicylic acid 1:1 + 10% PEO 
11. Carbamazepine : Salicylic acid 1:1 + 15% PEO 
12. Carbamazepine : Salicylic acid 1:1 + 25% PEO 
13. Carbamazepine : Salicylic acid 1:1 + 15% PVP VA64 
14. Carbamazepine : Salicylic acid 1:1 + 25% PVP VA64 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 110 110 110 100 80 60 40 25 
15. Carbamazepine: Saccharin 1:1 
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Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 145 145 145 130 100 70 50 25 
16. Carbamazepine : Saccharin 1:1 + 15% PEO 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 110 110 110 100 80 60 40 25 
17. Carbamazepine: Nicotinamide 1:1 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 140 140 140 120 100 70 50 25 
18. Carbamazepine :Nicotinamide 1:1 + 15% PEO 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 110 110 110 100 80 60 40 25 
19. Carbamazepine: Glutaric acid 1:1 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 110 110 110 100 80 60 40 25 
20. Carbamazepine :Glutaric acid 1:1+ 15% PEO 
Extruder 
barrel zone 
10 9 8 7 6 5 4 3 2 
Temp.(°C) 25 110 110 110 100 80 60 40 25 
3.6.1 Solution crystallisation  
3.6.1.1 CBZ: SAL 1:1 cocrystal 
CBZ:SAL 1:1 pure cocrystal were prepared by a solution crystallisation 
method. 11.8075 gm of CBZ and 6.91 gm of SAL were weighed accurately 
 
 
83 
 
and dissolved in 180 ml of HPLC grade acetonitrile with simultaneous stirring 
and heating. The resultant solution was allowed to cool and stand at room 
temperature for 24 hours. The resultant mixture was filtered and dried. The 
cocrystal yield was 87.6%.The material obtained was characterised for 
crystal form using powder X-ray diffraction (PXRD). 
3.6.1.2 CBZ:SACC 1:1 cocrystal 
CBZ:SACC 1:1 pure cocrystals were prepared by a solution method. For this 
purpose anhydrous CBZ (21 gms, 0.089M) and SACC (16.3 gms, 0.089M) 
were weighed accurately and dissolved in 280 ml of a mixture of ethanol: 
methanol (62.5:37.5 V/V) at 70 °C and heating continued till one hour under 
reflux. The temperature of the system was decreased by 10 °C increments 
until the solution precipitated. Precipitates were observed around in 60-50 
°C, finally temperature was decreased to 30 °C. The resultant mixture was 
filtered, separated and washed with cold ethanol. The resultant cocrystals 
were dried at room temperature. Yield for CBZ:SACC 1:1 CC was 86.5%. 
The material obtained was characterised for crystal form using PXRD. 
3.6.1.3 CBZ:NIC 1:1 cocrystal 
CBZ:NIC 1:1 pure cocrystals were prepared by solution method. For this 
purpose anhydrous CBZ 10.635 gms (0.045M) and NIC 5.497 gms (0.045M) 
were weighed accurately and dissolved in a 200 ml solvent mixture of 70:30 
V/V ethanol: methanol mixture. Solids were dissolved by heating a mixture at 
65 °C and refluxed for one hour under stirring. After required stirring the 
resultant mixture was cooled to room temperature, separated by filtration and 
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washed with 20 ml ethanol. The resultant cocrystals was dried at 30 °C for 
48 hours. Yield for CBZ:NIC 1:1 CC was 85.4%. The material obtained was 
characterised for crystal form using PXRD. 
3.6.1.4 CBZ: GLUT 1:1 cocrystal 
CBZ: GLUT 1:1 CC were prepared by solution method. For this purpose CBZ 
14.157 gms and GLUT 7.9245 gms were weighed accurately and dissolved 
in 150 ml of HPLC grade acetonitrile with heating and stirring. The solution 
was concentrated until all the solvent is evaporated and allowed to cool at 
room temperature for 24 hours. The resultant mixture was filtered, separated 
and air dried. Yield for CBZ:GLUT 1:1 CC was 80.4%. The material obtained 
was characterised for crystal form using PXRD. 
3.6.1.5 CAF:MAL 1:1 cocrystal 
CAF:MAL 1:1 CC were prepared by microwave assisted cocrystallisation. 
Cocrystallisation was performed using a microwave reactor (Monowave 300, 
Anton Paar GmbH, Austria). A 1:1 molar mixture of CAF and MAL (2.5 g) 
were weighed accurately and to this 100 uL water was added. Experiments 
were carried out in a 30 mL capacity glass tube under stirring at 600 rpm. 
The temperature for cocrystallisation was kept at 80 °C with holding period of 
90 secs. The material obtained was characterised for crystal form using 
PXRD. 
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3.6.1.6 PARA:OXA 1:1 cocrystal 
PARA: OXAL 1:1 CC were prepared by solution method. For this purpose 
PARA and OXAL were weighed accurately according to their molar ratio with 
1:1 stoichiometry. Solids were dissolved in 200 ml of solvent mixture of 1:1 
chloroform: methanol. The solution was evaporated slowly with gentle 
heating and cooled down to room temperature. The resultant solution was 
kept for 24 hours then filtered and separated. The material obtained was 
characterised for crystal form using PXRD. PARA:OXAL 1:1 CC yield was 
87%. 
All cocrystal batches were analysed for DSC, XRD, FT-IR, NIR analysis by 
using procedures described in previous sections respectively.  
3.6.2 Cocrystal dissolution 
The UV spectra of the drug and coformer were recorded and interference of 
the components was checked by overlaying the spectra of both components. 
For the pairs which did not show any significant interference a UV method 
was used whereas an HPLC method was developed for the pairs which 
showed overlap. The overlay spectra for different cocrystal pairs are shown 
in figures from Figure 3.10 to Figure 3.15.   
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Figure 3.10: Overlay of UV spectra of carbamazepine and salicylic acid 
 
Figure 3.11: Overlay of UV spectra of carbamazepine and saccharin 
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Figure 3.12: Overlay of UV spectra of carbamazepine and nicotinamide 
 
Figure 3.13: Overlay of UV spectra of carbamazepine and glutaric acid 
CBZ 
NIC 
CBZ 
GLU
T 
 
 
88 
 
 
Figure 3.14: Overlay of UV spectra of caffeine and maleic acid 
 
Figure 3.15: Overlay of UV spectra of paracetamol and oxalic acid 
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Except PARA: OXA all cocrystal pairs required HPLC or Ultra-HPLC 
separation. Paracetamol was estimated at 244 nm. Although glutaric acid did 
not interfere with CBZ estimation a UPLC method used for other CBZ pairs 
was used for estimation of dissolution of CBZ from this pair.  HPLC method 
was used for caffeine – maleic acid and all CBZ containing cocrystals were 
evaluated using a UPLC method.  Iminostibene was also estimated in all 
CBZ containing batches using the HPLC method.  
The major difference between HPLC and UPLC was higher precision for the 
simultaneous determination of drug and co-former in given mobile phase. 
Simultaneous elution was easily obtained in UPLC and after many attempts it 
was not possible in HPLC, which was possible due to the detectors could 
use very small amount of injection volume and flow rate in case of UPLC to 
differentiate between drug and co-former and elute them separately in single 
mobile phase and injection sample.   
3.6.2.1  HPLC method for caffeine and maleic acid 
HPLC analysis for CAF and MAL was used for dissolution analysis. The 
HPLC conditions used were as follows:  
Column: C18 Waters Symmetry, dimensions of 4.6× 250 mm with 5 um 
particles size. 
Solvent system: Solvent A: Methanol 
                          Solvent B: deionised water acidified with 0.1 % v/v 
orthophosphoric  acid. 
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Injection volume: 50 μL;   
Flow rate: 1.2 mL/min. 
Wavelengths: 209 nm 
Linearity range: 2-32 μg/mL 
3.6.2.2 CBZ cocrystal dissolution study 
All CBZ cocrystal dissolution studies were analysed by ultra-performance 
liquid chromatography (UPLC). UPLC gradient method details are as follows, 
Column: Waters Acquity column with dimensions of 130Å, 5 um particle size, 
4.6 mm internal diameter and 50 mm length  
Solvent system: Solvent A: Acetonitrile 
                          Solvent B: deionised water acidified with 0.1% 
orthophosphoric acid 
Injection volume: 50 μL;   
Flow rate: 0.6 mL/min. 
Wavelengths: CBZ- 285 nm, SAL- 296 nm, SAC- 269 nm, NIC- 262 nm 
Linearity range: 10-100 μg/mL 
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Chapter 4. Results and Discussion 
The results and discussion has been divided in four chapters.  
Chapter 4 will provide details about the basis for selection of drugs and 
polymers, selection of equipment and general processing conditions 
especially in case of S3M.  
Chapter 5 provides results and discussion concerning the application of S3M 
and HME technology for processing of solid dispersions. The major 
emphasis will be on understanding the differences in formulation 
requirements to achieve processability. It also provides comparative 
evaluation of drug release, morphology, physical and chemical stability of the 
solid dispersions processed using these two processing techniques.     
Chapter 6 deals with results and discussion concerning the application of 
S3M and HME techniques for manufacture of cocrystals. The properties of 
the cocrystals have been compared with cocrystals prepared by conventional 
solution crystallisation process. 
Chapter 7 this chapter provides an overall discussion about the challenges 
and opportunities in the shear based development enabling technologies for 
solid dispersion and cocrystal manufacture.  
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This research is focussed on exploring an innovative technology in the area 
of polymer processing to address challenges of pharmaceutical product 
development. S3M is a proprietary technology developed at Sichuan 
University, access to which was enabled through the EPSRC funded Science 
Bridges China collaboration.  
One of the major objectives of this research is to explore applications of S3M 
technology for manufacture of solid dispersions and cocrystals. To provide 
confidence in the enabling technology it is essential to demonstrate and 
study its application for drugs and polymers with the wide range of 
physicochemical properties.  
4.1 Selection of drugs and polymers 
The criteria for selection of drugs included water solubility, thermal stability, 
melting point and glass transition temperature. Safety and availability of the 
drugs were also important factors as the facility in China was in an 
engineering laboratory without any air handling facilities. Similarly, 
considering the scale of the operation required quantities of each drug in the 
order of 3- 4 Kg.  
DSC thermograms and PXRD patterns of the drugs are shown in Figure 4.1 
and Figure 4.2 respectively,  
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[A- Carbamazepine, B- Glibenclamide, C- Ibuprofen, D- Paracetamol] 
Figure 4.1 DSC thermograms of carbamazepine, glibenclamide, ibuprofen 
and paracetamol 
The melting endotherms were observed at 75 °C for Ibuprofen, 170 °C for 
paracetamol, 175 °C for glibenclamide and 191 °C for carbamazepine 
(Figure 4.1). 
Crystalline CBZ shows two melting endotherms, the first one at 175 ºC and 
the second one at 191 ºC due to the polymorphic change. The polymorphic 
transformation from CBZ form III to CBZ form I gives two melting endotherms 
(Grzesiak et al., 2002). 
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[A-Carbamazepine, B-Glibenclamide, C- Ibuprofen, D- Paracetamol] 
Figure 4.2 PXRD of the carbamazepine, glibenclamide, ibuprofen and 
paracetamol 
 
PXRD patterns of the drugs shows respective characteristic peaks at defined 
2θ values with respective peak intensities (Figure 4.2). The 2θ values from 
respective PXRD are given in Table 4.1 
Table 4.1 2θ values for selected drugs 
Drug 2θ values from PXRD 
Ibuprofen 6.12, 12.2, 16.72, 17.64, 19.04, 20.16, 22.32 
Glibenclamide 10.84, 11.68, 16.2, 18.92, 19.4, 20.96, 21.84, 23.16 
Paracetamol 12.45, 24.55, 26.9 
Carbamazepine 13.2, 13.72, 14.28, 15.44, 15.96, 17.24, 18.8, 19.6, 20.48, 
23.52, 24.66, 25.08, 26.84, 27.32 
 
DSC thermograms and PXRD patterns of the polymers are shown in Figure 
4.3 and Figure 4.4 which confirm the amorphous nature of the polymers. 
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[A- Ethyl cellulose, B- HPMCAS, C- PVP VA64, D- HPMCP HP55] 
Figure 4.3 DSC thermograms for Ethyl cellulose, HPMCAS, PVP VA64 and 
HPMCP HP55  
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[A-Ethyl Cellulose, B- HPMC AS, C- PVP VA64, D- HPMCP HP55] 
Figure 4.4 PXRD for ethyl cellulose, HPMCAS, PVP VA64 and HPMCP 
HP55 
 
PXRD patterns of polymers show that there was no crystalline peak which 
confirms that all polymers are amorphous in nature (Figure 4.4).  
During processing using S3M and HME, temperature increases due to 
friction in S3M or a combination of external heating and shear in HME. 
Therefore glass transition temperature of the drugs is an important selection 
criterion.  Processing of low Tg drugs becomes challenging due to 
plasticisation of polymers which limits the drug polymer ratio.  High 
temperature and shear also raises concerns about degradation of drugs and 
polymers during processing therefore molecules such as carbamazepine and 
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paracetamol which are susceptible to degradation were included. 
Degradation of polymers during HME is also well reported (Karandikar, et al. 
2015) therefore HPMCP, a cellulose ester, was selected as a polymer with 
potential for degradation. Another important criteria considered in the 
selection of these drugs was the potential to form cocrystals. Therefore drugs 
with known coformers were used for cocrystal experiments to prove the 
application of the technology.   
Drugs were selected based on the above discussed criteria include 
ibuprofen, paracetamol, carbamazepine and glibenclamide (Table 4.2). 
Glibenclamide was used only for the solid dispersion experiments due to 
constraints on availability whereas the rest of the molecules were used for 
preparation of solid dispersion as well as cocrystals.  
Table 4.2 Physico-chemical properties of the drugs 
Drug Solubility 
(mg/L) 
Tg (°C) Challenges Reference 
Ibuprofen 21 -50 Low Tg drug Brabender C, et al. 
2002 
Paracetamol 20 23 Formation of 4-
amino phenol and 
quinone-imine due 
to hydrolysis at 
high temperature 
(US006028222) 
Sibik et al. 2014, 
Nainar et al. 2012 
Carbamazepine 17.7 50 Formation of 
Iminostilbene at 
150°C 
Sethia and 
Squillante, 2004, 
Patterson et al. 
2008 
Glibenclamide 4 60 Low dose Babu and pandit, 
1999, Chauhan et 
al. 2005 
 
Pharmaceutical polymers with Tgs in the range of 110 – 145 °C were 
selected including a cellulose ester which is susceptible to thermal 
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degradation.  The polymers used in this study include PEO N80 (Tg- -45°C) 
(DOW, 2002), PVP VA64 (Tg- 110°C) (BASF, 2011), HPMCP HP55 (Tg- 
145°C) (Ghosh, et al. 2011, ShinEtsu, 2009), HPMCAS (Tg- 123°C) and 
ethyl cellulose (Tg- 140°C) (Hercules, 2011). 
4.2 Preliminary trials 
There are several reports about the application of S3M for preparation of 
polymer composites which were discussed in details in Section 2.4.2, but the 
objectives of these experiments were different to the current research and 
there is little opportunity for extrapolation of that understanding to 
pharmaceutical systems and the objectives set in this research.  Therefore 
preliminary experiments were essential to develop some understanding, 
develop skills and set up the experimental field.  
4.2.1 S3M trials  
S3M trials were conducted for salicylic acid as a model API, PVP VA 64 as a 
polymer for solid dispersion and nicotinamide as a coformer for 
cocrystallisation. The batches trial batches were processed on S3M1, S3M2 
and S3M3.  
Table 4.3 Preliminary trials on S3M and selection of S3M 
Batch details S3M1 S3M2 S3M3 
SAL:VA64 1:2 End product did 
not show formation 
of amorphous 
phase at the end of 
the cycles. 
No. Of cycles- 20 
Amount of shear 
was very less. 
The residence time 
was fraction of 
seconds and 
material flew 
through the gap 
between two pans 
with minimum or 
no shear. No 
amorphous end 
At the end of 3rd 
cycle there was 
complete 
conversion of drug 
and polymer 
mixture into 
amorphous end 
product. Relatively 
very high shear 
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product 
No. Of cycles- 5 
and rise in 
temperature of the 
product.  
SAL:NIC 1:1 10% 
PEO 
End product did 
not show partial or 
full conversion into 
cocrystals. 
No. Of cycles- 20 
Very less shear. 
End product did 
not show formation 
of cocrystals. 
Minimum or no 
shear during 
milling with least 
residence time. 
No. Of cycles- 5 
Complete 
conversion of drug 
and co-former into 
phase pure 
cocrystalline end 
product. Residence 
time was 5-10 secs 
with relatively very 
high shear during 
1st cycle. 
The observations were previously reported in section 3.3.1.1 and are 
summarised in Table 4.3 
In S3M n>2 and 0>α>π/2, the dihedral angle θ is the angle between the 
moving pan and the stationary pan δ slots. Consider that the pan is moving 
on the stationary pan when kth slot of the moving pan interacts with lth slot of 
the stationary pan the slot distances L and S are shown in Figure 4.5.  The 
lower bevel and upper bevel are denoted by λ and μ respectively. Another 
term commonly used in the cutting devices is turning angle which is the 
angle through which the moving pan turns on the stationary pan. 
The value of Ø is between 0 to 2π/n. At the beginning of the cycle Ø=0 when 
Ø changes from 0 to 2π/n at that instant θ becomes zero. This action is 
similar to the scissor action. Therefore S3M can be imagined as three 
dimensional scissors. This continuous pressure and cutting action provides 
extremely high shear in S3M. 
 
 
100 
 
 
Figure 4.5 Schematics of moving and stationary bevels of mill pan 
 
The preliminary trials of solid dispersion and cocrystal batches showed that 
S3M1 and S3M2 were not effective in causing transformation. In S3M1 the 
diameter of the pan is low, whereas in S3M2 the bevel angle α is high. The 
failure of S3M1 could be explained by understanding the relationship 
between radius R of the pan and the shear applied, Xu et al., derived an 
equation to explain the trajectory of the particles in the mill. It was observed 
that particle movement in the mill follow a spiral path. This suggested that the 
actual distance travelled by the particle is far greater than the radius of the 
pan. During the travel of the path across the spiral trajectory the particle is 
subjected to significant shear causing transformation to occur. The spiral 
path and angular velocity attained by the particles are a function of radius R 
and speed of rotation of the moving pan. In small mill the spiral path length is 
not enough to provide the ultimate stress required to rupture the crystal 
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lattice. Similarly, as the objective is to disturb the crystal lattice and not 
particle size reduction the multiple cycle approach alone was not effective as 
reported by other authors for generation of nanomaterials (Xia et al., 2004). 
The failure of S3M2 to generate solid dispersion can be attributed to high 
bevel angle. The relatively large space between two slots did not allow 
material residence and was unable to subject it to shearing action.  
 
Figure 4.6 PXRD for Salicylic acid: PVP VA64 1:2 solid dispersion at the end 
of cycle 3 processed by S3M 
In the case of S3M3 which has a medium bevel angle and a radius of 30 cm, 
it could hold the material long enough such that the polymeric system could 
be sheared easily.  Although there was partial conversion it was not 
completely amorphous at the end of cycle 1. The material after recycling for 
two additional consecutive cycles converted into the amorphous form (Figure 
4.6), in other words the process of achieving molecular dispersion could not 
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be completed in one cycle. It was not possible to estimate the exact shear 
provided per cycle because of the number of variables. The clearance 
between the pans was maintained minimum so ɗ of two pans meet each 
other so that shear applied would be high.   
The salicylic acid - nicotinamide cocrystal batches also worked only with 
S3M3. The challenge during processing of cocrystal batches was flow of the 
material. 
 
[A- S3M SAL:NIC 1:1 10% PEO, B-HME SAL:NIC 1:1 10% PEO] 
Figure 4.7 PXRD for Salicylic acid: nicotinamide 1:1 cocrystal with 10% PEO 
processed by A: HME, B: S3M and C: Reference PXRD pattern from CSD 
The mill was blocked and the powder was compacted in the spaces between 
consecutive slots. Addition of PEO enabled flow of material, avoided 
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compaction and application of shear. The generation of shear stress by the 
scissor action require a material which can be stretched and stressed. The 
stress fields could not be generated for the powder material of small organic 
molecules such as salicylic acid and nicotinamide but the presence of PEO 
helped to process the fine powder material through S3M (Figure 4.7).  
The use and selection of PEO was based on the actual trial and outcomes 
during the S3M processing. The way PEO behaved under high shear and 
stress environment of S3M with excellent stretch ability of its chains and at 
its melting point covering both drug and co-former into it. PEO being 
crystalline in nature was able to form phase pure cocrystals when added as 
processing aid during S3M processing, the crystalline nature of PEO in the 
cocrystalline matrix might have lost and it was difficult to find out due to the 
amount of PEO present in the total mixture of cocrystal matrix. 
The role of PEO could not be explained completely with the available data 
but it worked as an aid to improve flowability (SAL:NIC 1:1 showed an angle 
of repose of 19.65° whereas SAL:NIC 1:1 10% PEO showed 21.80°), 
lowering of eutectic point or melting point of either component (Table 4.4). 
The lowering of melting point onset and enthalpy of melting indicates that a 
small portion of the material has become miscible with the polymer. The 
polymer might have worked as a medium for the two components to interact 
in the molecular state. This hypothesis could not be proved at this stage but 
a similar hypothesis was proposed for slurry crystallisation process where 
the rate of cocrystallisation has been enhanced through application of shear 
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using ultrasound energy (Apshingekar, 2014) or accelerated solution process 
through use of microwaves (Pagire, et al. 2013). 
Table 4.4 Effect of PEO thermogram of processed 1:1 SAL:NIC pair 
% PEO Salicylic acid Nicotinamide 
 Onset 
(°C) 
End (°C) Enthalpy (J/g) Onset (°C)  End  
(°C) 
Enthalpy (J/g) 
0 157 166 173 124 135 190 
5 151 168 130 122 133 178 
10 138 167 121 119 135 167 
15 127 165 89 118 134 144 
 
At 5 % w/w PEO addition flow was found to be unsatisfactory whereas at 20 
% w/w of PEO the product showed reduced crystallinity. Therefore 
concentration of PEO was restricted to 10 % and 15% for the trial. 
4.2.2 HME trials 
Application of HME for manufacture of solid dispersions has been well 
established therefore feasibility trials were not conducted using HME. A 
comparative evaluation has been carried out using other pairs which are 
reported in Chapter 5.  
The application of HME for preparation of cocrystals has been well reported 
(Dhumal et al, 2010; Kelly et al, 2012). The advantages of this technology for 
cocrystallisation have been discussed in Section 2. A feasibility trial was 
conducted to explore the effect of addition of polymer, though recently Boksa 
et al reported development of carbamazepine – nicotinamide cocrystals in 
the presence of 21 % w/w  Soluplus (its polyvinyl caprolactam-polyvinyl 
acetate-polyethylene glycol graft copolymer with an amphiphilic chemical 
structure) and the process is termed  as matrix assisted cocrystallisation 
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using HME (Boksa et al., 2014). SAL – NIC cocrystals were produced 
successfully in the presence of 10 % PEO without loss of crystallinity or 
generation of amorphous phase. The amount of PEO to be present during 
the processing of cocrystals on S3M was based on trial and error approach. 
5-25% w/w PEO was added and tried for the formation of the phase pure 
cocrystals. The higher amount of PEO i.e. 25% w/w formed more like 
amorphous structure in the end product with very low crystalline nature of 
cocrystal and more of amorphous nature with reduced crystalline 
characteristic peaks in X-ray diffraction analysis, turning cocrystalline 
material into amorphous system will majorly affect the rapid release of drug 
through cocrystals and will slow it down due to the amorphous nature of the 
system, whereas in case of 10 and 15% w/w concentration of PEO it was 
possible to get phase pure cocrystals without losing its crystallinity.  The 
presence of cocrystals was confirmed using PXRD (Figure 4.3). The screw 
configuration and other processing parameters were used as described in 
the literature to maintain high shear.  
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Chapter 5. Results and discussions of solid dispersion 
This chapter will provide a detailed account of the development of solid 
dispersions using S3M3 and HME technology. The main objective is to 
exemplify the data using drugs and polymers with different physicochemical 
properties processed by these two technologies. The four drugs which have 
been selected as model molecules are ibuprofen, paracetamol, 
glibenclamide and carbamazepine. The chapter has been divided into four 
sections devoting a section for each drug.  
5.1 Ibuprofen  
Ibuprofen is a model molecule with low Tg, low melting point drug with high 
dose posing challenges in shear based processing. Ibuprofen solid 
dispersions were prepared with PVP VA64 and HPMCP HP55.  
5.1.1 Glass Transition Temperature 
Considering the challenge due to low Tg of ibuprofen, Tg of the ibuprofen- 
PVP VA64 system was first estimated using DSC as well as the Fox and 
Taylor equation. The 1:2 IBU: PVP VA64 physical mixture was heated to 100 
°C and subsequently cooled to -50° C after 10min hold at 100° C. It showed 
Tg of the mixture at 33.52 °C (Figure 5.1). 
The Tg of each drug-polymer mixture was predicted theoretically using the 
Fox equation (Fox and Flory, 1950) 
 
  
 
     
      
  
       
          
    …………………… Equation 1  
 
 
107 
 
Where, Wdrug is the weight fraction of the drug, and 1- Wdrug is the weight 
fraction of the polymer, Tg,drug is the glass transition temperature of the 
drug, Tg,polymer is the glass transition temperature of the polymer. The 
weight fraction of drug will have a direct effect on the glass transition 
temperature of the drug polymer mixture, as drug concentration will increase 
the composition and respective weight fractions will change. The predicted 
Tg using the Fox equation was found to be 39.51 °C. There seems to be 
confirmation between the experimentally determined and predicted Tg values 
of ibuprofen and PVP VA64 mixture, variation in the values can be attributed 
to variation in the ratio due to sampling error (sample may not contain exactly 
a 1:2 ratio of the drug :polymer) while carrying out DSC. Similarly the 
observed and predicted Tg for IBU: HP55 1:2 mixture was 41.75 °C and 
54.46 °C respectively. 
5.1.2 Calibration curve 
 
The calibration curve for IBU was linear over the concentration range of 1-10 
ug/ml. Linearity was calculated using the calibration curve, slope of the 
equation is 0.0526, constant -0.0022 with R2 of 0.9993 (Figure 5.1). From the 
calibration equation it can be confirmed that linearity follows Beer’s law and 
shows good linearity in the selected range. 
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Figure 5.1 Ibuprofen calibration curve by UV spectrophotometer at 221nm 
5.1.3 Processing of solid dispersion 
Accurately weighed 300 gm mixture of IBU: PVP VA64 in 1:2 ratios was 
blended using a turbula mixer. The resultant blend was then subjected to 
milling on S3M3. The material flow was good during the first cycle and at the 
end of first cycle slight lumps and agglomerates were observed.  The end 
product of first cycle was again fed into the S3M3 for a second milling cycle, 
during which there was a rise in mill temperature which caused complete 
melting of the drug: polymer mixture inside the mill. The molten mass was so 
sticky and caused adhesion of the rotary and stationary pans together. The 
S3M3 was blocked at the end of the second cycle which caused a difficulty 
for end product collection and cleaning of the mill. The sticky product was 
then collected and subjected to PXRD analysis to ensure the formation of a 
solid dispersion. In the case of IBU: HP55 1:2 experiments the flow of the 
mixture was excellent, at the end of the first cycle the material was powdery 
in nature and there was no formation of any agglomerated mass or lumps, at 
y = 0.0526x - 0.0022 
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the end of second cycle the small agglomerates started forming which were 
again fed back for the third cycle and at the end of the third cycle there was 
formation of agglomerates and solidified mass. The HME for IBU solid 
dispersion batches were carried out using the temperature profiles as 
mentioned in Section 3.5.2. During HME processing of IBU: VA64 1:2 very 
viscous extrudate strands were formed which were sticky in nature and when 
kept together strands formed a homogenous mass. In the case of HME 
processing of IBU: HP55 1:2 extrudates formed a good strand. 
The problems in processing due to formation of sticky molten mass with PVP 
VA64 is mainly due to the low Tg of the mixture which is about 39 °C 
whereas the processing issues were not encountered with HPMCP – 
Ibuprofen batches due to high Tg. 
5.1.4 Characterisation of solid dispersion 
End products from S3M3 and HME were subjected to characterisation to 
confirm their amorphous nature and assess pharmaceutical performance. 
5.1.4.1 PXRD 
PXRD was carried out as described in Section 3.4.2. [A-Ibuprofen, B-HME 
Ibuprofen:HP55 1:2, C-HME Ibuprofen:VA64 1:2, D-S3M Ibuprofen:HP55 
1:2, E-S3M Ibuprofen:VA64 1:2] 
Figure 5.2 shows PXRD pattern for ibuprofen and its solid dispersions with 
PVP VA64 and HPMCP HP55 processed by HME and S3M3, The PXRD 
pattern for ibuprofen shows characteristic peaks at various intensities 
whereas it clearly showed complete absence of characteristic peaks for 
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ibuprofen in solid dispersions with PVP VA64 and HPMCP HP55 in both the 
cases (HME and S3M3). 
 
[A-Ibuprofen, B-HME Ibuprofen:HP55 1:2, C-HME Ibuprofen:VA64 1:2, D-
S3M Ibuprofen:HP55 1:2, E-S3M Ibuprofen:VA64 1:2] 
Figure 5.2 PXRD for Ibuprofen solid dispersions with HPMCP HP55 and PVP 
VA64 processed by HME and S3M3 
5.1.4.2 DSC 
DSC was carried out as mentioned in Section 3.4.1. The DSC thermogram 
for ibuprofen showed a sharp melting endotherm at 75 °C (Figure 5.3), 
whereas B and C are physical mixtures of ibuprofen with respective polymers 
which show a melting endotherm for ibuprofen at 75 °C. Thermograms D and 
E are for HME processed solid dispersions for IBU: VA64 1:2 and IBU:HP55 
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1:2 respectively, which did not show any melting endotherm similar to S3M3 
processed IBU:VA64 1:2 (F) IBU:HP55 1:2 (G) solid dispersions which also 
showed an absence of crystalline endotherm for ibuprofen.  
 
[A- Ibuprofen, B- Ibuprofen:VA64 1:2 physical mixture, C- Ibuprofen:HP55 1:2 
physical mixture, D- HME Ibuprofen:VA64 1:2, E- HME Ibuprofen:HP55 1:2, F- S3M 
Ibuprofen:VA64 1:2, G- S3M Ibuprofen:HP55 1:2] 
Figure 5.3 DSC thermograms for ibuprofen solid dispersions processed by 
HME and S3M3 
5.1.4.3 SEM 
SEM was carried out as mentioned in Section 3.4.5. Surface features from 
SEM analysis for ibuprofen solid dispersions show that in the case of HME 
extrudates, the end product is completely non-porous and has smooth 
surface features whereas in case of S3M3, processed dispersions are highly 
porous, fractured and irregular surface (Figure 5.4).  
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Figure 5.4 Surface morphology by SEM of ibuprofen solid dispersions 
processed by HME and S3M 
 
The high porous nature of solid dispersions in case of S3M3 can be 
contributed to three dimensional scissoring actions which exerts very high 
shear on the material. This very high shear causes distortion of the polymer 
structure during S3M processing. Upon discussion with the S3M expertise at 
Sichuan University, China, it was revealed that in milling of higher molecular 
weight polymers, gases could be generated due to bond ruptures upon 
melting of polymers. These gases released from compact molten polymer 
mass may have caused generation of the porous structure. In case of IBU: 
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HP55 solid dispersions generation of highly porous structure during S3M3 
processing might be due to the presence of slight moisture in the mixture 
which released upon high shear application. In case of HME processed solid 
dispersions the highly compact and non-porous structure might have formed 
due to the molten and high pressure nature of flow in the extruder barrel and 
die. 
5.1.4.4 FTIR 
FT-IR was carried out as mentioned in Section 3.4.3. FT-IR spectral vibration 
for ibuprofen showed characteristic stretching at 1714 cm-1 which can be 
attributed to –COOH stretching (Xu, et al. 2007). Both processes showed 
exactly similar stretching in solid dispersion. The finger print stretching 
spectra for ibuprofen at 777cm-1 remained the same in IBU: HP55 1:2 solid 
dispersions and did not show any shift or broadening (Chen, et al. 2012) 
(Figure 5.7). Hydrogen bonds can formed in IBU:PVP VA64 and IBU:HP55 in 
respective functional groups as shown in Figure 5.5 and Figure 5.6. 
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Figure 5.5 Hydrogen bonding between Ibuprofen and PVP VA64 
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Figure 5.6 Hydrogen bonding between Ibuprofen and HPMCP HP55 
 
Figure 5.7 FT-IR spectra for Ibuprofen:HP55 1:2 solid dispersions processed 
by HME and S3M 
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Figure 5.8 FT-IR spectra for Ibuprofen: PVP VA64 1:2 solid dispersions 
processed by HME and S3M 
In the case of Ibuprofen VA64 solid dispersions the finger print stretching for 
ibuprofen at 942 cm-1 completely disappeared (Figure 5.7). A new stretching 
vibration appeared at wave number 3465 cm-1 which may be a contribution of 
the hydrogen bond formation between –COOH of ibuprofen with carbonyl 
bonds of PVP VA64 (Xu et al. 2007). The –OH stretching of –COOH of 
ibuprofen was broadened in case of both the solid dispersion samples. 
Therefore it can be concluded that ibuprofen forms good intermolecular 
hydrogen bonding with PVP VA64 (Figure 5.8). 
5.1.4.5 NIR 
NIR analysis was carried out as described in Section 3.4.4. NIR spectra for 
ibuprofen show highest absorbance at 1676 and 1692 nm in the first 
overtone region of characteristic NIR absorption spectra (Figure 5.8) (Burns 
and Ciurczak, 2009), whereas for PVP VA64 at 1685 nm and for HP55 at 
1662 nm. 
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Figure 5.9 NIR spectra for Ibuprofen solid dispersions processed by HME 
and S3M 
Ibuprofen solid dispersions with PVP VA64 did not show any significant or no 
absorption at the characteristic wavelength of ibuprofen and PVP VA64 in 
both the cases HME and S3M. The presence of hydrogen bonding between 
ibuprofen and PVP VA64 could not be confirmed by NIR spectra. In the case 
of HP55 solid dispersions the characteristic wavelengths of absorption were 
observed at 1676 and 1692 nm respectively in both the HME and S3M 
processed solid dispersions. Out of which HME processed solid dispersions 
showed higher absorption than S3M processed which might due to 
contribution of the higher extent of hydrogen bond formation between –
COOH group of ibuprofen and –COOR group of HP55 (Figure 5.6). 
5.1.4.6 Dissolution 
The content of IBU in both solid dispersions processed by HME and S3M3 
was assayed by UV spectroscopy. In the case of IBU: VA64 1:2 the assay for 
HME were 99.5±2.12% and S3M 98±1.41%, in the case of IBU: HP55 1:2 
the assay for HME 100.5±0.7% and S3M 99±1.4%. 
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Dissolution studies were carried out as mentioned in 3.5.3.1. and dissolution 
parameters were as described in Table 3.8. Dissolution profile for IBU solid 
dispersions shows a faster release in the case of PVP VA64 solid 
dispersions processed by HME and S3M whereas in the case of solid 
dispersions with HP55, HME processed dispersions show slightly higher 
release than S3M processed (Figure 5.9). In the case of IBU: VA64 1:2 
dispersion all the drug was released within one hour whereas in the case of 
IBU:HP55 1:2 dispersion only 80% drug was released within one hour and it 
took 4 hours to release all IBU present within the dispersion. 
 
 
Figure 5.10 Dissolution profile for IBU solid dispersions processed by HME 
and S3M 
There was not much difference in IBU release in the case of PVP VA64 solid 
dispersions as shown in Figure 5.10. This might be due to the dispersions 
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produced in both being converted into a solid viscous mass. In the case of 
IBU dispersion with HP55 although the S3M3 processed dispersion was 
highly porous compared to the HME processed dispersion there was 
relatively minor difference in drug release. The solid dispersions were 
crushed to powder form prior dissolution studies, which might have 
contributed to the smaller difference in drug release between dispersions 
processed by HME and S3M3. 
A T test was applied to IBU: HP55 1:2 solid dispersion drug releases at 
60mins and the calculated p values used to test if there was significant 
difference between HME and S3M3 processed dispersions. The T test gave 
a p value of 0.22 which is higher than 0.05, this concludes that there is no 
significant statistical difference between two processes with regard to drug 
release at given time points for IBU: HP55 1:2 dispersion. 
5.2 GLIBENCLAMIDE 
5.2.1 Glibenclamide calibration 
The calibration curve for GLIB was linear over the concentration range of 1-
10 ug/ml. The linearity equation was calculated using calibration curve, slope 
of the equation was 0.0526, constant 0.0044 and R2 0.9998. From the 
calibration equation it can be confirmed that absorbance v/s concentration 
follows Beer’s law (Figure 5.11). 
 
 
120 
 
 
Figure 5.11 Glibenclamide calibration curve by UV spectrophotometer at 
240nm 
5.2.2 Processing of solid dispersion 
Accurately weighed GLIB and respective polymers PVP VA64 and ethyl 
cellulose in the ratio 1:2 were mixed well and sieved through 80 mesh to 
achieve uniform particle size. The mixture was then subjected to turbula 
mixer for 10mins to get a uniform homogenous dispersion. Material feeding 
to S3M3 was good in the case of both the polymers. First and second cycle 
gave end product in the form of small agglomerated granular mass which 
was converted into a solid agglomerated molten mass at the end of the third 
cycle in case of PVP VA64. In the case of ethyl cellulose the end product 
was achieved in the third cycle. HME for GLIB solid dispersion batches were 
carried out using the temperature profiles as mentioned in Section 3.5.2. The 
extrusion processing for GLIB dispersions was smooth and plasticisers used 
helped to get good extrudate product in the form of cylindrical extruder die 
shaped extrudates with low processing torque levels. 
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5.2.2 Characterisation of solid dispersion 
The GLIB solid dispersions processed by HME and S3M3 were subjected to 
various characterisations 
5.2.2.1 PXRD 
PXRD for GLIB solid dispersions were carried out as described in Section 
3.4.2.  
 
[A-Glibenclamide, B- HME Glibenclamide:Ethyl Cellulose 1:2, C-HME 
Glibenclamide: VA64 1:2  , D-S3M Glibenclamide:Ethyl Cellulose 1:2 , E-S3M 
Glibenclamide:VA64 1:2 , F-Ethyl Cellulose  , G- PVP VA64] 
Figure 5.12 PXRD for glibenclamide solid dispersion processed by HME and 
S3M 
The PXRD pattern for GLIB shows all crystalline peaks at respective 2θ 
values with respective intensities (Table 4.1). Solid dispersions with VA64 
and ethyl cellulose processed by HME and S3M not show any crystalline 
peaks for GLIB (Figure 5.12). The plain polymers showed absence of any 
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characteristic peak due to their amorphous nature. This confirms that in the 
case of both the solid dispersions, drug particles were completely covered 
within the polymer chains. This will be confirmed upon DSC analysis. 
5.2.2.2 DSC 
DSC was carried out as mentioned in Section 3.4.1. The DSC thermogram 
for GLIB shows a sharp melting endotherm at 175 °C (A). A physical mixture 
of GLIB with VA64 (B) and ethyl cellulose (C) also shows a characteristic 
endotherm for GLIB (Figure 5.13). 
 
[A- Gilbenclamide, B- Glibenclamide:VA64 physical mixture, C- Glibenclamide:Ethyl 
cellulose physical mixture, D- HME Glibenclamide:VA64 1:2, E- HME 
Glibenclamide:Ethyl cellulose 1:2, F- S3M Glibenclamide:VA64 1:2, G- S3M 
Glibenclamide:Ethyl cellulose 1:2] 
Figure 5.13 DSC thermograms of Gilbenclamide solid dispersions processed 
by HME and S3M 
Solid dispersions with these both polymers processed by HME and S3M 
process showed an absence of any crystalline endotherms for GLIB. The 
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results show that in the case of physical mixtures of GLIB and polymers, a 
solid solution was not formed just by application of heat in DSC. Upon HME 
and S3M3 processing GLIB was completely solubilised in the polymer matrix 
and did not show any melting endotherm.   
5.2.2.3 SEM 
Surface features for GLIB solid dispersions were performed according to the 
procedure given in Section 3.4.5. 
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Figure 5.14 Surface morphology by SEM of glibenclamide solid dispersions 
processed by HME and S3M 
SEM analysis of HME processed solid dispersions showed very smooth and 
plain surface features whereas in the case of S3M, highly irregular and 
porous structures were observed on the surface (Figure 5.14). As discussed 
in IBU: HP55 dispersion case similar thing happened in GLIB dispersions, 
S3M3 processed solid dispersions with a porous structure can be attributed 
to trapped moisture or release of other gases during high shear processing. 
5.2.2.4 FT-IR 
FT-IR analysis was done according to procedure given in Section 3.4.3.  
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Figure 5.15 FT-IR spectra for glibenclamide: PVP VA64 1:2 solid dispersions 
processed by HME and S3M 
In the case of glibenclamide solid dispersions processed by S3M and HME 
the characteristic spectral stretching for glibenclamide at 3367 cm-1 and 3313 
cm-1 for strong -NH stretching disappeared in the case of PVP VA64 
dispersions and in case of S3M processed dispersions the peak at 3367cm-1 
shifted to a higher wavenumber which can be due to the strong 
intermolecular interaction between glibenclamide and VA64 (Chauhan et al. 
2005) (Figure 5.15).  
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Figure 5.16 Hydrogen bonding between glibenclamide with ethyl cellulose 
and PVP VA64 
The typical amide stretching vibration at 1716cm-1 completely disappeared 
and only showed characteristic spectra for VA64 at 1710 cm-1, possibly due 
to strong -H bonding between glibenclamide and VA64. The urea -NH 
stretching vibration at 1278 cm-1, 1618 cm-1, 1525 cm-1 and -SO2  stretching 
vibrations at 1342 cm-1, 1159 cm-1 were distinct in pure glibenclamide 
spectra but were broadened and shifted in the case of amorphous 
dispersions due to hydrogen bonding between the functional groups between 
the drug and polymer (Figure 5.16).  
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Figure 5.17 FT-IR spectra for glibenclamide: ethyl cellulose 1:2 solid 
dispersions processed by HME and S3M 
In the case of GLIB:EC 1:2 solid dispersions characteristic amide peak 
stretching vibrations at 3367 cm-1 and3313 cm-1 completely disappeared, and 
stretching at 1716 cm-1, 1618 cm-1, 1525 cm-1 were broadened and 
significantly reduced in the case of solid dispersion due to strong 
intermolecular hydrogen bonding between the drug and polymer (Figure 
5.17). 
5.2.2.5 NIR 
NIR was carried out as described in section 3.4.4. Glibenclamide showed 
characteristic NIR absorption at 2043 and 2069 nm in the first overtone 
region whereas in the same region PVP VA64 showed good absorption at 
2141 nm and moderate absorption for ethyl cellulose at 2046 nm (Figure 
5.18). 
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Figure 5.18 NIR spectra for glibenclamide solid dispersions processed by 
HME and S3M 
Glibenclamide solid dispersions with PVP VA64 processed by S3M showed 
a peak shift at 2035 nm and in the case of HME processed at 2021 nm which 
can be attributed to the presence of hydrogen bonds between the carbonyl 
group of VA64 and the -NH group of glibenclamide. In the case of solid 
dispersions of ethyl cellulose processed by S3M the NIR absorption peak 
shifted to 2032 nm and in the case of HME it showed significant shift to 2018 
nm which can be attributed to strong bond formation between -C=O groups 
of ethyl cellulose and -NH groups of glibenclamide. 
5.2.2.6 Dissolution 
The content of GLIB in both the solid dispersions processed by HME and 
S3M3 was assayed by UV spectroscopy. In the case of GLIB: VA64 1:2 the 
assay for HME 99±1.4% and S3M 99±2.8%, in the case of GLIB: EC 1:2 the 
assay for HME100+1.41 ±% and S3M 99±1.4%. 
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Dissolution parameters and procedure were carried out as described in 
Section 3.5.3.1.Dissolution studies of GLIB solid dispersions with VA64 
processed by S3M showed faster release compared to HME dispersion. In 
the case of dispersions with ethyl cellulose both the HME and S3M showed a 
similar kind of controlled release over the period of 24 hours. GLIB: VA64 1:2 
processed by S3M3 released 100% drug within 3 hours whereas HME 
processed dispersion showed a slightly delayed release and released 100% 
drug in 6 hours.  This slow release in the case of dispersions processed by 
HME can be attributed to compact and non-porous surface features of the 
extrudates whereas in the case of dispersions processed by S3M3 the 
surface was very rough and porous, although dispersions were converted to 
powder form prior to dissolution. The higher release in the case of S3M3 can 
be attributed to distortion of the surface features to particulate level. In the 
case of GLIB: Ethyl cellulose dispersions it took 10 hours to release 50% of 
the drug and another next 24 hours to release 100%. 
A T test was applied to GLIB: VA64 1:2 solid dispersion drug release at 
60mins and p values was calculated to test if there was there statistical 
difference between HME and S3M3 processed dispersions. The T test gave 
a p value of 0.0075 which is less than 0.05, this concludes that there was 
statistically significant difference between the two processes with regards to 
drug release at given time points. 
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Figure 5.19 Dissolution profiles for glibenclamide solid dispersions processed 
by HME and S3M 
5.3 PARACETAMOL 
5.3.1 Paracetamol calibration curve 
The calibration curve for PARA was linear over the concentration range of 1-
10 ug/ml. The linearity equation was calculated using the calibration curve, 
the slope of the equation was 0.0679, constant 0.0083 and R2 was 0.9995 
(Figure 5.20). There was good linearity found between concentration v/s 
absorbance. 
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Figure 5.20 Paracetamol calibration curve by UV spectrophotometer at 
243nm 
5.3.2 Procedure for solid dispersion 
Accurately weighed PARA: HP55 mixture in 1:2 ratio was mixed well and 
passed through an 80 mesh. This mixture was fed to a turbula mixer for 10 
mins to ensure homogenous dispersion. This mixture was then fed to S3M3. 
Material flow was good in the case of PARA dispersion. The end product of 
1st and 2nd cycles yielded a small granular mass which was fed to S3M3 for 
the 3rd cycle. At the end of 3rd cycle the product obtained was molten 
agglomerated mass. In case of HME for PARA dispersion, TEC was used as 
a plasticiser in concentration of 10% w/w. The temperature profiles and 
extrusion parameters were kept as described in section 3.5.2. HME yielded 
dispersion in the form of a cylindrical extrudates strands at the given 
extrusion temperature profiles. 
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5.3.3 Characterisation of the solid dispersion 
The end product obtained at the end of 3rd cycle of S3M3 and HME were 
characterised by various analytical techniques and for drug release. 
5.3.3.1 PXRD 
PXRD for PARA solid dispersion were carried out as described in Section 
3.4.2.
 
[A-Paracetamol, B-HME Paracetamol: HP55 1:2, C-S3M Paracetamol: HP55 1:2] 
Figure 5.21 PXRD for paracetamol solid dispersions processed by HME and 
S3M 
PXRD for PARA showed a sharp characteristic peak at 2θ values with 
respective intensities (Table 4.1) (Figure 5.21). In the case of PARA solid 
dispersions all peaks for crystalline PARA were absent. The absence of 
crystalline peaks in solid dispersions shows that drug particles are 
completely converted into amorphous form which is further confirmed 
thermal analysis by DSC. 
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5.3.3.2 DSC 
DSC was carried out as described in Section 3.4.1. The DSC thermograms 
were analysed for the presence of melting endotherm for PARA. 
 
[A- Paracetamol, B- Paracetamol:HPMCP HP55 physical mixture, C- HME 
Paracetamol:HPMCP HP55 1:2, D- S3M Paracetamol:HPMCP HP55 1:2] 
Figure 5.22 DSC thermograms of Paracetamol solid dispersions processed 
by HME and S3M 
DSC thermogram for crystalline PARA and physical mixture with HP55 
shows a sharp melting endotherm at 170 °C (Figure 5.22). In the case of 
dispersions processed by HME and S3M there is an absence of crystalline 
endotherm for PARA. The physical mixture showed similar melting 
endotherm to PARA which shows that heating of the physical mixture did not 
yield an amorphous dispersion. The absence of a melting endotherm in solid 
dispersions shows PARA is completely solubilised in HP55 polymer matrix 
which made it completely amorphous. 
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5.3.3.3 SEM 
SEM characterisation for various surface features of PARA solid dispersions 
using procedure as described in Section 3.4.5.  
 
Figure 5.23 Surface morphology by SEM of paracetamol solid dispersions 
processed by HME and S3M 
SEM analysis for HME processed dispersion shows smooth and plain 
surface features with very low porosity. S3M processed dispersion shows a 
highly porous surface and surface irregularity (Figure 5.23). Almost all the 
solid dispersions processed by S3M3 showed distorted and irregular, rough 
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surface features whereas in the case of HME processed dispersions all the 
extrudates showed smooth, plain and non-porous surface features. 
5.3.3.4 FT-IR 
FT-IR characterisations were carried out as described in Section 3.4.3.  
 
Figure 5.24 FT-IR spectra for paracetamol: HP55 1:2 solid dispersions 
processed by HME and S3M 
In the case of paracetamol amorphous dispersions with HPMCP HP55, 
Paracetamol showed characteristic -OH stretching at 3324 cm-1 and 3155 
cm-1 out of which 3155 cm-1 become prominent in case of dispersions and 
3324cm-1 showed a similar stretching pattern with no shift in position 
(Talegaonkar et al. 2007) (Figure 5.24). 
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Figure 5.25 Hydrogen bonding between paracetamol and HPMCP HP55 
 
The unsaturated stretching at 1610 cm-1, 1650 cm-1 remained similar in 
dispersion samples.  The 1054 cm-1 stretching vibration for -C-O-C in 
HPMCP HP55 showed broaden vibration in case of dispersions. This shows 
that there is hydrogen bond between –OH of paracetamol and –C-O-C of 
HPMCP HP55 (Figure 5.25)  
5.3.3.5 NIR 
NIR analysis was carried out as described in Section 3.4.4. Paracetamol 
shows high absorption in the second overtone region at wavelengths 1639 
and 1670 nm (Figure 5.26). 
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Figure 5.26 NIR spectra for paracetamol solid dispersions processed by 
HME and S3M 
 
HP55 shows NIR absorption in the second overtone region at 1662 nm. 
Paracetamol solid dispersion processed by HME show very high NIR 
absorption at 1639 and 1670 nm whereas in case of S3M processed solid 
dispersion it shows very low absorptions at 1639 and 1670 nm (Figure 5.26). 
The change in the intensity and shifts in the absorption for PARA 
characteristic absorption shows that there is potential hydrogen bond 
formation between –OH of PARA and –C-O-C of HP55.  
5.3.3.6 Dissolution 
The content of PARA in solid dispersions processed by HME and S3M3 was 
assayed by UV spectroscopy. In the case of PARA: HP55 1:2 the assay for 
HME was 100±1.4% and for S3M was 99.5±2.12%. 
Dissolution studies for PARA solid dispersion were carried out as mentioned 
in Section 3.5.3.1. Drug release pattern over the period of time is shown in 
Figure 5.27  
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Figure 5.27 Dissolution profile for paracetamol solid dispersions processed 
by HME and S3M 
Dissolution studies for PARA solid dispersion showed slightly faster release 
in case of HME processed dispersions compared to S3M. There was not 
much difference in drug release over the time points. Within one hour 90% of 
drug was released, HME processed solid dispersions showed 100% drug 
release after one hour whereas in case of S3M3 processed it took 3 hours to 
release 100% drug. 
Statistical analysis in case of PARA: HP55 1:2 was done using a t-test. P 
value was calculated using the t test to analyse the statistical difference 
between two processes. The p value from t test was found to be 0.019 which 
is less than 0.5 which signifies there is statistical difference between the two 
processes with regards to drug release at given time point. 
0.00 
20.00 
40.00 
60.00 
80.00 
100.00 
0 50 100 150 200 
%
D
R
U
G
 R
EL
EA
SE
 
TIME (min) 
S3M PARA HP55 12 
HME PARA HP55 12 
PARA 
 
 
139 
 
5.3.3.6 Degradation analysis 
PARA yields 4-amino phenol as degradation product when heated or 
extruded to higher temperatures (Bhimavarapu et al. 2011).   
5.3.3.6.1 4-amino phenol calibration  
The calibration curve for 4-amino phenol was linear over the concentration 
range of 20-160 ug/ml. The linearity equation was calculated using 
calibration curve, slope of the equation is 5656.8, constant 53496 and R2 
0.9872 (Figure 5.28). The calibration equation was used to calculate the 
amount of 4-amino phenol generated. 
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Figure 5.28 Calibration curve for 4-amino phenol by UV spectrophotometer 
at 227nm 
 
Figure 5.29 4-Amino phenol analysis in paracetamol: HP55 1:2 solid 
dispersions processed by HME and S3M 
The amount of 4-amino phenol generated in S3M3 was higher compared to 
HME (Figure 5.29). The reason for the higher degradation can be attributed 
to the uncontrolled rise in temperature during S3M processing as it does not 
have any opportunity to control temperature, it can also attributed to 
extremely high shear.  
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5.4 Carbamazepine 
5.4.1 Calibration curve for carbamazepine 
The calibration curve for CBZ was linear over the concentration range of 1-
10 ug/ml. The linearity equation was calculated using calibration curve, slope 
of the equation is 0.0506, constant 0.0016 and R2 0.9996 (Figure 5.30). The 
calibration equation due to good linear range was used for the calculation of 
drug release. 
 
Figure 5.30 Carbamazepine UV spectrophotometry calibration curve at 
288nm 
5.4.2 Procedure for solid dispersion 
CBZ with different polymers were explored to form solid dispersion in this 
study. As described in section 3.5.1 CBZ solid dispersions were attempted 
with all four selected polymers i.e. PVP VA64, HPMCP HP55, HPMCAS and 
ethyl cellulose. In the case of HPMCP HP55 and PVP VA64 two different 
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ratios were attempted for solid dispersions which are 1:1 and 1:2. All other 
CBZ dispersions were carried out in 1:2 CBZ: polymer ratio. All the drug: 
polymer blends obtained after mixing in a turbula mixer showed good flow in 
the S3M3 process.  The formation of agglomerated mass was observed at 
the end of the 3rd cycle during S3M3 process. In the case of CBZ:HP55 1:1 
and 1:2 batches there was formation yellow coloured mass with a distinctive 
smell at the end of the 3rd cycle. Similar products were obtained in case of 
CBZ: HPMCAS solid dispersion. In the case of PVP VA64 and ethyl cellulose 
products were in the form of a white coloured molten agglomerated mass. In 
the case of HME different temperature profiles and extrusion parameters 
were used as described in Section 3.5.2. 
5.4.3 Characterisation of solid dispersion 
All the CBZ solid dispersions obtained in S3M3 and HME processing were 
subjected to various characterisation techniques described as follows. 
5.4.3.1 PXRD 
Powder X-ray characterisation for both HME and S3M processed solid 
dispersion showed no crystalline peak for CBZ as shown in the figure below. 
Powder X ray diffraction for plain polymer samples did not show any 
crystalline peaks. The powder X-ray diffraction pattern for pure CBZ showed 
characteristic high intensity peaks at 2θ values of 13.2, 14.28, 15.44, 15.96, 
17.24, 18.8, 19.6, 20.48, 23.52, 24.24, 25.08 and 26.84º which matched the 
powder diffraction pattern reported for CBZ (Figure 5.31). All the solid 
dispersions showed the absence of the characteristic peaks for CBZ which 
confirms all solid dispersions were in a completely amorphous state which 
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can be again confirmed by DSC thermograms. Except for one solid 
dispersion, 50% drug loaded CBZ: PVP VA64 1:1 which showed a reduced 
intensity peak for CBZ at the same 2θ in case of both processes. This finding 
was contradictory when compared to DSC thermogram of 50% drug loaded 
CBZ: PVP VA64 1:1 batch as the DSC did not show a presence of 
endotherm for crystalline CBZ. 
 
[A-Carbamazepine, B-Ethyl cellulose, C-HPMCP HP55, D-PVP VA64, E-HME 
carbamazepine:VA64 1:1, F-HME carbamazepine: HP55 1:1, G-HME 
carbamazepine:HP55 1:2, H-HME carbamazepine:HPMCAS 1:2 , I- HME 
carbamazepine:Ethyl Cellulose 1:2, J-HME Carbamazepine:VA64 1:2] 
Figure 5.31 PXRD for carbamazepine solid dispersions processed by HME 
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[A-Carbamazepine, B-Ethyl cellulose, C-HPMCP HP55, D-PVP VA64, E-S3M 
carbamazepine:Ethyl Cellulose 1:2,F-S3M carbamazepine: HP55 1:1, G-S3M 
carbamazepine:HP55 1:2, H-S3M carbamazepine:HPMCAS 1:2 , I-S3M 
carbamazepine:VA64 1:1, J-S3M Carbamazepine:VA64 1:2] 
Figure 5.32 PXRD for carbamazepine solid dispersions processed by S3M 
5.4.3.2 DSC 
All samples for solid dispersions and pure drug molecules were subjected to 
DSC analysis. The presence or absence of the characteristic melting 
endotherm for the API gives an idea whether the drug is completely 
dissolved or dispersed in the polymer matrix. Crystalline CBZ shows two 
melting endotherms, at 175 ºC and at 191 ºC due to the polymorphic change. 
It is considered to relate to the polymorphic transformation of CBZ from form 
III to CBZ form I. The physical mixture shows a small endotherm at 170º C 
and there is absence of another endotherm which shows that the molten 
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polymer has dissolved the crystalline CBZ with the absence of the 
polymorphic transformation into CBZ form I (Figure 5.33). All the melt 
extruded amorphous dispersions showed an absence of either of the peaks 
for CBZ forms, which clearly shows that the drug has completely dissolved 
into the polymer matrix or converted into a polymer matrix of HPMCP HP55 
and HPMCAS polymer in both the concentrations 33% and 50% of CBZ. The 
high shear and temperature encountered during melt extrusion helped the 
solubilisation of CBZ into the respective polymer matrices of HPMCP HP55 
and HPMCAS. In the case of S3M processed CBZ dispersions a similar 
trend was observed, despite the fact that in S3M only shear caused a rise in 
temperature as there is no external heating or cooling available or applied 
during S3M. All the S3M processed CBZ dispersions were amorphous in 
nature as shown in Figure 5.34. 
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[A- Carbamazepine, B- Carbamazepine: HP55 physical mixture, C- 
Carbamazepine:HPMCAS physical mixture, D- Carbamazepine:PVP VA64 physical 
mixture, E- Carbamazepine:Ethyl cellulose physical mixture] 
Figure 5.33 DSC thermograms for physical mixtures of carbamazepine and 
selected polymers to be processed by HME and S3M 
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[A- Carbamazepine, B- HME carbamzepine:HP55 1:2, C- HME 
carbamazepine:HP55 1:1, D- HME carbamazepine:HPMCAS 1:2, E- HME 
carbamazepine:VA64 1:2, F- HME CBZ VA64 11, G- HME CBZ Ethyl cellulose 1:2] 
Figure 5.34 DSC thermograms for carbamazepine solid dispersions 
processed by HME 
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[A- Carbamazepine, B- S3M carbamzepine:HP55 1:2, C- S3M 
carbamazepine:HP55 1:1, D- S3M carbamazepine:HPMCAS 1:2, E- S3M 
carbamazepine:VA64 1:2, F- S3M CBZ VA64 11, G- S3M CBZ Ethyl cellulose 1:2] 
Figure 5.35 DSC thermograms for carbamazepine solid dispersions 
processed by S3M 
In the case of CBZ dispersions with PVP VA64 and ethyl cellulose both the 
dispersions processed by HME and S3M showed absence of both the 
endotherm in thermogram (Figure 5.34 and Figure 5.35). 
The processing temperature in hot melt extrusion needed to be modified 
according to the softening point of the respective polymer for PVP VA64 and 
ethyl cellulose. To achieve melt temperature profile for PVP VA64 at 110 ºC 
and for ethyl cellulose at 140 ºC required addition of plasticisers using PEG 
2000 and TEC respectively. Processing at these temperatures made the 
drug miscible in the polymer matrix and was not dispersed which can be 
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confirmed from absence of crystalline endotherm in the solid dispersion 
processed by both techniques.   
5.4.3.3 SEM 
SEM anaylysis for various CBZ solid dispersions showed various 
morphological features.  
 
Figure 5.36 Surface morphology by SEM of carbamazepine solid dispersions 
processed by HME and S3M 
SEM analysis for CBZ solid dispersion with HP55 showed distorted surface 
features in the case of HME processed samples whereas S3M processed 
dispersion showed a very irregular surface feature with a porous structure 
(Figure 5.36). 
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Figure 5.37 Surface morphology by SEM of carbamazepine solid dispersions 
with PVP VA64 processed by HME and S3M 
SEM analysis of CBZ dispersions with VA64 showed smooth and plain 
surface features in the case of HME processed samples with very low 
surface porosity whereas in the case of S3M processed dispersions the 
surface shows high porosity and surface roughness (Figure 5.37).  
5.4.3.4 FT-IR 
FT-IR analysis for carbamazepine solid dispersions were done as described 
in Section 3.4.3. S3M processed CBZ and PVP VA64 solid dispersion 
samples are shown in figure below. CBZ shows characteristic stretching for -
NH at 3462 cm-1 with sharp peak and shows spectra for -NH asymmetrical 
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stretching at 3159 cm-1 which are reduced in the solid dispersion samples in 
case of 33% drug loading and 50% drug loading. CBZ stretching at 1382 cm-
1 typically shows -C-NH2 vibrations which are broadened in the case of solid 
dispersion samples (Figure 5.38 and Figure 5.40). Spectra broadening or 
shifting can be considered as bonding between respective functional groups 
of drug and polymer. The PVP VA64 spectra showed typical stretching at 
1728 cm-1 and 1672 cm-1 for carbonyl bonds. 1672 cm-1 stretching shows 
reduced intensity in the case of solid dispersion samples which can be owed 
to hydrogen bonding present in CBZ and PVP VA64 (Patterson et al. 2008). 
In the case of HME processed solid dispersion batches all the spectra 
showed similar behaviour to the S3M processed dispersions (Figure 5.41). 
The characteristic -H bond stretching near 3000 cm-1 spectrum was 
broadened in the case of solid dispersion batches as compared to pure 
polymer which suggested the presence of hydrogen bonding between CBZ 
and PVP VA64.  
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Figure 5.38 FT-IR spectra for carbamazepine:PVP VA64 solid dispersions 
processed by S3M. 
 
Figure 5.39 Hydrogen bond formation between carbamazepine and 
respective functional groups of polymers PVP VA64, HPMCP HP55, 
HPMCAS and ethyl cellulose 
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Figure 5.40 FT-IR modified spectra for carbamazepine: PVP VA64 solid 
dispersions processed by S3M 
 
Figure 5.41 FT-IR spectra for carbamazepine:VA64 solid dispersions 
processed by HME 
 In the case of HPMCP HP55 solid dispersion samples with both S3M and 
HME samples, the characteristic stretching at 1054cm-1 shows -C-O-C 
vibrations which shows broadening in solid dispersion spectra. In particular 
broadening in HME processed dispersions was more significant as 
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compared to S3M processed which can be due to the possible hydrogen 
bonding between HPMC and CBZ (Douroumis et al. 2007). Characteristic 
stretching at 1731cm-1 in pure HPMCAS and HPMCP HP55 spectra shows 
reduced intensity in the case of all the dispersions (Figure 5.42 and Figure 
5.43).   
 
Figure 5.42 FT-IR spectra for carbamazepine solid dispersions with 
HPMCAS and HPMCP HP55 processed by S3M 
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Figure 5.43 FT-IR spectra for carbamazepine solid dispersions with 
HPMCAS and HP55 processed by HME 
In the case of CBZ:EC 1:2 solid dispersion batches, EC shows a 
characteristic stretching at 1050cm-1 due to -C-O-C vibration stretch in cyclic 
ether which remained the same or slightly broadened in the case of 
amorphous dispersion in both processes (Figure 5.44). The asymmetric 
stretching vibrations at   2980cm-1 and 2865cm-1 showed similar spectra for 
both types of dispersions. The characteristic spectra in CBZ at 3462cm-1 for -
NH stretching showed a reduced intensity which might be due to molecular 
level interaction between CBZ and EC. 
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Figure 5.44 FT-IR spectra for carbamazepine: Ethyl cellulose solid 
dispersions processed by HME and S3M 
5.4.3.5 NIR 
NIR spectra for CBZ show characteristic absorbance in the second overtone 
region at a wavelength 1468 nm (Figure 5.45). 
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Figure 5.45 NIR spectra for carbamazepine solid dispersions processed by 
HME 
CBZ solid dispersions processed by HME showed similar absorption at 1468 
nm in the order of highest absorption for CBZ: VA64 1:1 solid dispersion and 
the lowest for CBZ: HPMCAS 1:2 solid dispersions. In the case of CBZ: Ethyl 
cellulose 1:2 the absorption showed a peak shift to 1464 nm. The reduced 
intensities owing to the solid dispersion of CBZ with different polymers can 
be due to change in the intensity and nature of hydrogen bonding present in 
CBZ and respective polymer, which needs to be confirmed by FT-IR 
analysis. 
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Figure 5.46 NIR spectra for carbamazepine solid dispersions processed by 
S3M 
In the case of NIR absorption spectra for S3M processed CBZ solid 
dispersions, the spectra were similar but with reduced intensity absorption at 
wavelength 1468 nm in case of CBZ: VA64 1:1 only whereas there was a 
shift in peak absorption at 1459 nm in the case of solid dispersions CBZ: 
HP55 1:1, at 1521 nm for CBZ: HP55 1:2 and CBZ: HPMCAS 1:2 and at 
1466 nm for CBZ: Ethyl cellulose 1:2 (Figure 5.46). The shifts in NIR spectra 
explain that there is formation of hydrogen bonds between –NH of CBZ and 
respective functional groups of the polymers.      
5.4.3.6 Dissolution 
Assay: The content of CBZ in both solid dispersions processed by HME and 
S3M3 was assayed by UV spectroscopy. The assay values are shown in 
Table 5.1  
Table 5.1 Assay values for carbamazepine solid dispersions 
Solid dispersion HME assay S3M assay 
CBZ:HP55 1:1 99±1.4% 99.5±2.12% 
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CBZ:HP55 1:2 100±2.8% 99±2.8% 
CBZ:VA64 1:1 98.5±2.1% 99±0.7% 
CBZ:VA64 1:2 99.5±0.7% 101±2.8% 
CBZ:HPMCAS 1:2 98.5±0.7% 100±1.4% 
CBZ:EC 1:2 99.5±2.1% 97.5±2.12% 
 
All CBZ solid dispersion dissolutions were carried out as detailed in Section 
3.5.3.1.  
 
 
Figure 5.47 Dissolution profiles for carbamazepine solid dispersions with 
HPMCAS and HP55 processed by HME 
 
HME processed CBZ dispersions with HP55 (1:2) and HPMCAS show 100% 
drug release within two hours whereas HP55 (1:1) showed slightly slow 
release (Figure 5.47).  
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Figure 5.48 Dissolution profiles for carbamazepine solid dispersions with 
HPMCAS and HP55 processed by S3M 
 
Dissolution studies for S3M processed solid dispersions with HPMCAS 
showed faster and complete drug release within one hour, whereas 33% 
drug loaded HP55 dispersion showed slower but complete release after two 
hours (Figure 5.48). In the case of 50% drug loaded HP55 dispersion, 
complete drug release occurred after one hour. 
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Figure 5.49 Dissolution profiles for carbamazepine solid dispersions with 
PVP VA64 processed by HME and S3M 
Dissolution profiles for CBZ dispersions with VA64 in both cases and both 
drug loading ratios showed complete drug release after one hour                    
(Figure 5.49). Statistical analysis and variance was calculated at a given 
point in the dissolution by a t test and p value was calculated to analyse the 
variance between two processes. The T test was applied to the drug release 
at 30 mins and the p value was found to be 0.421 which shows that drug 
release by two processes at the given point have good correlation and are 
statistically similar.  
Dissolution profiles for CBZ solid dispersion with ethyl cellulose showed slow 
release over a period of 48 hours which was slightly higher in case of S3M 
processed dispersion (Figure 5.50). 
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Figure 5.50 Dissolution profile for carbamazepine solid dispersions with ethyl 
cellulose processed by HME and S3M 
5.4.3.7 Degradation analysis 
5.4.3.7.1 Iminostilbene determination 
The United State Pharmacopoeia (USP) have recommended 0.2% w/w of 
iminostilbene as a maximum allowable limit in CBZ or its formulations (USP 
30/ NF 25). The thermal degradation of CBZ into iminostilbene is known and 
thus it is important to know the extent of degradation of CBZ into 
iminostilbene during HME and S3M processing (Figure 5.51).  
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Figure 5.51 Carbamazepine to iminostilbene conversion as degradation 
product 
The estimation of iminostilbene in HME and S3M processed samples was 
performed using HPLC analysis. First, the calibration curve for iminostilbene 
was constructed and the generated regression equation was used for 
calculating the amount of iminostilbene in the processed samples. 
Figure 5.52 shows the calibration curve for iminostilbene. 
 
Figure 5.52 Calibration curve for iminostilbene by UV spectrophotometer at 
253nm 
Regression equation 
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Figure 5.53 Chromatogram for carbamazepine and iminostilbene 
Figure 5.53 shows a representative chromatogram where CBZ and 
iminostilbene eluted at different retention times suggesting that the capability 
of developed HPLC for detecting CBZ and iminostilbene simultaneously. 
 
Figure 5.54 Degradation analysis of carbamazepine by imminostilbene 
determination in carbamazepine solid dispersions processed by HME and 
S3M 
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From Figure 5.54 it can be observed that generation of iminostilbene was 
consistently higher in the case of S3M processed dispersions compared to 
HME processed solid dispersions. Highest CBZ degradation was observed in 
case of the CBZ: HP55 1:2 solid dispersions batch which is contradictory to 
the amount of degradation observed in CBZ: HP55 1:1 solid dispersions, 
whereas the CBZ degradation was least in case of CBZ: HPMCAS 1:2. It can 
be observed that the amount of polymer present in mixture plays an 
important role for drug degradation during high shear processes such as 
HME and S3M3. As the concentration of polymer increased in dispersions 
the amount of shear exerted on the material was higher which resulted in 
more degradation of drug. The polymer chains were stretched and entangled 
during S3M and HME process whereas CBZ being small molecular weight 
drug which cannot experience shear or stress as itself, stretching of polymer 
chains under high stress environment of S3M and HME made drug 
experience same amount of shear which caused higher degradation of API.   
Similarly HPMCP HP55 polymer was analysed for degradation by calculating 
the amount of phthalic acid and subsequently phthalic anhydride generated 
during HME and S3M3 processing.  
5.4.3.7.2 Phthalic acid determination 
Phthalic acid is generated as a degradation product when HPMCP is 
processed at higher temperatures and the generated phthalic acid further 
degrades into phthalic anhydride (Figure 5.55) 
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Figure 5.55 HPMCP degradation into phthalic acid and subsequent phthalic 
acid degradation into phthalic anhydride 
Calibration curve 
The HPLC calibration curve for phthalic acid was linear over concentration 
range of 10-60 ug/ml. The linearity equation was calculated using calibration 
curve, slope of the equation is 72667.3377, constant -16465.8202 and R2 
0.9998 (Figure 5.56). The calibration equation was used to calculate the 
amount of the phthalic acid generated. 
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Figure 5.56 Calibration curve for phthalic acid 
The degradation analysis by HPLC showed that the melt extruded and pan 
milled amorphous dispersion has phthalic acid content below 1% as shown 
in Figure 5.57 
 
Figure 5.57 phthalic acid determinations in carbamazepine: HP55 solid 
dispersions processed by HME and S3M  
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The amount of phthalic acid generated was higher in the case of HME 
processed CBZ: HP55 dispersions. The amount of phthalic acid generated 
did not vary with the polymer concentration. It was slightly higher in case of 
CBZ: HP55 1:2 compared to CBZ: HP55 1:1, this finding is complementary to 
generation of iminostilbene. The degradation of polymer and drug is 
dependent on the amount of polymer and not on the drug. The higher 
generation of phthalic acid may have enhanced the generation of more 
iminostilbene in the case of CBZ: HP55 1:2 dispersion. Blank HPMCP HP55 
showed highest degradation and generated 2.5% of phthalic acid. Shear 
exerted by S3M3 is based on the amount of polymer which clearly showed in 
case of phthalic acid generated in the case of blank HP55. 
5.4.3.7.3 Phthalic anhydride analysis 
Phthalic anhydride calibration curve 
The HPLC calibration curve for phthalic anhydride was linear over 
concentration range of 10-60 ug/ml. The linearity equation was calculated 
using calibration curve, slope of the equation was 162467.1299, constant -
51355.1665 and R2 0.9989 (Figure 5.58).  
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Figure 5.58 Phthalic anhydride calibration curve 
 
The amount of phthalic anhydride generated was expected to be higher 
where phthalic acid generation is higher (Karandikar, et al. 2014), the formed 
phthalic acid is unstable and will try to convert it into more stable phthalic 
anhydride form. S3M processed CBZ: HP55 1:2 dispersion showed higher 
generation of phthalic anhydride compared to HME processed dispersions 
(Figure 5.59).  
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Figure 5.59 Phthalic anhydride determination in carbamazepine: HP55 solid 
dispersions processed by HME and S3M 
5.4.3.8 DVS 
DVS was carried out as described in Section 3.4.6. For this purpose selected 
carbamazepine solid dispersions were analysed for amount of vapour 
sorption and desorption at different humidity conditions. CBZ: VA64 solid 
dispersions processed by HME and S3M with variable drug concentrations 
showed significant vapour sorption at 60% RH (Figure 5.60). In both the 
cases CBZ:VA64 1:1 and 1:2 S3M processed solid dispersions showed 
lower vapour sorption compared to HME processed dispersions. Plain PVP 
VA64 showed highest vapour sorption being hygroscopic in nature. The 
higher vapour sorption values in HME processed solid dispersions may have 
contributed to the use of PEG as plasticiser. 
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Figure 5.60 DVS at 60% RH for carbamazepine: VA64 solid dispersions 
processed by HME and S3M 
In the case of CBZ: HP55 solid dispersions the vapour sorption was 
independent of concentration of drug and polymer. In case of CBZ: HP55 1:1 
case the vapour sorption was higher in case of HME processed solid 
dispersion which can be contributed to the plasticiser (TEC) used in HME 
solid dispersion. In the case of CBZ:HP55 1:2 solid dispersions the vapour 
sorption showed the opposite behaviour to 1:1 solid dispersions, S3M 
processed solid dispersion showed higher vapour sorption compared to HME 
processed (Figure 5.61). Plain HPMCP HP55 showed higher vapour sorption 
which changed significantly on incorporation of drug. 
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Figure 5.61 DVS at 60% RH for carbamazepine: HP55 solid dispersions 
processed by HME and S3M 
 
In the case of CBZ:HPMCAS 1:2 solid dispersions HME processed 
dispersions showed slightly higher vapour sorption compared to S3M 
processed dispersion, the higher vapour sorption values can be attributed to 
the presence of plasticiser (TEC) in the case of HME processed dispersion. 
Plain HPMCAS showed higher vapour sorption as compared to CBZ 
dispersions (Figure 5.62), the weight change observed in plain polymer is 
almost double which shows that plain polymer has higher vapour sorption 
value which changes or reduces on incorporation of CBZ. 
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Figure 5.62 DVS at 60% RH for carbamazepine: HPMCAS 1:2 solid 
dispersions processed by HME and S3M 
 
In the case of CBZ: EC 1:2 solid dispersion vapour sorption was slightly 
higher for S3M processed dispersions as compared to HME. The presence 
of plasticiser (PEG) in HME processed dispersions did not have a significant 
effect on vapour sorption (Figure 5.63). Plain ethyl cellulose showed higher 
vapour sorption values at all % relative humidity. 
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Figure 5.63 DVS at 60% RH for carbamazepine: HPMCAS 1:2 solid 
dispersions processed by HME and S3M 
5.4.3.9 Surface energy 
Surface energy analysis was done for few samples to check whether there 
was a difference in surface energies between solid dispersions processed by 
HME and S3M3 and whether it had an effect on performance of solid 
dispersions. Surface energy analysis was done as described in Section 
3.4.7.  
The surface energy values for CBZ: HP55 1:2 processed by HME showed 
positive correlation with the area, value of the surface energy goes on 
increasing with as surface area coverage goes on increasing (Figure 5.64). 
The reverse was observed in for S3M3 processed CBZ: HP55 1:2 solid 
dispersion which showed a good correlation up to limited area coverage. 
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Figure 5.64 iGC analysis for carbamazepine: HP55 1:2 solid dispersion 
processed by HME and S3M 
 
The irregularity in the surface features area may have caused improper area 
coverage which hinders the effective surface energy of the dispersion. 
Surface hydrophobicity can be the reason for the variations in surface energy 
values between dispersions produced by two processes; this can be 
contributed to surface groups on the dispersions exposed experimental 
environment. The drop in surface energy in case of S3M processed sample 
can be contributed to surface relaxation due to aging of the surface 
(Hasegawa and Buckton, 2008). 
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Figure 5.65 iGC analysis for carbamazepine: PVP VA64 1:2 solid dispersion 
processed by HME and S3M 
The area coverage for CBZ: PVP VA64 1:2 solid dispersions processed by 
HME and S3M3 showed good surface exposure. The surface energy showed 
good correlation with the area covered which increased with increasing area 
(Figure 5.65). The solid dispersions with PVP VA64 exhibited a higher 
number of surface groups which resulted in higher surface area coverage 
and in turn higher surface energy values. 
In the case of CBZ: EC 1:2 solid dispersions processed by HME and S3M3, 
these showed similar surface energy behaviour as CBZ: HP55 1:2 
dispersions (Figure 5.66). Previously Shah, et al. 2012 has shown the effect 
of particle size and particle defects on the extent of change in surface energy 
as particle size or surface defects goes on increasing surface energy 
increases with it.  
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Figure 5.66 iGC analysis for carbamazepine: ethyl cellulose 1:2 solid 
dispersion processed by HME and S3M 
This irregular behaviour in the surface energy in CBZ solid dispersions 
processed by HME and S3M3 can be due the extreme processing conditions 
with high shear in case of S3M3 which yield a dispersion with surface 
properties with variable properties with exposure of different groups on the 
surface, whereas surface properties in case of HME processed solid 
dispersions are very regular and smooth. There is no direct correlation 
between extent of surface energy shown by CBZ solid dispersions with drug 
release and its amorphous nature. 
HME and S3M being high shear processes showed lot of variability in there 
processing conditions and resultant end product. Various analytical 
characterisations were used to compare processes for the drug: polymer 
combination pairs. This helped to understand how product characteristics 
change with respect to amorphous nature of the end product and its 
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pharmaceutical performance. HME is being widely explored for the formation 
of amorphous dispersions was very useful as comparative method to explore 
S3M as new technology for manufacturing amorphous dispersions. HME and 
S3M have various comparative advantages and disadvantages over each 
other, such as it was possible to process drug: polymer mixture without 
plasticiser which is not always possible in HME. Another example in process 
variability is process control features in HME and S3M; in case of HME 
process control parameters are excellent which helps to have very good 
control on the outcome of the end product, whereas in for S3M process 
parameters or process parameters cannot be controlled as well as in HME. A 
simple comparative example to understand the difference in product 
characteristic with respect to drug release from solid dispersions processed 
by HME and S3M is given in Table 5.2. Table has given the release of 
respective drug from solid dispersions from HME and S3M. 
Differences in processing of solid dispersion and cocrystals were basically 
depending upon the respective polymer and co-former present in the 
mixture. The processing conditions in case of solid dispersions were majorly 
based on the Tg of the polymer present and were processed at respective 
temperatures as described in experimental section. In case of cocrystals the 
processing of mixture was dependent on the eutectic temperature of the drug 
and co-former or at the melting temperature of the co-former and all the 
cocrystal batches were processed at respective temperatures. The effect of 
these processing conditions in case of solid dispersions was complete 
softening of polymer to solubilise the present drug into it and convert system 
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into complete amorphous form whereas in case of cocrystals the processing 
conditions made drug:co-former mixture to convert them into phase pure 
cocrystalline end product.  
Table 5.2 Comparative drug release from solid dispersions with respective 
time points 
Sr. 
No. 
Solid dispersion Time point 
(min)  
HME  
(% drug release) 
S3M  
(%drug release) 
1 IBU:VA64 1:2 5 45% 43% 
2 IBU:HP55 1:2 45 86% 76% 
3 GLIB: VA64 1:2 60 31% 88% 
4 GLIB: EC 1:2 60 42% 31% 
5 PARA: HP55 1:2 30 99% 92% 
6 CBZ: VA64 1:1 15 88% 82% 
7 CBZ:VA64 1:2 15 69% 58% 
8 CBZ: HP55 1:1 15 30% 58% 
9 CBZ: HP55 1:2 15 64% 29% 
10 CBZ: HPMCAS 1:2 15 43% 69% 
11 CBZ: EC 1:2 1200 29% 12% 
 
Table 5.2 shows how the drug releases from different drug: polymer 
composition changes at given time point, this can be attributed to the nature 
of product characteristics and process characteristics of HME and S3M. 
The two high shear processes HME and S3M are continuous (S3M 
potentially if used in series), solvent free and has good potential for 
scalability and production of the amorphous formulations for various 
pharmaceutical APIs. In similar way S3M has been explored for the 
production of pharmaceutical cocrystals and how it differs from HME is given 
in Chapter 6. 
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Chapter 6. Results and discussions of co crystals 
 
This chapter will deal with the formation and performance of different 
cocrystals of ibuprofen, caffeine, paracetamol and carbamazepine with range 
of co-formers. Cocrystals produced by S3M3 and HME will be compared with 
each other as well as with cocrystals generated by solution crystallisation.  
6.1 Ibuprofen: nicotinamide 1:1 cocrystal (IBU: NIC 1:1) 
IBU: NIC 1:1 was chosen as first pair for cocrystal formation during S3M 
processing. The product quality varied significantly in the sense with 
physicochemical properties and drug release processed by S3M and HME. 
IBU:NIC 1:1 cocrystal with 10%  PEO and 10% PVP VA64 yielded a good 
agglomerated product but with HME processed batches a  molten mass was 
formed through agglomeration with 10% of PEO and 10% PVP VA64. IBU 
being a low Tg drug as discussed in chapter 5, in combination with PEO and 
VA64 may have further affected to the Tg of the mixture and turned into a 
viscous molten mass in HME. Residence time in HME is significantly high 
compared to S3M3; this longer residence in HME might have caused 
homogenisation of the molten IBU with polymer to form molten lump. HME 
end product was in the form molten liquid which made product collection 
difficult whereas in the case of S3M3 processing IBU:NIC 1:1 cocrystals with 
10% PEO and 10% VA64 showed good product characteristics. S3M 
processed IBU:NIC with polymers gave phase pure cocrystals (Figure 6.1). 
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[A- Ibuprofen, B- Nicotinamide, C-IBU: NIC 1:1 cocrystal reference CSD, D) 
S3M IBU:NIC 1:1 10% VA64, E) S3M IBU:NIC 1:1 10% VA64, F) HME 
IBU:NIC 1:1 without polymer] 
Figure 6.1 PXRD patterns for Ibuprofen: Nicotinamide 1:1 cocrystal 
processed by HME and S3M 
Further analysis was not done for this cocrystal pair due to the liquid end 
product in HME processing which made direct comparison between two 
processes difficult.  
6.2 Caffeine: maleic acid 1:1 cocrystal (CAF: MAL 1:1) 
6.2.1 Crystal structure data 
The CAF: MAL 1:1 cocrystal crystallises as a monoclinic form. Hydrogen 
bonding is one of the attractive forces involved in the formation of cocrystals. 
The reactive group responsible for the hydrogen bond formation are –N 
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(imidazole) of CAF and –COOH of the MAL (Trask et al., 2005). There is 
intramolecular hydrogen bonding within the two cis oriented carboxylic acid 
groups of MAL that has retained in the cocrystal from MAL precursor. The 
crystal structure data, calculated PXRD pattern and important space group 
details for this cocrystal form is shown in Figure 6.2, Figure 6.3 and Table 
6.1. The PXRD pattern shows characteristic peaks at 2θ = 9, 11.18, 13.2, 
14.4 and 15.5 °.  
Table 6.1Crystal structural database and space group details for CAF:MAL 
1:1 cocrystal 
Empirical formula C8 H10 N4 O2,C4 H6 O5 
Crystal system Triclinic 
Space group P 1 
a (Å) 9.139 
b (Å) 9.306 
c (Å) 9.771 
α (°) 85.131 
β (°) 65.297 
γ  (°) 71.185 
 
 
 
Figure 6.2 Crystal structure of caffeine: maleic acid 1:1 cocrystal and crystal 
packing in unit cell. (adopted from CSD) 
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Figure 6.3 Calculated PXRD pattern for caffeine: maleic acid 1:1 cocrystal 
Form I. (adopted from CSD-HOLVOV and processed in OriginPro 8) 
6.2.2 Processing of cocrystal 
Accurately weighed CAF and MAL in molar ratios were mixed well and 15% 
w/w HPMCP HP55 polymer was added as a process aid. This mixture was 
then seived through an 80 mesh seive and blended in a turbula mixer for 
10mins. The blended mixture was subjected to S3M3, material flow was 
good, HPMCP HP55 help to improve the S3M3 process flow. At the end of 
the 1st  and 2nd  cycle there was no tranformation in physical form of the 
material, when end product of 2nd cycle fed to S3M3 for 3rd cycle there was 
rise in temperature of the mill and at the end of the third cycle of a hard cake 
mass was formed as the end product. HME of CAF:MAL 1:1 cocrystal was 
carried out as per temperature and extrusion profiles given in Section 3.7. It 
was possible to extrude and process blank CAF:MAL without the aid of 
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polymer, so CAF:MAL 1:1 with and without polymer were processed. Pure 
cocrystals for CAF:MAL  were produced using a microwave reactor for 
comparitive purpose and performance was evaluated (Section 3.7.1). The 
resultant end products of both processes were analysed by various 
characterisation techniques. 
6.2.3 Calibration 
6.2.3.1 Caffeine calibration 
The calibration curve for CAF was linear over the concentration range of 10-
70 ug/ml. The linearity equation was calculated using calibration curve, slope 
of the equation was 270214, constant 38365 and R2 0.9998 (Figure 6.4). The 
calibration was used to calculate the release of CAF. 
 
Figure 6.4 Calibration curve for caffeine using HPLC at 209nm 
The HPLC retention time of CAF was 12 mins. The chromatogram for CAF is 
shown in Figure 6.5  
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Figure 6.5 Caffeine chromatogram in HPLC analysis 
6.2.3.2 MAL calibration 
The calibration curve for MAL was linear over the concentration range of 1-
20 ug/ml. The linearity equation was calculated using calibration curve, slope 
of the equation was 267609, constant -20204 and R2 0.9988 (Figure 6.6). 
 
Figure 6.6 Calibration curve for maleic acid using HPLC at 209nm 
The HPLC retention time for maleic acid was 5min, the HPLC chromatogram 
is given in Figure 6.7.  
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Figure 6.7 Maleic acid chromatogram in HPLC analysis 
6.2.4 PXRD 
The PXRD procedure was followed as described in Section 3.4.2. The PXRD 
pattern for pure CAF: MAL shows 2θ values at 9, 11.18, 13.2, 14.4 and 15.5 
° respectively. Figure 6.8 clearly shows that all cocrystal samples processed 
by HME and S3M matched with the phase pure CAF: MAL 1:1 cocrystal (A) 
as well as with the 2θ values given in the CSD database (Figure 6.8). The 
CAF: MAL 1:1 cocrystal with HP55 shows slightly suppressed characteristic 
peaks at given 2θ values which might be attributed to the effect of polymer 
chains which must have affected the exposed crystallinity to X-rays (D,E). 
Use of polymer as a process aid in S3M3 made it possible for plain drug and 
co-former blend to flow smoothly. It can be concluded that use of HP55 acted 
as shear aiding material during S3M3 and when shear was applied to 
polymer approaching at its melting point, the polymer it may have acted as a 
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solvent for solubilising CAF and MAL in molar ratio to yield phase pure 
cocrystal.   
 
[A: Caffeine, B: CAF:MAL 1:1 PURE CC, C: HME CAF:MAL 1:1, D: HME CAF:MAL 1:1 15% 
HP55, E: S3M CAF:MAL 1:1 15% HP55] 
Figure 6.8 PXRD for caffeine: maleic acid 1:1 cocrystals processed by HME 
and S3M 
These PXRD findings were confirmed by thermal analysis of CAF:MAL 1:1 
cocrystal by DSC 
6.2.5 DSC 
DSC analysis for CAF: MAL 1:1 cocrystal was carried out as described in 
Section 3.4.1. Crystalline CAF gives a sharp melting endotherm at 238 °C 
and MAL at 143.26 °C. The phase pure CAF: MAL 1:1 cocrystal shows a 
sharp melting endotherm at 105 °C (Figure 6.9). The HME and S3M 
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processed CAF: MAL 1:1 cocrystal with HP55 showed melting endotherms at 
103.77 °C and 104.66 °C respectively which confirmed that those are phase 
pure crystal and support PXRD findings. The HME processed CAF: MAL 1:1 
cocrystal without HP55 shows two melting endotherms (C) first one at 100 °C 
and 105.7 °C. The melting endotherm at 105.7 °C confirms that it has formed 
phase pure cocrystal, the first endotherm might be due to some eutectic of 
mixture CAF:MAL 1:1. 
 
[A: Caffeine, B: CAF:MAL 1:1 PURE CC, C: HME CAF:MAL 1:1, D: HME CAF:MAL 1:1 15% 
HP55, E: S3M CAF:MAL 1:1 15% HP55] 
Figure 6.9 DSC thermograms for caffeine: maleic acid 1:1 cocrystals 
processed by HME and S3M 
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6.2.6 SEM 
Surface morphology for CAF: MAL 1:1 cocrystals were analysed by SEM as 
described in Section 3.4.5. Figure 6.10 shows how cocrystals generated by 
three different processes vary in morphology and surface features.  
 
[A- CAF: MAL 1:1 PURE CC, B- S3M CAF: MAL 1:1, C-HME CAF: MAL 1:1] 
Figure 6.10 Surface morphology by SEM of caffeine: maleic acid 1:1 
cocrystals processed by HME and S3M 
CAF: MAL 1:1 pure cocrystals formed a sharp needle like structure and 
pointed features whereas S3M3 processed cocrystals showed thread like 
structures distributed within in a matrix like structure. In case of HME 
processed cocrystals, a  compressed form of morphology was observed 
somewhat like crystals embedded in polymer matrix. This can be due to 
uniform and highly compacting nature of the extruder screw geometry, which 
formed the product like a flighted screw shape.  
6.2.7 FT-IR 
FT-IR analysis for CAF: MAL 1:1 cocrystals was done by as described in 
Section 3.4.3. As Trask, et al. Explained CAF and MAL has excellent 
hydrogen bonding which exist between their respective functional groups, 
between –N (imidazole) from CAF and –COOH from MAL.  FT-IR for CAF 
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shows -OH····N stretching at 1237 cm-1 and 1282 cm-1 and -O-C = O 
stretching in MAL at 1703 and weaker stretching at 1213 due to C-O (Figure 
6.11 and Figure 6.12). Pure CAF: MAL cocrystal showed a reduction in the 
intensity to 1230 and an increase to 1285 cm-1 whereas peak intensity for 
MAL increased to 1707 cm-1, CAF: MAL 1:1 cocrystal processed with HP55 
showed exactly similar stretching as pure cocrystal which confirms that 
cocrystals processed with HP55 are pure in structure and exhibit similar 
hydrogen bonding as pure cocrystals (Figure 6.12). 
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Figure 6.11 FT-IR spectra for caffeine: maleic acid 1:1 cocrystals with 
HPMCP HP55 processed by HME and S3M 
 
Figure 6.12 FT-IR spectra for caffeine: maleic acid 1:1 cocrystals with 
HPMCP HP55 processed by HME and S3M 
6.2.8 NIR 
NIR analysis for CAF: MAL 1:1 cocrystals was carried out as described in 
Section 3.4.4. 
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Figure 6.13 NIR spectra for caffeine: maleic acid 1:1 cocrystal with HPMCP 
HP55 processed HME and S3M 
Caffeine showed good NIR absorption in the second overtone region at 1670 
and 2249 nm (Figure 6.13) whereas maleic acid showed NIR absorption in 
first overtone region at 2093 nm. The pure cocrystals of CAF:MAL 1:1 shows 
NIR absorption at wavelengths 1625 and 2249 nm. These shifts in NIR 
absorption can be attributed to the hydrogen bond formation between -
CONH of caffeine and -COOH of maleic acid.  HME processed CAF:MAL 1:1 
cocrystals without polymer  and cocrystals with 15% HP55 which showed 
peak shifts to 1665 and 1612 which deviates further absorption shift from 
pure cocrystals this can be attributed to extent of hydrogen bonding present 
in the cocrystals. In case of S3M processed cocrystals did not show any 
change in NIR peak absorption spectra when compared to pure cocrystals 
which showed that formed cocrystals have good intermolecular bonding.  
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6.2.9 Dissolution 
CAF: MAL 1:1 cocrystal dissolution studies were carried out using HPLC. 
The dissolution profiles and HPLC method details are described in Section 
3.7.1 and 3.7.2 respectively. 
 
Figure 6.14 Dissolution profiles for caffeine: maleic acid 1:1 cocrystals with 
HPMCP HP55 processed by HME and S3M 
 
CAF: MAL 1:1 cocrystal processed by HME without polymer and S3M 
processed with HP55 showed fastest release and released all CAF within 15 
mins whereas CAF:MAL 1:1 with 15% HP55 processed by HME showed 
slow CAF release and took one hour to release 100% drug (Figure 6.14). 
The delayed release of HME processed cocrystal with polymer can be 
attributed to the highly compact nature of cocrystal extrudates. Polymer has 
covered the formed cocrystal during HEM and reduced exposure to 
surrounding media during dissolution studies. S3M processed cocrystal the 
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distribution of the formed cocrystal in polymer matrix is such that allowed the 
dissolution media to penetrate inside the cocrystal matrix and improve overall 
wettability and hence dissolution.  
6.3 Paracetamol: oxalic acid 1:1 cocrystal (PARA: OXAL 1:1) 
6.3.1 Crystal structure data 
Paracetamol forms good hydrogen bonding with oxalic acid upon solution 
crystallisation and exhibits a 1:1 cocrystal, Karki et al., studied the effect of 
co-former on compression properties of PARA by forming cocrystal with 
various co-formers including OXAL. 
The crystal structure database bond length and angle details between the 
PARA: OXAL 1:1 cocrystal are given in Table 6.2 
Table 6.2 Crystal structural database and space group details for PARA: 
OXAL 1:1 cocrystal 
Empirical formula C8 H9 N O2,C2 H2 O4 
Crystal system Monoclinic 
Space group P 21/c 
a (Å) 5.164 
b (Å) 11.732 
c (Å) 17.593 
α (°) 90.000 
β (°) 94.329 
γ  (°) 90.000 
 
The cocrystal structure structure exhibit a hydrogen bond between the 
functional groups –OH of PARA and –COOH of OXAL as shown in single 
crystal structure in Figure 6.15 
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Figure 6.15 Crystal structure of paracetamol: oxalic acid 1:1 cocrystal and 
crystal packing in unit cell. (adopted from CSD) 
 
Calculated characteristic 2θ values for PARA:OXAL 1:1 cocrystal can be 
observed in Figure 6.16, showing respective peaks at θ, 9.02, 15.92, 18.18, 
21.42 and 27.68 
 
Figure 6.16 Calculated PXRD pattern for paracetamol: oxalic acid 1:1 
cocrystal (adopted from CSD-LUJTAM and processed in OriginPro 8). 
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6.3.2 Processing of cocrystal 
 
Accurately weighed PARA and OXAL in 1:1 molar ratio were mixed well and 
15% PEO was added as a processing aid. This mixture was blended using a 
turbula mixer. The resultant homogenous mixture was fed to S3M3. During 
the first cycle as soon as the material was fed to the hopper of S3M3 within 
10 to 15 secs, the first cycle started to yield an agglomerated thread like 
product which continued until all material was processed. The difference in 
processing time of the PEO as aid is highly variable as compared to HP55 in 
CAF: MAL processing due to variable softening temperatures of two 
polymers. The short processing time can be attributed to the low melting and 
low Tg of PEO which made it easier to process PARA:OXAL on S3M3. HME 
was carried out for PARA: OXAL 1:1 with and without PEO according to the 
temperature profiles and extrusion parameters described in Section 3.7 and 
Table 3.10. Resultant end products were analysed by various analytical 
techniques. 
6.3.3 Calibration 
As shown in Section 3.6 the PARA and OXAL does not show any overlap 
between their UV absorbances. Drug release was analysed using UV 
spectroscopy, and a similar calibration was used for PARA as given in PARA 
solid dispersion studies. 
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6.3.4 Characterisation  
6.3.4.1 PXRD 
PXRD studies for PARA: OXAL were carried out as described in Section 
3.4.2. The respective 2θ values for pure PARA: OXAL 1:1 cocrystal shows 
characteristic peaks at 9.02, 15.92, 18.18, 21.42 and 27.68 as shown in 
Figure 6.17. The HME and S3M3 processed PARA:OXAL 1:1 with PEO 
showe identical 2θ values in PXRD with slightly variable intensities which can 
be attributed to the process variability. The similar 2θ values confirm the 
HME and S3M3 processes yielded a pure cocrystal. HME processed PARA: 
OXAL 1:1 without PEO showed very low intensity 2θ values in addition to 
some characteristic peaks for PARA and OXAL which show that there was 
partial cocrystal conversion with some impurities from parent materials. 
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[A: Paracetamol, B: PARA: OXAL 1:1 PURE CC, C:HME PARA:OXAL 1:1, D: HME 
PARA:OXAL 1:1 15% PEO, E: S3M PARA:OXAL 1:1 15% PEO] 
Figure 6.17 PXRD for paracetamol: oxalic acid 1:1 cocrystals processed by 
HME and S3M 
6.3.4.2 DSC 
DSC analysis was carried out as described in section 3.4.1. DSC results 
complement the PXRD findings. PARA showed a sharp melting endotherm 
at 169.93 °C and OXAL at 100.23 °C, whereas PARA: OXAL 1:1 cocrystal 
gave a characteristic melting endotherm at 151 °C (Figure 6.18). HME and 
S3M3 processed cocrystals also show similar endotherms matching 
calculated melting endotherm values of pure cocrystal at 149.95 in case of 
HME and 151.06 in case of S3M3. This confirmed formation of phase pure 
cocrystal.  
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[A: Paracetamol, B: PARA:OXAL 1:1 PURE CC, C:HME PARA:OXAL 1:1, D: 
HME PARA:OXAL 1:1 15% PEO, E: S3M PARA:OXAL 1:1 15% PEO] 
Figure 6.18 DSC thermograms for paracetamol:oxalic acid 1:1 cocrystals 
processed by HME and S3M 
In case of HME processed PARA:OXAL 1:1 cocrystal without PEO shows 
melting endotherm at 98 °C which differs significantly from pure cocrystal 
melting endotherm and matches the endotherm of OXAL, which can be 
attributed to a major OXAL impurity in the formed cocrystal, these findings 
supports PXRD results for partial cocrystal formation. 
 
6.3.4.3 S3M 
Surface morphology studies for PARA: OXAL cocrystals were carried out as 
described in Section 3.4.5.  
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[A- PARA: OXAL 1:1 PURE CC, B- S3M PARA: OXAL 1:1, C-HME PARA: OXAL 1:1] 
Figure 6.19 Surface morphology by SEM of paracetamol: oxalic acid 1:1 
cocrystals processed by HME and S3M and solution method 
As Figure 6.19 shows that cocrystals produced by solution method exhibited 
sharp, needle like structures whereas, HME and S3M3 processed cocrystals 
showed compact and broken crystals embedded in the polymer matrix. 
There was little difference between HME and S3M3 processed cocrystals. It 
was very difficult to vary the broken crystal size as crystal size was very 
much different; there was no uniformity in the size and shape of the crystals.   
6.3.4.4 FT-IR 
FT-IR analysis for PARA: OXAL 1:1 cocrystals was carried out using the 
method described in Section 3.4.3. PARA showed –OH stretching at 3324 
cm-1 and 2982 cm-1 whereas OXAL showed characteristic –COOH stretching 
at 3417 and 1686 cm-1 and stretching for unsaturation in structure was at 
1653 and 1610 cm-1. PARA (Figure 6.20). PARA: OXAL pure cocrystal 
showed characteristic stretching shift at 3420 whereas cocrystal with 15% 
PEO showed stretching shifts at 3344 and 3386 cm-1 in both the cases HME 
and S3M3 (Figure 6.21). Karki et al., has explained characteristic stretching 
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at 3384 cm-1 can indicate hydrogen bond formation between –CONHR of 
PARA and –COOH of OXAL which was similarly observed in HME and S3M 
processed samples and in the case of solution cocrystal as well.  
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Figure 6.20 FT-IR spectra for paracetamol: oxalic acid 1:1 cocrystals with 
PEO processes by HME and S3M 
 
Figure 6.21 FT-IR spectra for paracetamol: oxalic acid 1:1 cocrystal with 
PEO processed by HME and S3M 
 
6.3.4.5 NIR 
NIR analysis was carried out as described in Section 3.4.4. 
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Figure 6.22 NIR spectra for paracetamol: oxalic acid 1:1 cocrystals 
processed by HME and S3M 
Paracetamol shows good NIR absorption spectra in the second overtone 
region at 1639 and 1670 nm respectively. Oxalic acid owing to its acid 
functional group (-COOH) did not show NIR absorption spectra which can be 
attributed to the low sensitivity of detection for oxalic acid in the near infrared 
region. The pure cocrystal for PARA:OXAL 1:1 showed good NIR absorption 
at 1615 and 1680 nm which can be attributed to the formation of hydrogen 
bond between the functional groups of paracetamol (-CONHR) and oxalic 
acid (-COOH) (Figure 6.22). Cocrystals processed by S3M showed identical 
NIR spectra absorption at 1615 and 1680 nm whereas HME processed 
paracetamol cocrystals with and without polymer showed identical NIR 
spectra absorption at 1634 and 1664. This change in absorption spectra can 
be attributed to the extent of hydrogen bonding and purity of the cocrystals 
formed.  
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6.3.4.6 Dissolution 
Dissolution studies for PARA: OXAL cocrystal were carried out as per the 
dissolution parameters followed for PARA solid dispersion. Dissolution 
studies showed cocrystal prepared by solution method exhibited fastest drug 
release and release 100% drug within 10mins. HME processed PARA:OXAL 
cocrystals without polymer showed second highest dissolution rate; 100% 
release in 20 mins (Figure 6.23). It was observed that S3M3 and HME 
processed cocrystal with PEO showed slow drug release; and HME 
processed cocrystals exhibited slowest release. The slow release of PARA 
from HME and S3M3 processed cocrystal with PEO was due to the compact 
and dense nature of product which may have hampered the media 
penetration inside cocrystal matrix and resulted in slow or less exposure to 
media. 
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Figure 6.23 Dissolution profiles for paracetamol: oxalic acid 1:1 cocrystals 
with PEO by HME and S3M 
6.4 Carbamazepine cocrystal 
CBZ was explored for cocrystal formation with four co-formers salicylic acid, 
saccharin, nicotinamide and glutaric acid. CBZ: SAL pair was studied with 
different levels of polymers as processing aid in HME and S3M3 PEO (levels 
5-25% w/w) and PVP VA64 (15-25% w/w), CBZ with other co-formers was 
studied with 15% PEO as a processing aid during HME and S3M3. 
6.4.1 Carbamazepine: salicylic acid 1:1 cocrystal (CBZ: SAL 1:1) 
6.4.1.1 Crystal structure data 
CBZ and SAL forms a cocrystal in 1:1 molar which shows unique structural 
characteristics different from CBZ and SAL, CBZ SAL forms a cocrystal with 
a monoclinic form. The cocrystal exhibits hydrogen bonds between the –NH2 
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of CBZ and –COOH of SAL (Figure 6.24). The cocrystal structural data, 
group spacing, bond angles and length details are given in Table 6.3. 
Table 6.3 Crystal structural database and space group details for CBZ: SAL 
1:1 cocrystal 
Empirical formula C
15
H
12
N
2
O, C
7
H
6
O
3
 
Crystal system Monoclinic 
Space group P21/n 
a (Å) 5.106 
b (Å) 19.783 
c (Å) 18.328 
α (°) 90.000 
β (°) 97.903 
γ  (°) 90.000 
 
The crystal structure of CBZ: SAL 1:1 cocrystal developed and adopted from 
CSD database and its crystal packing in unit cell is given in Figure 6.24. 
Figure 6.25 shows PXRD for CBZ: SAL 1:1 cocrystal which shows 
characteristic 2θ values at 6.6, 8.92, 9.72 and 13.22.  
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Figure 6.24 Crystal structure of carbamazepine: salicylic acid 1:1 cocrystal 
and crystal packing in unit cell. (adopted from CSD) 
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Figure 6.25 Calculated PXRD pattern for carbamazepine: salicylic acid 1:1 
cocrystal (adopted from CSD- MOXWAY and processed in OriginPro 8) 
6.4.1.2 CBZ UPLC calibration 
The UPLC calibration curve for CBZ was linear over concentration range of 
10-100 ug/ml. The linearity equation was calculated using calibration curve, 
slope of the equation was 2146.9, constant 2084.6 and R2 0.9998 (Figure 
6.26). The calibration equation was used to calculate the amount of CBZ 
released. 
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Figure 6.26 Carbamazepine calibration curve using UPLC at 288nm 
CBZ shows a retention time in UPLC of 2.3 mins as shown in figure 6.26. 
 
Figure 6.27 Carbamazepine chromatogram from UPLC analysis 
The UPLC calibration curve for SAL was linear over concentration range of 
10-100 ug/ml. The linearity equation was calculated using calibration curve, 
slope of the equation was 998.04, constant -1263.6 and R2 0.9968. SAL 
shows retention time in UPLC at 1.8 min (Figure 6.28). 
y = 2146.9x + 2084.6 
R² = 0.9998 
0 
50000 
100000 
150000 
200000 
250000 
0 20 40 60 80 100 
A
re
a 
Conc. (ug/ml) 
 
 
210 
 
 
Figure 6.28 Salicylic acid calibration curve using UPLC at 296nm 
 
 
Figure 6.29 Salicylic acid chromatogram in UPLC analysis 
6.4.1.3 PXRD 
PXRD studies for CBZ: SAL 1:1 cocrystals were carried out as per Section 
3.4.2. The PXRD for CBZ: SAL 1:1 pure cocrystal produced using the 
solution method shows characteristic 2θ values at 6.48, 8.84, 13.08, 16.44 
which were similar to those what was observed in the CSD structure for CBZ: 
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SAL 1:1 cocrystal. CBZ:SAL 1:1 with 5%, 10% PEO and 15%, 25% VA64 
showed identical 2θ values to the pure cocrystal which confirms that S3M3 
and HME produced pure cocrystal with these polymer aids in given 
concentrations (Figure 6.30 and Figure 6.31).  
 
[A: Carbamazepine, B: CBZ:SAL 1:1 PURE CC, C: HME CBZ:SAL 1:1, D: HME 
CBZ:SAL 1:1 5% PEO, E: HME CBZ:SAL 1:1 10% PEO, F: HME CBZ:SAL 1:1 15% 
PEO, G: HME CBZ:SAL 1:1 25% PEO, H: HME CBZ:SAL 1:1 15% VA64, I: HME 
CBZ:SAL 1:1 25% VA64] 
Figure 6.30 PXRD for carbamazepine: salicylic acid 1:1 cocrystals processed 
by HME 
15%, 25% PEO in HME and 25% PEO in S3M3 batches showed reduced or 
non-characteristic intensities in the end product, which can be result of the 
higher polymer concentrations having solubilised CBZ and SAL and turned 
into an amorphous system. In the case of the 15% PEO S3M3 batch, strong 
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characteristic 2θ peaks were observed as shown by pure cocrystal, which 
shows the formation of pure cocrystal 
The PEO polymer added in 15%, 25% in HME and 25% in S3M3 turned the 
processed CBZ: SAL 1:1 in to an amorphous system. This may have 
happened due to the high shear applied in S3M3 and HME which made the 
crystalline CBZ and SAL soluble in PEO at its softening/ melting, PEO acted 
as a solvent in the melt state which solubilised CBZ and SAL. The surface of 
the end product showed smooth features with very less exposure to X-rays 
during PXRD studies. Addition of a polymer processing aid plays an 
important role during these high shear processes and thus polymer 
concentration and type of polymer should be selected carefully as these 
types of results were not observed with PVP VA64. 
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[A: Carbamazepine, B: CBZ:SAL 1:1 PURE CC, C: S3M CBZ:SAL 1:1 5% 
PEO, D: S3M CBZ:SAL 1:1 10% PEO, E: S3M CBZ:SAL 1:1 15% PEO, F: 
S3M CBZ:SAL 1:1 25% PEO, G: S3M CBZ:SAL 1:1 15% VA64, H: S3M 
CBZ:SAL 1:1 25% VA64] 
Figure 6.31 PXRD for carbamazepine: salicylic acid 1:1 cocrystals processed 
by S3M 
6.4.1.4 DSC 
DSC analysis was carried out for CBZ: SAL 1:1 as described in Section 
3.4.1. Crystalline CBZ showed a sharp melting endotherm at 191.26 °C and 
a small melting endotherm at 175 °C due to conversion of form III to I as 
discussed in chapter 5. SAL shows a melting endotherm at 160 °C, CBZ: 
SAL 1:1 cocrystal shows melting endotherm at 159 °C which is close to 
SAL’s endotherm (Figure 6.32 and Figure 6.33). All the polymer aided 
 
 
214 
 
CBZ:SAL 1:1 cocrystal by HME and S3M3 showed similar melting 
endotherms with slightly variable intensities.  
 
[A: Carbamazepine, B: CBZ:SAL 1:1 PURE CC, C: HME CBZ:SAL 1:1, D: 
HME CBA:SAL 1:1 5% PEO, E: HME CBZ:SAL 1:1 10% PEO, F: HME 
CBZ:SAL 1:1 15% PEO, G: HME CBZ:SAL 1:1 25% PEO, H: HME CBZ:SAL 
1:1 15% VA64, I: HME CBZ:SAL 1:1 25% VA64] 
Figure 6.32 DSC thermograms for carbamazepine:salicylic acid 1:1 
cocrystals processed by HME 
No melting endotherm was observed for processing aid polymers (PEO and 
VA64) which showed that at the polymers melting point, CBZ and SAL may 
have utilised all the polymer as a solvent system to convert whole system in 
cocrystal matrix. DSC findings complement PXRD results and also confirmed 
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that a higher concentration of PEO was also able to form cocrystal which 
was bit difficult to understand from PXRD. 
 
[A: Carbamazepine, B: CBZ:SAL 1:1 PURE CC, C: S3M CBA:SAL 1:1 5% 
PEO, D: S3M CBZ:SAL 1:1 10% PEO, E: S3M CBZ:SAL 1:1 15% PEO, F: 
S3M CBZ:SAL 1:1 25% PEO, G: S3M CBZ:SAL 1:1 15% VA64, H: S3M 
CBZ:SAL 1:1 25% VA64] 
Figure 6.33 DSC thermograms for carbamazepine: salicylic acid 1:1 
cocrystals processed by S3M 
6.4.1.5 SEM 
Surface morphology for CBZ: SAL cocrystals was done as described in 
Section 3.4.5. As shown in Figure 6.34 it shows that as polymer 
concentration increase there was a significant change in cocrystal structure 
on polymer surfaces. At lower polymer concentrations, the structure looked 
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more compact whereas there seemed to be good crystal growth as polymer 
content increased. These variable structural morphologies will affect the 
dissolution of these cocrystals, and polymer concentration will influence the 
drug release.  
 
[A- S3M 5% PEO, B- S3M 10% PEO, C- S3M 15% PEO, D- S3M 25% PEO, E- 
S3M 15% VA64, F- S3M 255 VA64; G- HME 5% PEO, H- 10% PEO, I- 15% PEO, 
J- 25% PEO, K- 15% VA64, L- 25% VA64; M,N,O- Solution cocrystal] 
Figure 6.34 Surface morphology by SEM of carbamazepine: salicylic acid 1:1 
cocrystals processed by HME and S3M 
Cocrystals produced by the solution method shows needle type long crystals 
which were difficult hard to observe in the case of polymer assisted 
cocrystals. 
6.4.1.6 FT-IR 
FT-IR studies were carried out as described in Section 3.4.3. CBZ shows 
strong amide group stretching which can be symmetrical or asymmetrical in 
nature (Childs et al. 2008; Schultheiss and Newman, 2009). These amide 
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vibrations are observed at 3465, 3155 cm-1, -C=O stretching are observed at 
1677 cm-1 and C=C and –NH deformation vibrations at 1593 and 1603 cm-1 
respectively (Figure 6.35). Similarly SAL shows characteristic stretching 
vibrations for –C-H at 3069, 3037 and 3019 cm-1, -O-H stretching at 1292 
cm-1 and strong stretching at 1651 cm-1 for C=O (Figure 6.36). HME and 
S3M3 processed cocrystals showed identical vibrations to pure cocrystals at 
3504 cm-1 for –NH stretching, -C=O stretching were reduced to 1661 in both 
the processes which shows the presence of hydrogen bond between –NH of 
CBZ and –C=O of SAL. 
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Figure 6.35 FT-IR spectra for carbamazepine: salicylic acid 1:1 cocrystals 
with PEO by HME 
 
Figure 6.36 FT-IR spectra for carbamazepine: salicylic acid 1:1 cocrystals 
with PEO by HME 
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Figure 6.37 FT-IR spectra for carbamazepine: salicylic acid 1:1 cocrystals 
with PEO by S3M 
 
Figure 6.38 FT-IR spectra for carbamazepine: salicylic acid 1:1 cocrystals 
with PEO by S3M 
In FT-IR studies of CBZ: SAL cocrystals processed with VA64 as a 
processing aid, the strong symmetrical vibrations for –NH at 3465 and 3155 
cm-1 the 3155 cm-1 vibrations disappeared from pure cocrystal and also in 
VA64 processed cocrystal batches processed by HME and S3M3 (Figure 
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6.39 and Figure 6.40). C=C and –C=O vibrations at 1593 and 1603 cm-1 
disappeared completely in pure cocrystal and VA64 based cocrystal batches 
processed by HME and S3M3. The effect of the presence of PEO or VA64 
cannot be directly determined by the FT-IR analysis as its total concentration 
is less in final cocrystal matrix, or its effect on hydrogen bond formation.  
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Figure 6.39 FT-IR spectra for carbamazepine: salicylic acid 1:1 cocrystals 
with PVP VA64 by HME and S3M 
 
Figure 6.40 FT-IR spectra for carbamazepine: salicylic acid 1:1 cocrystals 
with PVP VA64 by HME and S3M 
6.4.1.7 NIR 
NIR analysis for CBZ: SAL cocrystals was carried out as described in 
Section 3.4.4. 
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Figure 6.41 NIR spectra for carbamazepine: salicylic acid 1:1 cocrystals with 
PEO and VA64 by HME 
As discussed in the carbamazepine solid dispersions, NIR analysis shows 
characteristic absorption in second overtone region at 1468 nm. Salicylic 
acid owing to its acid functionality shows good NIR absorption in the first 
overtone region at 1656 nm. Pure cocrystals of CBZ:SAL 1:1 showed good 
NIR absorption spectra in the second overtone region at 1448 and 1474 nm 
which is completely different than the starting components (Figure 6.41). This 
distinct change in NIR absorption peaks may due to hydrogen bond 
formation between -NH of carbamazepine and -COO of salicylic acid. All the 
CBZ:SAL 1:1 cocrystals processed by HME with PEO and PVP VA64 
showed identical NIR absorption at 1445, 1465, 1651 and 1670 nm with 
highest peak intensity for CBZ:SAL 1:1 15% PEO and lowest for CBZ:SAL 
1:1 cocrystals without polymer. This drastic change in intensity can be 
attributed to the extent of hydrogen bonding between the formed cocrystals. 
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Figure 6.42 NIR spectra for carbamazepine: salicylic acid 1:1 cocrystals 
processed by S3M 
In the case of S3M processed CBZ:SAL 1:1 cocrystals, unlike HME 
processed these cocrystals showed identical NIR absorption in the second 
overtone region at 1448 and 1474 nm. The intensity for NIR absorption was 
highest in the case of CBZ: SAL 1:1 25% PEO but lowest for CBZ: SAL 1:1 
25% VA64 (Figure 6.42). This identical NIR absorption can be attributed to 
the similar pattern of hydrogen bonding between parent components as with 
pure cocrystals. 
6.4.1.8 DISSOLUTION 
Dissolution studies for CBZ:SAL 1:1 cocrystal were carried out as per 
parameters explained in section 3.7.2. Dissolution behaviour of the cocrystal 
processed by HME and S3M3 with variable amount of polymers were of 
particular interest. 
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Figure 6.43 Dissolution profiles for carbamazepine: salicylic acid 1:1 
cocrystals with PEO by HME 
 
Figure 6.43 clearly shows drug release from HME processed CBZ:SAL 1:1 
cocrystal batches with PEO. CBZ:SAL 1:1 cocrystals produced by the 
solution method showed fastest release and released 100% drug within 20 
mins, HME processed cocrystals with 5% PEO show the second fastest 
release followed by HME processed cocrystals without any polymer, only 
above three batches were able to release 100% CBZ; polymer aided batches 
with 10%, 15%, 25% PEO showed the slowest release among all and took 
almost 3 hours and to release about 80% of the total drug. Similar 
observations were made in HME processed cocrystal batches with VA64 as 
the aiding polymer. 15% VA64 cocrystal batch showed slightly higher release 
of 75% of the drug within 3 hours, whereas cocrystal batches with 25% VA64 
showed slower release only 50% of CBZ in 3 hours (Figure 6.44).  
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Figure 6.44 Dissolution profiles for carbamazepine: salicylic acid 1:1 
cocrystals with PVP VA64 by HME 
 
Slower release of the CBZ through cocrystal batches with higher polymer 
concentration can be explained by the surface properties of respective 
cocrystals. The higher concentration polymer cocrystal batches were more 
compact in nature which not allows dissolution media to penetrate through 
the polymer chains into the cocrystal matrix. This reduced overall wettability 
and exposure which resulted in slower and incomplete CBZ release from 
those batches. 
CBZ:SAL 1:1 cocrystal batches processed by S3M3 showed more complex 
results which differed from HME processed batches. In the case of S3M3, 
fastest release was observed batches with 10% and 25% PEO whereas for 
5% and 15% it was observed that CBZ release was slower and could only 
release around 80% of the total drug (Figure 6.44). 
0.00 
20.00 
40.00 
60.00 
80.00 
100.00 
120.00 
0 50 100 150 200 
%
 D
R
U
G
 R
EL
EA
SE
 
TIME (min) 
HME CBZ SAL 11 15%VA64 
HME CBZ SAL 11 25%VA64 
CBZ SAL 11 PURE CC 
HME CBZ SAL 11 PLAIN 
CBZ 
 
 
226 
 
 
Figure 6.45 Dissolution profile for carbamazepine: salicylic acid 1:1 
cocrystals with PEO by S3M 
 
For S3M3 cocrystal batches with VA64 showed similar kind of release as 
observed in HME processed batches (Figure 6.45). Cocrystal batches with 
15% VA64 showed 100% release over 3 hours whereas the 25% VA64 batch 
which could only release 45% of CBZ in 3 hours. 
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Figure 6.46 Dissolution profile for carbamazepine: salicylic acid 1:1 
cocrystals with PVP VA64 by S3M 
 
Drug release results of S3M3 processed cocrystal batches with PEO could 
not be correlated with the amount of polymer present. This may be due to the 
total amount of polymer present at the ɗ surface of S3M3 during its three 
dimensional scissoring action made it less or more available. The part of 
material used from the cocrystal batches may have different amount of 
polymer present which are used for dissolution studies. The other reason for 
this can be explained as some parts of the aid polymer may have experience 
very high shear which might have caused degradation of either polymer or 
drug or it would have formed highly dense structure specially in case of the 
samples used for dissolution studies. 
6.4.1.9 DVS 
DVS analysis for CBZ: SAL 1:1 cocrystals showed variable vapour sorption 
behaviour. HME processed plain CBZ:SAL 1:1 cocrystal without polymer 
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vapour sorption results were similar to pure cocrystal and the weight change 
contributed to less than 0.01% w/w. CBZ:SAL 1:1 cocrystals with 10% PEO 
processed by S3M showed higher vapour sorption as compared to HME 
processed. Weight change in the case of S3M processed cocrystal was more 
than 0.2 % w/w whereas in case of HME processed cocrystal it was less than 
0.2% w/w (Figure 6.47). The higher value for vapour sorption in S3M 
processed cocrystal batches can be attributed to the three dimensional 
scissoring shear actions on material during processing. Due to this highly 
distorted structure the vapour penetration might have increased for S3M3 
processed cocrystal samples with 10% PEO. PEO is highly hygroscopic in 
nature, In the case of HME processed cocrystal batches it formed a very 
compact product and surface with low porosity which made all the crystal 
embedded in polymer layer of PEO and hindered the overall exposure to the 
vapour during DVS analysis.  
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Figure 6.47 DVS analysis at 60% RH for carbamazepine: salicylic acid 1:1 
cocrystals processed by HME and S3M 
 
In the case of S3M3 processed cocrystal batches the distribution of PEO was 
uniform all over the cocrystal matrix and overall exposure to the environment 
with high surface roughness and porosity made it absorb more vapours. 
6.4.1.10 Surface energy  
Surface energy analysis was carried out for the batches which were 
analysed for DVS. Surface energy analysis was kept similar for all the 
batches and the procedure followed as described in Section 3.4.5. Surface 
energy analysis was carried out to analyse the effect of two different high 
shear processes on respective product surfaces and their related surface 
energies. 
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Figure 6.48 iGC analysis for carbamazepine: salicylic acid 1:1 cocrystals 
processed by HME and solution crystallisation 
 
As Figure 6.48 shows pure cocrystal shows high surface energy values and 
HME processed cocrystal batch without polymer also shows surface energy 
values increasing with increase in surface coverage area. This can be 
attributed to the surface groups available on these cocrystals, surface 
hydrophobicity has a positive effect on surface energy and these cocrystals 
without polymer have shown lowest vapour sorption in DVS studies. These 
findings can be directly correlated to drug release, higher the surface energy 
the higher is the release.     
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Figure 6.49 iGC analysis for carbamazepine: salicylic acid 1:1 cocrystals with 
10% PEO processed by HME and S3M 
 
In case of cocrystals with 10% PEO, HME processed cocrystals surface 
energies showed higher values compared to S3M and was consistent as the 
coverage area increased (Figure 6.49). The cocrystal produced by S3M3 had 
highly compacted features with uneven or irregular crystal distribution at the 
surface embedded in the polymer matrix. These findings cannot be directly 
correlated to drug release or vapour sorption studies.  
6.4.2 Carbamazepine: saccharin 1:1 cocrystal (CBZ: SACC 1:1) 
6.4.2.1 Crystal structure data 
Carbamazepine forms a monoclinic 1:1 cocrystal with saccharin. The CBZ: 
SACC cocrystal pair is extensively studied among the CBZ cocrystals.  CBZ: 
SACC 1:1 cocrystal exhibit in two polymorphic forms Form I and II 
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respectively. As shown in Figure 6.50 the CBZ and SACC form a hydrogen 
bond between their respective functional groups, -NH of CBZ and -SO2N of 
SACC. The single crystal data and space group features with other important 
crystal parameters are given in Table 6.4  
Table 6.4 Crystal structural database and space group details for CBZ: 
SACC 1:1 cocrystal 
Empirical formula C
15
H
12
N
2
O, C
7
H
5
NO
3
S 
Crystal system Monoclinic 
Space group C2/c 
a (Å) 35.719 
b (Å) 6.837 
c (Å) 16.111 
α (°) 90.000 
β (°) 98.026 
γ  (°) 90.000 
 
 
Figure 6.50 Crystal structure of carbamazepine: maleic saccharin 1:1 
cocrystal and crystal packing in unit cell. (adopted from CSD) 
 
The CBZ: SACC 1:1 cocrystal exhibits characteristic 2θ peaks at 6.46, 11.76, 
13.36, 13.8° respectively as shown in Figure 6.51.  
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Figure 6.51 Calculated PXRD pattern for carbamazepine: saccharin 1:1 
cocrystal. (adopted from CSD- UNEZAO01 and processed in OriginPro 8) 
6.4.2.2 Processing of cocrystal 
CBZ and SACC were weighed accurately and mixed in molar ratios; to this 
15% w/w PEO was added as a processing aid. This mixture was subjected to 
turbula mixer for making all three components homogenous; this was then 
transferred to S3M3 hopper. Material flow was excellent. Product started 
coming out in the form of agglomerated threads as soon as the material was 
added to the feeder. It took only 10-15 secs during first cycle to start giving 
out the product. Agglomerated threads varied in the size length (0.5 mm to 1 
cm) and overall structural features. HME for CBZ:SACC cocrystal was 
carried out according to the temperature profile and extrusion parameters 
given in section 3.7 (Table 3.10). Extrusion was carried out for CBZ: SACC 
1:1 with and without PEO as it was feasible to process drug polymer alone 
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on HME. The end product was half broken screw type structural features. 
The end product of both processes was characterised by various analytical 
tools and for drug release. 
6.4.2.3 SACC Calibration 
The calibration curve for SACC was linear over the concentration range of 
10-100 ug/ml. The linearity equation was calculated using calibration curve, 
slope of the equation was 347.78, constant -359.94 and R2 0.9996 (Figure 
6.52). The SACC release was calculated using calibration equation. 
 
Figure 6.52 Saccharin calibration curve using UPLC at 269nm 
 
The retention time for saccharin in UPLC was 1.30 mins in the total runtime 
of 5mins as shown in Figure 6.53. 
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Figure 6.53 saccharin chromatogram in UPLC analysis 
6.4.2.4 PXRD 
PXRD studies for CBZ: SACC 1:1 cocrystals were carried out as described in 
Section 3.4.2. The characteristic 2θ values for CBZ: SACC 1:1 cocrystals 
were observed at 6.46, 11.76, 13.36, 13.8° which matches the structural data 
from CSD. Characteristic 2θ values for CBZ at 13.16, 14.2, 15.36, 15.92, 
18.72, 19.56, 20.4 and SACC were observed at 9.44, 16.04, 18.92, 20.12°, 
which completely differs from the cocrystal values. CBZ: SACC cocrystals 
without polymer processed by HME showed that it has some characteristic 
peaks at or near 2θ of CBZ and SACC (Figure 6.54) and it also shows 
characteristic peaks for pure cocrystal also. From this it can be concluded 
that there is partial conversion into cocrystal and need to modify the HME 
process to get phase pure cocrystal with more appropriate temperature and 
shear profile. CBZ: SACC 1:1 cocrystal with 15% PEO as an aid processed 
by HME and S3M3 shows all the characteristic peaks at 2θ values of pure 
cocrystals, which confirms that both the processes yielded phase pure 
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cocrystal. The justification for getting phase pure cocrystal using polymer as 
aid can be explained as discussed in CBZ: SAL cocrystal study, at very high 
shear PEO acted as solvent or common media to dissolve CBZ SACC in 
equal proportion which helped them to form hydrogen bond. 
 
[A: Carbamazepine, B: CBZ:SAC 1:1 PURE CC, C: HME CBZ:SAC 1:1, D: 
HME CBZ:SAC 1:1 15% PEO, E: S3M CBZ:SAC 1:1 15% PEO] 
Figure 6.54 PXRD for carbamazepine: saccharin 1:1 cocrystals processed by 
HME and S3M 
6.4.2.5 DSC 
Thermal properties of the cocrystal were studied to support PXRD findings. 
DSC studies were carried out as described in Section 3.4.1. As discussed 
earlier CBZ shows characteristic melting endotherm at 175 °C and 191 °C, 
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whereas SACC shows this at 229 °C. The CBZ: SACC 1:1 pure cocrystal 
showed a characteristic melting endotherm at 178 °C. HME processed 
cocrystal without PEO the endotherm was observed at 173°C (Figure 6.55). 
whereas cocrystal with 15% PEO processed by HME showed endotherm at  
172 °C and S3M3 processed at 170 °C. The slight difference in melting 
endotherm with pure cocrystal can explained as sample for DSC analysis 
used was small (2-3 mg) and in that respective sample amount of polymer, 
the amount of cocrystal present might have varied which made endotherms 
exhbit at different temperatures.   
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[A: Carbamazepine, B: CBZ:SACC 1:1 PURE CC, C: HME CBZ:SACC 1:1, 
D: HME CBZ:SACC 1:1 15% PEO, E: S3M CBZ:SACC 1:1 15% PEO] 
Figure 6.55 DSC thermograms for carbamazepine: saccharin 1:1 cocrystals 
processed by HME and S3M 
6.4.2.6 SEM 
Surface morphology studies were carried out as discussed in Section 3.4.5. 
The structural surface features and properties were similar to those observed 
in CBZ: SAL cocrystals with the respective processes. Figure 6.56 shows 
that the HME processed PEO based cocrystals were more compact in nature 
whereas S3M3 showed compact but distorted structural features (Figure 
6.52). 
 
 
239 
 
 
[A- CBZ: SACC 1:1 PURE COCRYSTAL, B- HME, C- S3M3] 
Figure 6.56 Surface morphology by SEM of carbamazepine: saccharin 1:1 
cocrystals processed by HME and S3M 
6.4.2.7 FT-R 
FT-IR analysis was carried out as detailed in Section 3.4.3. As discussed 
earlier CBZ shows characteristic symmetrical or asymmetrical –NH vibrations 
at 3465 and 3155 cm-1, -C=O stretching at 1677 cm-1 and C=C, -C=O 
vibrations and –NH deformation at 1593 and 1603 cm-1 respectively. SACC 
shows characteristic –NH and C=O secondary amide stretching at 3093 and 
1715 cm-1 respectively with asymmetric –SO2 streching at 1332 and 1175 
cm-1 (Figure 6.57). Pure coccrystal there was a shift in stretching at 3496 and 
3182 respectively, exactly similar kind of strechings were observed in HME 
and S3M3 processed cocrystals with PEO. The peaks were broadened in all 
the cocrystal batches and due to slight change in –SO2 streching vibrations 
(Figure 6.58).  
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Figure 6.57 FT-IR spectra for CBZ:SACC 1:1 cocrystals by HME and S3M 
with PEO 
 
Figure 6.58 FT-IR spectra for carbamazepine: saccharin 1:1 cocrystals 
processed by HME and S3M with PEO 
The shift in the stretching vibrations to such extent can be due to hydrogen 
bond formation (Schultheiss and Newman, 2009, Maheshwari et al. 2009) 
and it can be concluded that there is hydrogen bond formation between –NH 
of CBZ and –SO2 of SACC. 
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6.4.2.8 NIR 
NIR analysis was carried out as discussed in Section 3.4.4. Formation of 
new peak or stretching is generally considered as representative cocrystal 
peak in NIR analysis. 
 
Figure 6.59 NIR spectra for carbamazepine: saccharin 1:1 cocrystals 
processed by HME and S3M 
Saccharin showed good NIR absorption in the first overtone region at 1651 
nm. The CBZ:SACC 1:1 pure cocrystal showed high NIR absorption in the 
second overtone region at 1454 and 1475 nm (Figure 6.59). The S3M 
processed CBZ:SACC 1:1 with PEO showed identical NIR absorption at 
1454 nm whereas HME processed CBZ:SACC 1:1 cocrystals with and 
without polymer both showed NIR absorption at 1448 and 1465 nm which is 
a lower wavelength shift compared to pure cocrystal. The NIR findings 
complemented FT-IR outcomes and the presence of hydrogen bonds can be 
confirmed. 
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6.4.2.9 Dissolution  
The dissolution profiles were performed as per Section 3.7.2 and the 
dissolution analysis was done by UPLC. HME processed CBZ: SACC 1:1 
cocrystal without PEO showed slow CBZ release compared to PEO based 
cocrystals released 80% of CBZ in one hour and 100% in next three hours. 
The CBZ: SACC 1:1 cocrystal with 15% PEO showed 90% of CBZ release 
within 45mins and 100% within one hour (Figure 6.60).    
 
Figure 6.60 Dissolution profile for carbamazepine: saccharin 1:1 cocrystals 
with PEO processed by HME and S3M 
 
The slow release for cocrystals without polymer can be contributed to a lower 
wettability due to the absence of polymer. The PEO based cocrystal enabled 
dissolution media to penetrate cocrystal matrix readily and showed faster 
dissolution. 
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6.4.3 Carbamazepine: nicotinamide 1:1 cocrystal (CBZ: NIC 1:1) 
6.4.3.1 Crystal structure data 
CBZ forms cocrystal with NIC in a 1:1 molar ratio which exhibits in an 
orthorhombic form. Many researchers have reported this pair as a good 
solubility improvement medium for CBZ. The crystal structure details, space 
groups and bond lengths and angles are described in Table 6.5. 
Table 6.5 Crystal structural database and space group details for CBZ: NIC 
1:1 cocrystal 
Empirical formula C
15
H
12
N
2
O, C
6
H
6
N
2
O
 
Crystal system Orthorhombic 
Space group P21/n 
a (Å) 5.096 
b (Å) 17.595 
c (Å) 19.647 
α (°) 90.000 
β (°) 90.917 
γ  (°) 90.000 
 
 
Figure 6.61 Crystal structure of carbamazepine: nicotinamide 1:1 cocrystal 
and crystal packing in unit cell. (adopted from CSD) 
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As shown in Figure 6.61 CBZ and NIC forms hydrogen bond with each other 
between respective functional groups –NH from CBZ and –C=O of NIC 
(Figure 6.58). 
The PXRD for CBZ:NIC 1:1 cocrystal shows characteristic 2θ values at 6.44, 
8.64, 9.92° respectively calculated from CSD database (Figure 6.62). 
 
Figure 6.62 Calculated PXRD pattern for carbamazepine: nicotinamide 1:1 
cocrystal (adopted from CSD- UNEZES and processed in OriginPro 8) 
 
6.4.3.1 Processing of cocrystal 
Accurately weighed CBZ and NIC were mixed in 1:1 proportion and 15% w/w 
PEO was added to this mixture. Following homogenous blending in a turbula 
mixer, the mixture was subjected to S3M3 processing. The product 
characteristics and process time was the same as CBZ: SACC and CBZ: 
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SAL cocrystals with both the processes HME and S3M3 process. The 
extrusion and temperature profiles were set as described in Section 3.7 
(Table 3.10). The resultant end product of both the processes were analysed 
by various analytical techniques and for drug release.  
6.4.3.2 Nicotinamide calibration 
The calibration curve for NIC was linear over concentration range of 10-100 
ug/ml. The linearity equation was calculated using calibration curve, slope of 
the equation is 783.52 and constant 584.4 and R2 is 0.9982 (Figure 6.63). 
Calibration equation was used to calculate NIC release. 
 
Figure 6.63 Nicotinamide calibration curve using UPLC at 262nm 
The retention time for NIC in the UPLC method was found to be 1.3mins as 
shown in Figure 6.64. 
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Figure 6.64 Nicotinamide chromatogram in UPLC analysis 
6.4.3.3 PXRD 
PXRD analysis was carried out as per Section 3.4.2. The characteristic 2θ 
values for CBZ were observed at 13.16, 14.2, 15.36, 15.92, 18.72, 19.56, 
20.4° respectively as discussed earlier whereas pure CBZ:NIC 1:1 cocrystal 
showed characteristic 2θ values at 6.44, 8.64, 9.92°, similar to the CSD 
database for CBZ: NIC 1:1 cocrystal. The HME processed CBZ: NIC 1:1 
without PEO showed 2θ values at 6.76, 9.83, 10.32° whereas PEO based 
cocrystal by S3M3 and HME showed 2θ values at 6.34, 8.52, 9.9° and 6.8, 
8.92, 10.28 respectively (Figure 6.65). This confirms formation of pure 
CBZ:NIC 1:1 cocrystal processed by both the processes. The slight change 
in 2θ values can be attributed to the amount and type of surface exposed to 
X-rays during PXRD. 
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[A: Carbamazepine, B: CBZ:NIC 1:1 PURE CC, C: HME CBZ:NIC 1:1, D: HME CBZ:NIC 1:1 
15% PEO, E: S3M CBZ:NIC 1:1 15% PEO] 
Figure 6.65 PXRD for carbamazepine: nicotinamide 1:1 cocrystals processed 
by HME and S3M 
6.4.3.4 DSC 
Thermal analysis by DSC for CBZ:NIC 1:1 was carried out as described in 
Section 3.4.1. The CBZ melting endotherms at 175 and 191°C were not 
observed in any cocrystal batch (Figure 6.66). The CBZ:NIC 1:1 cocrystal 
shows a typical melting endotherm at 159 °C, which was observed in HME 
processed CBZ:NIC 1:1 cocrystal without PEO. The melting endotherm in 
case of S3M3 cocrystal  was observed at 157 °C and in case of HME 
processed it was observed at 159 °C. The slight difference in the melting 
temperature can be attributed to the amount of polymer present in the DSC 
 
 
248 
 
sample. Thermal endotherms for respective cocrystals confirms that there is 
formation of phase pure cocrystal.  
 
[A: Carbamazepine, B: CBZ:NIC 1:1 PURE CC, C: HME CBZ:NIC 1:1, D: 
HME CBZ:NIC 1:1 15% PEO, E: S3M CBZ:NIC 1:1 15% PEO] 
Figure 6.66 DSC thermograms for carbamazepine: nicotinamide 1:1 
cocrystals processed by HME and S3M 
6.4.3.5 SEM 
Surface morphology studies were carried out as described in Section 3.4.5. 
CBZ:NIC 1:1 cocrystals showed similar surface features and compacted 
physical form properties to those seen in CBZ:SAL and CBZ:SACC 
cocrystal. The HME cocrystals showed a similar compacted structure and 
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crystal embedded in the polymer matrix whereas S3M3 processed cocrystal 
had similar properties with distorted surface features (Figure 6.67) 
 
 
 
[A- CBZ: NIC 1:1 PURE CC, B- HME, C- S3M] 
Figure 6.67 Surface morphology by SEM of carbamazepine: nicotinamide 1:1 
cocrystals processed by HME and S3M 
6.4.3.6 FT-IR 
FT-IR analysis was carried out to confirm the presence of hydrogen bonding 
between CBZ and NIC. The procedure was carried out as described in 
Section 3.4.3. CBZ shows characteristic stretching at 3465 and 3155 cm-1 for 
primary amide stretching of –NH. Similar vibrations were also observed for 
NIC at 3358 and 3146 cm-1, -C=O stretching was observed at 1677 in CBZ 
and at 1672 cm-1 NIC (Figure 6.68). CBZ: NIC 1:1 cocrystal showed 
stretching vibrations at 3448 and 3210 cm-1 typically with peak broadening. 
The same vibrations were seen in case of CBZ: NIC 1:1 cocrystal processed 
with 15% PEO by HME and S3M3 (Figure 6.69). The presence of hydrogen 
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bond between –NH and –C=O of NIC can be confirmed due to the shift in 
FT-IR vibrations and peak broadening. 
 
Figure 6.68 FT-IR spectra for carbamazepine: nicotinamide 1:1 cocrystal 
processed by HME and S3M with PEO 
 
Figure 6.69 FT-IR spectra for carbamazepine: nicotinamide 1:1 cocrystals 
processed by HME and S3M with PEO 
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6.4.3.7 NIR 
NIR analysis for CBZ:NIC cocrystals was carried out to support the FT-IR 
findings, procedure was followed as described in Section 3.4.4.  
 
Figure 6.70 NIR spectra for carbamazepine: nicotinamide 1:1 cocrystals 
processed by HME and S3M 
 
Nicotinamide showed characteristic NIR absorption in the second overtone 
region at 1505 and 1672 nm. Pure cocrystal CBZ:NIC 1:1 showed good NIR 
absorption in the first overtone region at 1463 and 1514 nm (Figure 6.70). 
Similarly  way S3M and HME processed cocrystals showed identical NIR 
absorption as the pure cocrystal which shows that the extent of hydrogen 
bonding was similar for all CBZ:NIC 1:1 cocrystals. 
6.4.3.8 Dissolution  
Drug release studies were performed as described in Section 3.7.2. Figure 
6.71 shows the drug release from different cocrystals processed by S3M3 
and HME. S3M3 processed cocrystal with 15% PEO showed the fastest drug 
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release compared to HME cocrystals, S3M3 cocrystal exhibited maximum 
drug release in one hour. For HME processed cocrystals with 15% PEO the 
drug release was slow, 20% of drug in one hour and 3 hours to release about 
70% of total drug. However, HME processed cocrystals without PEO showed 
good drug release around 70% in one hour and 100% in 3 hours.  
 
Figure 6.71 Dissolution profile for carbamazepine: nicotinamide 1:1 
cocrystals with PEO processed by HME and S3M 
 
The slower release of HME processed cocrystals can be attributed to the 
highly compacted nature of the end product which produced surface area 
and low surface porosity, reducing penetration of the dissolution media into 
the cocrystal matrix. The release of drug from S3M can be attributed to the 
highly crystalline and distorted, irregular surface features which improved 
penetration of media in crystal matrix. 
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6.4.4 Carbamazepine: glutaric acid 1:1 cocrystal (CBZ: GLUT 1:1) 
6.4.4.1 Crystal structure data 
CBZ forms a monoclinic cocrystal wit GLUT in 1:1 symmetry, this cocrystal 
exhibits monoclinic symmetry. GLUT has not been extensively studied by 
researchers as compared to the above discussed co-formers. GLUT, being a 
dicarboxylic acid and has –COOH functional readily available to form 
hydrogen bond with –NH of CBZ. The hydrogen bond formation is shown in 
Figure 6.72. The crystal structural database, space group details are given in 
Table 6.6.  
Table 6.6 Crystal structural database and space group details for CBZ: 
GLUT 1:1 cocrystal 
Empirical formula C
15
H
12
N
2
O, C
5
H
8
O
4
 
Crystal system Monoclinic 
Space group P21/n 
a (Å) 18.562 
b (Å) 5.120 
c (Å) 19.459 
α (°) 90.000 
β (°) 106.839 
γ  (°) 90.000 
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Figure 6.72 Crystal structure of carbamazepine: glutaric acid 1:1 cocrystal 
and crystal packing in unit cell. (adopted from CSD) 
 
The CBZ:GLUT 1:1 cocrystal shows characteristic 2θ values at 9.48, 9.88, 
13.36° respectively as shown in Figure 6.73 
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Figure 6.73 Calculated PXRD pattern for carbamazepine: glutaric acid 1:1 
cocrystal (adopted from CSD- MOXVOL and processed in OriginPro 8) 
6.4.4.2 Processing of cocrystal 
The S3M3 procedure for CBZ:GLUT processing and its respective product 
characteristic were same as seen in case of CBZ: SAL, CBZ: NIC cocrystals. 
The HME was carried out as per the temperature and extrusion profiles 
described in Section 3.7 (Table 3.10). No difficulties were found in 
processing this cocrystal pair like others. End products of both the processes 
were characterised by various analytical techniques and for drug release 
6.4.4.3 Glutaric acid calibration 
As GLUT neither shows any UV absorbance nor gave any peak in UPLC 
analysis. A calibration study was not carried out for GLUT. The drug release 
studies were restricted to the CBZ release only.  
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6.4.4.4 PXRD 
The PXRD for CBZ: GLUT 1:1 cocrystal was carried out by procedure 
described in Section 3.4.2. As discussed earlier CBZ shows characteristic 2θ 
values at 13.16, 14.2, 15.36, 15.92, 18.72, 19.56, 20.4° respectively, 
whereas GLUT shows at 13.88, 19.76, 21.44, 22.04, 24.12°. The pure CBZ: 
GLUT 1:1 cocrystal showed characteristic 2θ values at 9.48, 9.88, 13.36° 
which were identical to those seen in CSD structural database (Figure 6.74). 
With CBZ: GLUT cocrystal processed by HME without PEO, there was only 
one 2θ value was seen at 9.15°, with no other peaks observed. This can be 
attributed to partial transformation into cocrystal and HME process would 
need to be modified to get phase pure cocrystal. PXRD in the case of HME 
processed cocrystal with 15% PEO showed 2θ values at 9.72, 10.24, 13.36° 
and for S3M3 at 9.32, 9.8, 12.96° respectively, which shows that these 2θ 
values matches with the pure cocrystal. The slight difference in 2θ values 
can be explained as discussed earlier by the surface area of cocrystal 
exposed to X-rays during PXRD studies as well as due to process variations 
between HME and S3M3. 
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[A: Carbamazepine, B: CBZ:GLUT 1:1 PURE CC, C: HME CBZ:GLUT 1:1, 
D: HME CBZ:GLUT 1:1 15% PEO, E: S3M CBZ:GLUT 1:1 15% PEO] 
Figure 6.74 PXRD for carbamazepine: glutaric acid 1:1 cocrystals processed 
by HME and S3M 
6.4.4.5 DSC 
Thermal analysis for CBZ: GLUT 1:1 cocrystals were performed as described 
in Section 3.4.1. As discussed earlier CBZ shows characteristic endotherms 
at 175 and 191 °C, in case of GLUT an endotherm was observed at 98 °C. 
The CBZ: GLUT 1:1 pure cocrystal showed characteristic melting endotherm 
at 124 °C. For HME processed cocrystal without PEO endotherms were 
observed 112 and 124 °C, first endotherm at 112 °C can be attributed to 
GLUT impurity and the endotherm at 124 °C show that there was formation 
of cocrystal. In the case of S3M3 processed CBZ: GLUT cocrystal with 15% 
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PEO an endotherm observed at 123.53 °C and in case of HME at 121.89 °C 
(Figure 6.75), which are near or close to the melting endotherm of pure 
cocrystal. This confirms the usefulness of PEO as aid in both the processes, 
which proved to be a good carrier for cocrystal formation. 
 
[A: Carbamazepine, B: CBZ:GLUT 1:1 PURE CC, C: HME CBZ:GLUT 1:1, D: HME 
CBZ:GLUT 1:1 15% PEO, E: S3M CBZ:GLUT 1:1 15% PEO] 
Figure 6.75 DSC thermograms for carbamazepine:glutaric acid 1:1 cocrystal 
processed by HME and S3M 
6.4.4.6 SEM 
Surface morphology studies for CBZ: GLUT cocrystals were carried out as 
described in Section 3.4.5. The surface morphology was found to be similar 
to that in CBZ: SAL and CBZ: NIC cocrystals with PEO. CBZ:GLUT 
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cocrystals with PEO processed by HME showed a highly compacted 
structural morphology whereas S3M3 processed equivalents rough surface 
features with distorted morphology (Figure 6.76) 
 
[A- CBZ: GLUT 1:1 PURE CC, B- S3M, C-HME] 
Figure 6.76 Surface morphology by SEM of carbamazepine: glutaric acid 1:1 
cocrystals processed by HME and S3M 
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6.4.4.7 FT-IR 
FT-IR analysis of CBZ: GLUT 1:1 cocrystal was carried out as described in 
section 3.4.3. The formation of hydrogen bond between –NH of CBZ and –
COOH of glutaric is an essential factor to convert CBZ and GLUT into a 
cocrystal. As discussed earlier CBZ specific –NH stretching can be seen at 
3465 and 3155 cm-1 which are primary amide group asymmetrical or 
symmetrical stretching.  GLUT specifically shows stretching at 1686 cm-1 
(Figure 6.77), the resultant cocrystal shows unique stretching shifts at 3464 
and 3182 cm-1. For pure cocrystal generated by solution method whereas 
cocrystal with 15% PEO processed by S3M3 and HME showed stretching 
vibrations at 348 and 3182 cm-1 respectively with peak broadening (Figure 
6.78). These peak shifts and peak broadening can be attributed to the 
hydrogen bond formation between CBZ and GLUT (Schultheiss, and 
Newman, 2009, Maheshwari et al. 2009). 
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Figure 6.77 FT-IR spectra for carbamazepine: glutaric acid 1:1 cocrystals 
with PEO by HME and S3M 
 
Figure 6.78 FT-IR spectra for carbamazepine: glutaric acid 1:1 cocrystal with 
PEO processed by HME and S3M 
 
6.4.4.8 NIR 
NIR analysis for CBZ: GLUT 1:1 cocrystal was carried out to support the FT-
IR results and to confirm the nature and extent of hydrogen bonding. 
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Figure 6.79 NIR spectra for carbamazepine: glutaric acid 1:1 cocrystals 
processed by HME and S3M 
 
Glutaric acid shows good NIR absorption in the first overtone region at 1701 
and 1737 nm. Pure cocrystals of CBZ:GLUT 1:1 showed characteristic NIR 
absorption at 1467 and 1519 nm. The S3M processed CBZ:GLUT 1:1 
cocrystals with 15% PEO showed peaks at 1451 and 1465 nm; similar NIR 
absorption peaks were observed in case of CBZ:GLUT 1:1 cocrystal without 
PEO from HME. Cocrystals processed by HME with PEO showed NIR 
absorption shift to 1457 and 1482 nm respectively (Figure 6.79). The 
formation of new peaks or this major shift from CBZ and GLUT can be 
attributed to the formation of hydrogen bond between CBZ and GLUT.   
6.4.4.9 Dissolution 
The dissolution studies were carried out as per the method and procedure 
described in Section 3.7.2.  
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Figure 6.80 Dissolution profile for carbamazepine: glutaric acid 1:1 cocrystal 
with PEO by HME and S3M 
 
Dissolution profiles for CBZ: GLUT 1:1 cocrystal (Figure 6.80) showed similar 
drug release to that shown by CBZ: NIC 1:1 cocrystals. The S3M3 processed 
cocrystal with PEO showed fastest release but slow release as compared to 
other S3M3 processed cocrystal with SAL, NIC or SACC as co-formers. Only 
80% of the drug was released in 3 hours, and a similar kind of observation 
was made in case of HME processed cocrystal without PEO as an aid. The 
HME processed cocrystal with PEO showed slowest release as compared to 
the other two and could release only about 50% of the total drug; this can be 
attributed to the compacted nature of the extrudates as discussed earlier.  
All the cocrystals processed on S3M3 included polymer from 5-25% w/w of 
total composition, it was very important to see that does this amount of 
polymer will have any effect on the degradation of drug, co-former or on 
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polymer itself. Degradation studies were carried out for CBZ cocrystal 
batches as it is majorly focussed drug in this study. 
6.4.5 Degradation analysis 
All the CBZ cocrystal batches with and without polymers were subjected to 
iminostilbene analysis. Most of the CBZ solid dispersion showed degradation 
by generating iminostilbene during HME and S3M processing. The 
iminostilbene generation results are shown in Figure 6.81. All S3M 
processed CBZ cocrystal batches showed none or negligible amount of 
iminostilbene except for the CBZ:SAL 1:1 with 25% PVP VA64 cocrystal 
batch, which showed significant iminostilbene generation. HME processed 
CBZ:SAL 1:1 cocrystal batches also showed significant generation of 
iminostilbene. The highest generation of iminostilbene was observed  in 
cocrystals with 25% PVP VA64>15% PVP VA64>5% PEO> HME CBZ:SAL 
1:1 plain cocrystal without polymer> HME CBZ:SACC 1:1 plain cocrystal 
without polymer> HME CBZ:GLUT 1:1 15% PEO> HME CBZ:GLUT 1:1 plain 
cocrystal without polymer> HME CBZ:SACC 1:1 15% PEO> HME CBZ:SAL 
1:1 25% PEO> HME CBZ:SAL 1:1 10% PEO. 
From Figure 6.81 it can be observed that CBZ degradation for CBZ: SAL 
cocrystals was seen when 25% VA64 was used as a processing aid during 
S3M3 and that there was no CBZ degradation observed in the case of the 
other CBZ: SAL cocrystal batches with other polymer concentrations. This 
confirms that for drug degradation, the amount of polymer plays an important 
role, as application of shear on the  total drug: polymer system is governed 
by the polymer and not the drug in S3M3 processing. In HME the reason for 
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CBZ degradation is likely to be due to the residence time in the extruder 
barrel during HME processing. The HME process would require modification 
to control the extent of drug degradation. 
 
Figure 6.81 Iminostilbene analysis in carbamazepine cocrystals with and 
without PEO and PVP VA64 processed by HME and S3M 
This can be achieved by control on process parameters such as screw 
configuration and screw rotation speed. The S3M3 process is rather basic in 
nature, scalable but primarily used for plastics. However, it has shown great 
potential in producing pharmaceutical cocrystals with minimal degradation. 
Cocrystals can be efficiently formed using the S3M3 process, but it has a 
limitation of a dependency on polymeric processing aids. Without the aid a 
polymer it is very hard to process the plain drug and co-former mixture. 
Different concentrations of polymer had different structural effects in various 
cocrystal pairs; performance of the cocrystals formed can be manipulated by 
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the concentration and type of polymer used. HME has major advantage over 
S3M3 as it is not dependent on polymeric processing aids to form the 
cocrystals.  
Processing aid used in case of CBZ cocrystals were PEO and PVP VA64 
both the polymer aid was able to form phase pure cocrystals so it was very 
difficult to differentiate between these two which one is better over other. 
Both the polymers can be used as processing aids.  
In case of solid dispersions, S3M3 has an advantage in the sense that its 
drug polymer mixtures can be directly processed without use of plasticisers 
as discussed in previous chapter. 
The S3M3 mechanism, its control and its three dimensional scissor shear 
action need to be understood well, as it governs the product performance in 
all sense. The overall observations and results from solid dispersions and 
cocrystals manufactured by both these processes has shown that S3M3 can 
be a potentially important process for the pharmaceutical industry to 
manufacture solid dispersions and cocrystal formulations on large scale. 
The nature of products and product performance in both solid dispersions 
and cocrystals showed significant differences; the next chapter will provide a 
brief explanation and discussion of the understanding between the 
physicochemical changes in the products developed by two the processes 
and provide a process comparative study. 
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Chapter 7. Global discussion 
The effect of processing technology on the product properties has been 
discussed in the chapter 5 and chapter 6. The major aim of this discussion is 
to develop some understanding based on the difference in the processing 
requirements for solid dispersions and cocrystals. The solid dispersion 
batches which are two component systems produced at relatively high 
polymer concentrations (50-66% w/w) whereas a three component system 
(drug: co-former: polymer) 5-20% w/w in case of co-crystal batches. The 
objective in solid dispersion is to achieve miscibility of the solid dispersion as 
two component system (containing drug and polymer (50-66%w/w), the 
cocrystal batches were ternary system containing drug-coformer and 
polymer (5-20%w/w). Though the SFCC technique using HME reported from 
our lab demonstrated generation of cocrystals from two phases system 
without polymer. There have been attempts to produce cocrystals in the 
ternary systems using HME. An attempt has been reported include generate 
ibuprofen-nicotinamide cocrystals in presence of 50% xylitol, but there is not 
clear evidence of achieving cocrystals. Hence, xylitol addition shown has 
limited success. Whereas Boksa et al., reported matrix assisted 
cocrystallisation of carbamazepine-nicotinamide in presence of 20% soluplus 
using HME technique. This clearly shows that selection of the third 
component is critical. The third component concentration was maintained 
constant during batches by both the techniques. The lower concentration of 
polymer in cocrystal batches was improving processability but above critical 
concentrations (20%) solid dispersion is favoured. 
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In the present study carbamazepine was selected as a model molecule due 
to its degradation challenge at high temp. Carbamazepine is common in 
cocrystal as well as solid dispersion batches. It was observed that 
HME and S3M both being a high shear solid state processing technologies 
showed a completely different end product characteristics. The solid 
dispersions and cocrystals produced by these techniques varied in all 
physicochemical aspects as well as in terms of drug release and 
degradation. PXRD and DSC analysis showed similar results for HME and 
S3M processed samples whereas SEM analysis showed a drastic variability 
in terms of morphology and surface features between end products of these 
processes. The distorted and highly rough surfaces in case of S3M 
processed plasticiser free amorphous dispersions can be contributed to the 
three dimensional scissoring shear actions during S3M processing; these 
highly rough surfaces affected the dissolution of the amorphous dispersions 
which was faster than HME processed dispersions. The faster drug release 
was not observed in all the drugs solid dispersions processed by S3M, some 
of the dispersions showed similar kind of drug release pattern without any 
major delay or difference during dissolution studies. The highly rough and 
porous surfaces will surely help in improving wettability and penetration of 
dissolution medium into the solid dispersion matrix; this will be very useful 
during the downstream processing during conversion of milled solid 
dispersions into powder form due to their easily crushable nature. In case of 
HME processed solid dispersions due to plasticisation the surface features of 
solid dispersions were very smooth and completely non-porous and unlike 
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S3M processed solid dispersions these were very hard to break due to high 
plasticity, which made them difficult to break into fine powders during milling. 
This shows that S3M processed product will exhibit easy downstream 
processing compared to HME. In case of cocrystals both the processes 
produced phase pure cocrystals. It was possible in HME to process plain 
drug: co-former blends as such whereas in case of S3M it was mandatory to 
use polymer aid. The type of end products in HME and S3M processing 
using polymer aids for cocrystal preparation showed similar structural 
features but differed in shape size and overall morphology. The polymer aid 
cocrystals showed crystals embedded in polymer matrix as shown in SEM 
analysis. The critical polymer concentration needed to form phase pure 
cocrystal during S3M processing was very important, in case of CBZ: SAL 
1:1 cocrystals PEO concentration varied from 5-25%. The 5% PEO aided 
material showed formation of phase pure cocrystals whereas 25% aided also 
showed formation of phase pure cocrystals but with reduced intensity 
crystalline peaks in PXRD analysis and which seems near to get converted 
into amorphous structure. The 10% and 15% of PEO as polymer aid showed 
formation of phase pure cocrystals in that 15% PEO aided cocrystals showed 
good structural morphology. 15% polymer aid was then finalised as standard 
polymer aid for other cocrystals. In case of HME it’s not compulsory to have 
polymer aid as it is possible to process the drug: conformer blend easily at 
the eutectic temperature of the mixture. The use of polymer aid might have 
acted as solvent in molten form at softening or melting temperature of 
respective polymers (PEO/ PVP VA64/ HP55) during S3M processing, which 
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eventually made drug: co-former blend to get dissolved in the polymer melt 
and form a phase pure cocrystals. One more interesting fact is that in case of 
S3M there is no external heating facility or temperature controlling ability, the 
polymer aid was melted due to high shear applied during S3M processing, 
temperature rise in S3M processing was only due to high shear mechanism 
of S3M and due to friction of two pans over each other. In case of HME plain 
drug: co-former mixture without external heat application was not able to 
produce cocrystals, similar observation was found when experiment was 
carried out without polymer aid. It is compulsory in HME processing to have 
external heating or temperature controlling facility without that the shear 
applied by twin screws was not sufficient enough to generated required heat 
during processing to convert drug: co-former into cocrystals. It was then 
mandatory to keep the HME processing temperature at or slightly above the 
melting or softening temperature of polymer aid.  
Recently Liu et al., studied the use of cocrystallisation with solid dispersion 
using HME processing to form chemically stable solid dispersions of CBZ: 
NIC 1:1 cocrystals. The polymer used was PVP VA64, soluplus and HPMC. 
They observed that CBZ can be processed at 160 °C i.e. 30° below its 
melting point to avoid its degradation. As it was discussed in case of CBZ 
solid dispersions with HPMCP and HPMCAS there was significant CBZ 
degradation in both the processes S3M and HME whereas in case of all CBZ 
cocrystals processed at 110 °C which is 80° below melting temperature of 
CBZ. Though CBZ cocrystal were processed at well below its melting point 
still there was some degradation found which was quantified by generation of 
 
 
272 
 
iminostilbene. In case of S3M processed CBZ cocrystals with polymer aid 
CBZ degradation was observed when 25% PVP VA64 was used as a 
polymer aid. All other CBZ cocrystals processed by S3M did not show any 
CBZ degradation whereas in case of HME all CBZ cocrystals showed CBZ 
degradation which was increased as polymer aid concentration was 
increased. These findings were contradictory with Liu et al., findings, as Liu 
et al., did not show any iminostilbene generation data and did TGA analysis 
for degradation studies. The HPLC analysis for iminostilbene for 
quantification of CBZ degradation gives better analysis of CBZ degradation.  
It can be concluded that HME is plasticiser dependent and S3M is plasticiser 
free processing in case of solid dispersions whereas S3M is polymer aid 
dependent for cocrystal manufacturing whereas HME is independent of 
polymer aid.  As the polymer concentration increases in case of S3M 
degradation will also be enhanced as seen in CBZ degradation analysis. The 
main reason for degradation of drug or polymer in case of HME can be 
contributed to the residence time and temperature profiles used during 
process as well as plasticiser concentration in case of solid dispersions. The 
shear applied in S3M processing was same for all the solid dispersions and 
cocrystals but the residence time and shear applied was mainly dependent 
on the polymer concentrations. 
 One aspect which is not clear is whether the energy requirement for 
disruption of crystal lattice and achievement of a molecular dispersion 
require more energy compared to formation of cocrystals. This is also 
evident that formation of cocrystals can be achieved with relatively low 
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energy input as in ball milling whereas generation of solid dispersions require 
significantly high energy input. Considering this, an attempt to enhance 
understanding of energy consumption during processing has been initiated 
but it is still in a preliminary stage (Figure 7.1) 
Milling of the end product in HME and S3M is most important step in 
downstream processing. Extrudates from HME and agglomerates from S3M 
need to be reduced to a certain particle size to formulate them into suitable 
dosage forms such as tablets or capsules. Energy consumption during 
downstream processing might change the physicochemical structure of the 
product.  
 
Figure 7.1 Schematics of energy measurement system 
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Energy measurement components: IKA cutter mill, PICO TECHNOLOGY 
TC-08, ACCUENERGY ACCUVIM 100, PICO log recorder. 
Weighing balance with analogue output: A&D GX-200-EC 210g x 0.001g, 
Pan size: 128 x 128mm & Analogue Output Option (GX-OP-06). 
For simultaneous analysis of energy, mass output and temperature during 
the milling process, power output was measured by an ACCUVIM 100 
directly from the mill which was recorded by a PICO log recorder to convert 
and log the exact amount of energy. For mass output, the analogue output 
from the balance connected to PICO recorder which converted the exact 
mass output into the system. For simultaneous temperature monitoring a 
thermocouple was fixed beneath sieve of mill which was fixed in PICO log 
recorder to monitor fluctuations or rise in temperature during milling.  
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Chapter 8. Conclusion and future work 
From the research carried out here, the following conclusion can be drawn: 
 S3M has shown great potential in manufacturing of solid dispersions 
and cocrystals in continuous manner. It shows similar potential as 
HME and can be a good alternative technology for large scale 
production of solid dosage forms. HME has proved its potential in 
many ways to improve the existing pharmaceutical dosage forms and 
by avoiding conventional upstream processing which is generally 
followed in production of solid unit dosage forms tablets and capsules. 
HME being widely accepted technology need to come over some 
processing hurdles with respect to different pharmaceutical APIs.  
 One need a very good process control in terms of temperature profile 
and different process variable, as we discussed earlier plasticisation is 
must in some cases to lower down the processing temperatures and 
avoid subsequent degradation. At present S3M being very basic 
model and majorly been explored for higher molecular weight plastic 
polymers and unfit for the pharmaceutical processing at this stage, 
use of S3M for pharmaceutical processing is at very early stage and 
being firstly getting noticed and reported here.  
 S3M has some major advantages over HME in case of processing 
times, plasticisation free processing and quality of end products 
obtained in case of solid dispersions and cocrystals. The 
pharmaceutical market keeps thriving on existing technologies to 
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improve them and to look for substantial technologies which can 
replace existing ones with minimal or no drawbacks.  
 S3M can be a successful single step, continuous processing 
technology for pharmaceutical manufacturing. There was provision of 
S3M in series (2-3 S3M kept vertically or horizontally in series) for 
large and continuous processing of polymers which can be 
implemented while developing pharmaceutical products which will 
specifically help in product development which need more than one 
S3M cycles to convert them into suitable product. S3M potential has 
been explored for production of solid dispersions and cocrystals, 
development of other and challenging pharmaceutical dosage forms 
will test the real efficiency in pharmaceutical field.  
 Future work will majorly focus on improving S3M process to an 
pharmaceutical industry standard with an excellent process control in 
terms of temperature, shear, process time, improved material of S3M 
construction (Pharma grade SS with low or no wear and tear) and 
different size, shape and designs of pans will make S3M. This might 
turn S3M in a new edge technology for pharmaceutical field with very 
wide applications for development of existing and new kind of 
pharmaceutical dosage forms.  
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